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ABSTRACT 
The Human Papillomavirus (HPV) E6 oncoprotein from cancer-causing HPV types 
is highly multi-functional, capable of targeting many different cellular partners and 
pathways. Integral to this multi-functionality is its regulation by phosphorylation. 
Here I describe studies to firstly investigate when E6 is phosphorylated within the 
PDZ binding motif (PBM), and demonstrate a complex pattern of phosphorylation 
events which take place upon the exposure of the cells to different forms of stress. 
Most important of which is phosphorylation by kinases belonging to the core of the 
DNA Damage Response (DDR) machinery. Functionally this redirects E6 from 
interaction with PDZ substrates to association with 14-3-3 proteins. This in turn 
appears to contribute towards the ability of E6 to inhibit p53 transcriptional activity 
on a subset of p53 responsive promoters, thereby linking DDR signaling to the 
function of the E6 PBM. Functionally I have also been able to precisely dissect the 
sequence constraints within the E6 PBM governing phosphorylation by different 
kinases, PDZ recognition and interaction with different 14-3-3 isoforms. I also show 
that phospho-regulation of the E6AP ubiquitin ligase can also play a role in these 
pathways, and can be utilized and redirected by different HPV E6 oncoproteins with 
varying degrees of efficiency. Depending upon the specific HPV E6 protein, I also 
show the first evidence for phosphorylation at a site outside of the PBM and provide 
insights into the potential functional consequences thereof. Taken together, these 
studies shed new light on the role of E6 phosphorylation in a range of different 
biological activities, and begin to explain the multi-functional nature of the high risk 
HPV E6 proteins. 
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CHAPTER 1: INTRODUCTION 
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Cancer: A multifactorial disease 
 
Cancer is a group of diseases that involve uncontrolled and deregulated cell growth 
with the potential to invade or spread to different parts of the body. The development 
of cancer involves various complex factors and steps. The hallmarks of cancer 
comprise six major biological activities. They include: sustaining proliferative 
signaling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, and activating invasion and metastasis. 
Underlying these events, several other steps occur, such as genome instability, 
immune destruction and inflammation that further contribute towards the progression 
of malignancy (Hanahan and Weinberg 2011).  
There are several factors that are responsible for cancer development. The majority 
of cancers are caused by genetic mutations resulting from causes in the natural 
environmental, such as exposure to ultraviolet (UV) light. Other factors, which could 
be defined as effects of the life-style environment, such as exposure to chemicals or 
gamma radiation also contribute to cause cancer. Importantly, approximately 12% of 
human cancers are caused by virus infection (Bouvard, Baan et al. 2009, de Martel, 
Ferlay et al. 2012, Humans 2012), in which viral oncogenic mechanisms and the host 
cofactors together contribute towards the development of malignancy (de Martel, 
Ferlay et al. 2012).  The viruses that can contribute to cancer development include 
hepatitis B virus, (HBV) hepatitis C virus (HCV), Epstein Barr Virus (EBV), Human 
Papillomaviruses (HPVs), Human T lymphotropic Virus-1 (HTLV-1), HIV, Merkel 
Cell Polyomavirus (MCV) and Kaposi’s sarcoma herpesvirus (KSHV). Viruses 
hijack the host cell machinery for their replication, immune evasion and survival. As 
a part of their life-cycle, human oncoviruses have evolved very powerful anti-
apoptotic and proliferative strategies that can directly contribute to cancer hallmarks 
(Moore and Chang 2010).  
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Cervical cancer   
Cervical cancer is the fourth most common cancer affecting women worldwide, after 
breast, colorectal, and lung cancers, and it is the most common cancer in the less 
developed countries of sub-Saharan Africa. Approximately 530 000 new cases of 
cervical cancer arise every year.  It is also the fourth most common cause of cancer 
death (270 000 deaths in 2015) in women worldwide (WHO), and almost 90% of 
cervical cancer deaths occur in poorly developed regions. Cervical cancer ranks as 
the 2
nd
 most frequent cancer among women in India. About 5% of women are 
estimated to have cervical HPV-16 and/or 18 infections at any given time, and 83.2% 
of invasive cervical cancers are attributed to HPV 16 or 18 infections 
(http://www.hpvcentre.net/statistics/reports/IND_FS.pdf).   
Human papillomavirus and cancer 
HPV is one of the most important causes of sexually transmitted disease worldwide. 
The virus is associated with cervical and other anogenital cancers, and with head-
and-neck cancers (Garbuglia 2014, Wakeham and Kavanagh 2014). The high risk 
virus types are estimated to cause about 5% of the cancer burden worldwide, which 
includes 99% of cervical cancers, 25%–60% of head-and-neck cancers, 70% of 
vaginal squamous cell carcinomas, 88% of anal cancers, 43% vulvar and 50% of 
penile cancers (Gillison, Castellsague et al. 2014, Giuliano, Nyitray et al. 2015). 
Therefore, HPV continues to be an important subject for research, since the rate of 
HPV-related diseases is increasing day by day. There are over 200 HPV types, but 
only the so-called high-risk types are cancer-causing. HPVs are classified into 5 
genera: α, β, γ, ν and µ, based on differences in their life cycles, their DNA 
sequences and also their disease association (Doorbar 2006, Bernard, Burk et al. 
2010, Ekstrom, Bzhalava et al. 2011, Doorbar, Quint et al. 2012). It is now believed 
that viruses from the beta and gamma genera complete their life-cycle, causing 
asymptomatic infections in immunocompetent individuals, without causing any 
apparent disease phenotype (Forslund 2007, Nindl, Gottschling et al. 2007, 
Gottschling, Goker et al. 2009, Bottalico, Chen et al. 2011, Ekstrom, Bzhalava et al. 
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2011). HPVs from the alpha genus are categorized as either cutaneous types or 
mucosal types (Bernard, Burk et al. 2010), based on their ability to infect basal 
epithelial cells of the skin or inner lining of tissues. (Harwood, Spink et al. 1999, 
Burd 2003, Gillison and Shah 2003). The alpha type HPVs can also be grouped into 
high-risk and low-risk HPV types, based on their association with cervical cancer 
and its precursor lesions. Low-risk HPV types include types 6, 11, 42, 43, and 44. 
High-risk HPV types include 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 
and 70 (zur Hausen and de Villiers 1994, Bouvard, Baan et al. 2009, Bernard, Burk 
et al. 2010, de Villiers 2013). Squamous cell carcinomas (SCC) are the most 
common cervical cancers followed by adenocarcinomas (ADC) (Smith, Lindsay et 
al. 2007). HPV-16 is more commonly associated with SCC (55%) than with ADC 
(33%), while HPV-18 is more commonly associated with ADC (37%) than with SCC 
(13%) (Clifford, Smith et al. 2003, Smith, Lindsay et al. 2007). Infection with low-
risk HPV types, such as HPV-6, -11, 42, -43 and -44, do not typically cause 
neoplasia but are responsible for the development of benign genital warts (Laimins 
1993, Middleton, Peh et al. 2003). Some of the beta-type HPVs are also associated 
with cutaneous cancers. The patients presenting epidermodysplasia verruciformis 
(EV) have an increased susceptibility for developing such cancers, and a large 
number of different HPV types are found in the skin of  those patients including 
HPV types 5, 8, 9, 12, 14, 15, 17, 19–25, 36–38, 46, 47, 49 and 50 (Cobb 1990) 
(Gewirtzman, Bartlett et al. 2008), although only HPV-5 and -8 are defined by the 
WHO as cancer causing in those individuals.  
 
Among the alpha HR HPV types, HPV-16 and -18 are described as the most potent 
cancer-causing agents commonly found worldwide (Munger and Howley 2002, 
Munger, Baldwin et al. 2004, Snijders, Steenbergen et al. 2006), and these are 
especially responsible for invasive cervical cancers (Smith, Lindsay et al. 2007, Li, 
Franceschi et al. 2011).   
 
6 
 
Deregulation of viral life cycle: progression towards cervical Cancer  
The virus particle infects basal keratinocytes, to which it gains access through micro-
traumas in the epithelium; it then enters the cell and releases its viral genomic DNA, 
into the nucleus where is retained as an episome. The virus alters the normal 
differentiation process in the lower epithelial tissues during early infection, which 
results in the formation of low-grade squamous intraepithelial lesions (LSIL), 
clinically manifested as cervical intraepithelial neoplasia grade 1 (CIN1). The viral 
infection in this low-grade lesion may progress normally, or sometimes the virus 
becomes latent for several weeks to months. Generally, the virus is eliminated by the 
immune system from these differentiated cells. Detection of CIN1-like features can 
occur about 4 months after viral infection (Winer, Kiviat et al. 2005). Although 99% 
of cervical cancers are associated with High Risk HPVs (zur Hausen 1991, zur 
Hausen 1996), in the vast majority of cases the infection does not develop into the 
cancer. Most of the time, HPV infections are cleared by the host immune system. In 
certain cases, if the host immune system fails to clear the infection, or if the host is 
immunosuppressed, then the cells can remain persistently infected for many years. 
Such infected tissues can progress to severe dysplasia or high-grade squamous 
intraepithelial lesions (HSIL) also called CIN2 and CIN3, which can arise anywhere 
upto 14 months post-infection.  Such severe dysplastic lesions may remain as HSIL, 
or advance to invade below the basement membrane, leading to local invasion 
(McMurray, Nguyen et al. 2001).  The viral oncoproteins E6 and E7 play key roles 
in promoting the progression to cancer. In addition, accumulation of DNA damage 
and acquisition of chromosome instability contribute towards the development of 
cervical malignancy (Pett, Alazawi et al. 2004). The viral genome is often found 
integrated into the host genome in high-grade lesions, resulting in upregulation of the 
E6 and E7 viral oncoproteins, and loss of most of the other viral genes that are 
required for the viral life cycle (Schwarz, Freese et al. 1985, Shirasawa, Tomita et al. 
1989, Jeon and Lambert 1995). It has been shown that approximately 70% of 
metastatic cells have integrated HPV genomes, which indicates that viral DNA 
integration is a common step in the pathogenesis of cervical malignancy (McMurray, 
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Nguyen et al. 2001). Although integration is more likely in HPV-18 positive tumours 
compared to HPV-16 positive (Cullen, Reid et al. 1991, Badaracco, Venuti et al. 
2002, Fehrmann and Laimins 2003, Vinokurova, Wentzensen et al. 2008). The 
preferred sites for viral genome integration into the host chromosome are called 
common fragile sites (CFS); the suggested CFS include FRA13C (13q22), FRA3B 
(3p14.2), and FRA17B (17q23) (Thorland, Myers et al. 2003). The E2 ORF is 
identified as the preferential site of integration, since it is more commonly disrupted 
or deleted than any other site (Badaracco, Venuti et al. 2002). It is possible that 
integration can happen at any point in the HPV genome, but only those that disrupt 
E2 have any growth advantage for the cell. The E2 protein negatively regulates 
expression of E6 and E7 oncoproteins only when the genome is integrated (Bechtold, 
Beard et al. 2003), therefore, loss of E2 during integration results in increased 
expression of the transforming E6 and E7 oncoproteins (Romanczuk and Howley 
1992). Thus, integration of the HPV genome results in the enhanced and deregulated 
expression of the E6 and E7 viral oncogenes, which further promotes cellular 
transformation.  
Little is known about the process whereby HPV genomes are integrated into the host 
genome. However, several studies have suggested that the DNA damage response 
may play a role in HPV integration. A study in W12 cells, which stably express 
HPV16 episomes, demonstrated that when double strand breaks (DSBs) were 
generated by depletion of Ku70 (a crucial mediator of Non Homologues End 
Joining), new HPV16 viral integration events occurred (Winder, Pett et al. 2007). It 
has also been shown that the activity of DNA-dependent protein kinase (DNA-PK), 
an important molecule involved in DSB repair, was found to be significantly reduced 
in patients with cervical cancer (Someya, Sakata et al. 2006). These studies indicate 
that DSBs may be associated with HPV episome loss and integration in cervical 
cancer. In the case of Hepatitis B Virus, it has been shown that integration frequency 
increases with DNA damage, and that viral DNA integration coincides with severe 
dysplasia, leading to hepatocellular cancer (Dandri, Burda et al. 2002). Therefore, it 
is reasonable to expect that DNA damage to both the viral episome and the host 
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genome might enhance the integration of viral DNA into that of the host. Another 
potential mechanism by which HPV integration could occur is ‘Inflammation-
mediated DNA damage’. Indeed, inflammation has been implicated in the 
progression of a variety of cancers. It has been suggested that excessive amounts of 
reactive oxygen species (ROS) are generated during chronic inflammation and these 
play a critical role in promoting DNA damage, ultimately leading to carcinogenesis 
(Kawanishi, Hiraku et al. 2006). In the case of HPV-associated cancers, 
inflammation would also facilitate the integration of the viral genome by inducing 
breaks in both the viral and host genomes. It is likely that there is epigenetic 
modulation, such as DNA methylation and chromatin modifications, of the 
integration site that further determines whether the integration site is active or 
silenced (Chaiwongkot, Vinokurova et al. 2013, Groves, Knight et al. 2016).  
Additionally, the initial integration event is thought to occur in a cell that also 
harbors extrachromosomal HPV genomes expressing E1 and E2. The E1 and E2 
proteins may cause overamplification, or onion skin replication, of the integrated 
HPV genome. This results in generation of heterogeneous replication intermediates 
that serve as substrates for recombination and repair, resulting in rearrangements, 
deletions, and amplification of viral and host sequences (Kadaja, Sumerina et al. 
2007, Kadaja, Isok-Paas et al. 2009). This can lead to genomic instability of the host 
region at the common fragile sites, and further continued expression of E6/E7 
contributes to genetic instability. Therefore, many events are likely contributed to the 
HPV integration event and its subsequent evolution, which is a strong driver of 
carcinogenesis. (Figure 1)   
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Figure 1.  Schematic representation of the progression of cervical malignancy.  
HPV infection of cells in the lower levels of the cervical epithelium leads to an 
alteration of the normal differentiation process in the lower epithelial tissues, which 
results in the formation of low-grade squamous intraepithelial lesions (LSIL), 
clinically manifested as cervical intraepithelial neoplasia grade 1 (CIN1). This 
usually has a high rate of regression back to normal cells. CIN2 represents a mixure 
of low- and high-grade lesions and, thus, further progress towards high-grade 
dysplasia, CIN3. At this stage, excessive amounts of reactive oxygen species (ROS) 
are generated during chronic inflammation and which may play a critical role in 
promoting DNA damage, ultimately leading to carcinogenesis. At this stage, the 
HPV genome is often found integrated into the host genome.   
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HPV genome: Structure, organization and function  
 
HPVs are small, non-enveloped viruses, 55 nm in diameter. They have an 
icosahedral capsid composed of 72 capsomers, with two capsid proteins, L1 and L2. 
Each capsomer is composed of 360 copies of pentamer of the major L1 capsid 
protein. Each virion capsid also contains upto 72 copies of the minor capsid protein, 
L2 (Sapp, Volpers et al. 1995, Buck, Cheng et al. 2008). The HPV genome consists 
of a double-stranded circular DNA molecule of approximately 7,900 bp, associated 
with histones which forms chromatin-like structures (Favre 1975). As shown in 
Figure 2, HPV has approximately eight open reading frames (ORFs), and all protein-
coding sequences are transcribed from one single strand. The genome is functionally 
divided into three regions, the Upstream Regulatory Region (URR), the Early region 
and the Late region. HPV DNA replication is regulated by controlling the 
transcription of the ORFs, and this regulation is mediated by the p97 promoter in 
HPV-16, the p99 in HPV-31 and the p105 in HPV-18, along with many enhancer 
and silencer sequences. The URR also contains an origin of DNA replication, around 
which are the binding sites for E1 and E2 proteins. The Early region consists of 
ORFs E1, E2, E4, E5, E6, and E7, often referred to as early genes, which are 
involved in viral replication. The Late region contains the ORFs encoding the 
structural capsid proteins, L1 and L2, and are expressed during the later phases of the 
viral life cycle. Extensive alternative splicing also increases the coding capacity of 
the genome.  
 
The E1 protein is about 600 to 650 amino acids long depending on the papilloma 
virus (PV) type, and is the only PV encoded enzyme that possesses DNA helicase 
activity. E1 serves various functions that are required for the initiation of viral DNA 
replication, including ori-specific DNA-binding activity, DNA-dependent ATPase 
activity and helicase activity (Ustav, Ustav et al. 1991, Wilson and Ludes-Meyers 
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1991, Seo, Muller et al. 1993, Thorner, Lim et al. 1993, Lusky, Hurwitz et al. 1994). 
The E2 transcriptional activator protein is much smaller than E1, being 350 to 500 
amino acids in length depending on the PV type. The interaction between the E1 and 
E2 proteins results in the formation of a complex called the ‘E1-E2-ori complex’ on 
the origin of replication (ori) (Sedman and Stenlund 1995, Sedman and Stenlund 
1996). This interaction has several consequences, one of which is that the specificity 
of binding of the E1 protein to the ori is enhanced significantly. Moreover, in the 
presence of E2, the DNA-binding capacity of E1 is substantially higher (Sedman and 
Stenlund 1996).   
 
Transcriptional regulation of early viral gene products is a central regulatory event 
for viral infection. The initiation of transcription is activated by host cell 
transcription factors, which bind to the URR upstream of the early promoters of 
high-risk HPVs. The activity of these promoters is further modulated by the viral E2 
protein through its interaction with four highly conserved E2-binding sites (E2-BS) 
located in the URR of all high-risk HPVs, which are essential for a productive viral 
life cycle. Binding of E2 to promoter BS1 affects recognition of the neighboring 
TATA box by TBP, whilst binding of E2 to BS2 and BS3 may contribute to 
promoter repression by competition with cellular transcription factors such as SP1 
(Demeret, Yaniv et al. 1994, Demeret, Desaintes et al. 1997). E2 binding at BS4 
leads to an upregulation of viral early gene expression and E2 binding at BS3 is 
essential for viral DNA replication. Thus, at low concentrations of E2, BS4 is 
occupied, therefore, the E6/E7 promoter is activated (Romanczuk, Thierry et al. 
1990). Similarly, as E2 expression increases, the E6 promoter activity is suppressed 
(Steger and Corbach 1997), concomitant with E2 occupation of BS1 and BS2 
(Sanders and Maitland 1994). Therefore, the E2-DNA-binding events correlate with 
an increased E2 expression and co-ordinate early gene expression (Thierry and 
Howley 1991, Bouvard, Storey et al. 1994).  E2 transcriptional activity is controlled 
by p300-mediated acetylation of lysine 111. This represents a novel mechanism by 
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which papillomavirus gene expression is regulated. E2 also plays a pivotal role in 
ensuring the correct distribution of viral episomes to the daughter cells during 
mitosis and cell division and this is achieved by tethering the viral episomes to the 
host chromosome through its association with the cellular Brd4 protein (McKinney, 
Kim et al. 2016).  
 
The HPV E4 protein is approximately 17kDa protein, and is synthesised as an E1^E4 
fusion protein, as a result of mRNA splicing (Chow, Reilly et al. 1987, Ozbun and 
Meyers 1997, Milligan, Veerapraditsin et al. 2007, Wang, Meyers et al. 2011); 
although designated as an early protein, its expression is mostly detected later in 
infection, after the activation of the late promoter (Doorbar 2013). Although there is 
considerable debate on the role of E1^E4 during the viral life cycle, studies on high-
risk HPV types-16, -18 and -31 have suggested multiple roles during the late stages 
of the viral replication cycle. The leucine structure within E1^E4 protein has been 
shown to be important for E4 protein self-association, and this confers on E4 the 
ability to form structures resembling amyloid fibres, allowing manipulation of the 
host cell cytokeratin network potentially for subsequent virion release (McIntosh, 
Martin et al. 2008, McIntosh, Laskey et al. 2010). Furthermore, epithelial cells 
expressing E4 from HPV-16, HPV-18 and HPV-31 were shown to undergo cell cycle 
arrest in  G2 phase, owing to the inhibition of Cyclin/Cdk1 nuclear accumulation 
(Davy, Jackson et al. 2002, Davy, Jackson et al. 2005, Knight, Turnell et al. 2006). 
More recent studies showed that loss of E4 has marked effect on viral genome 
amplification and L1 expression upon differentiation.  However, HPV-16 showed a 
much clearer E4 dependency for viral genome amplification than HPV-18 (Egawa, 
Wang et al. 2017), the reasons for which remains to be determined.  
 
The E5 protein is 75 to 100 amino acids long depending on PV type, and is a 
transmembrane-associated hydrophobic protein, which binds with intracellular 
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membranes, most notably those of the endoplasmic reticulum, Golgi apparatus, and 
perinuclear region. The E5 protein is frequently referred to as the HPV minor 
oncoprotein. HPV16 E5 has been shown to induce anchorage-independent growth in 
human keratinocytes and in murine fibroblasts (Pim, Collins et al. 1992). High levels 
of E5 expression in the transgenic mouse model has been shown to induce epithelial 
hyperproliferation, resulting in tumor formation in the skin. Furthermore, these mice 
showed increased dysplastic disease in the cervix (Genther Williams, Disbrow et al. 
2005, Maufort, Williams et al. 2007, Maufort, Shai et al. 2010). E5 has also been 
involved in activation of epidermal growth factor receptor (EGFR) signaling, thereby 
enhancing extracellular signal-regulated kinase (ERK) and mitogen-activated protein 
kinase (MAPK) activity (Straight, Hinkle et al. 1993). In addition, E5 perturbs 
maturation of the endosome (Disbrow, Hanover et al. 2005), resulting in delayed 
EGFR degradation (Suprynowicz, Krawczyk et al. 2010), and E5 expression has also 
been associated with reduced levels of apoptosis (Oh, Kim et al. 2010) and immune 
evasion (Ashrafi, Haghshenas et al. 2005). Recently, E5 has been classified as 
viroporin-a channel-forming viral membrane protein. Thus the function of E5 is 
appears very closely linked to various vesicle trafficking pathways, and its loss from 
the viral genomes has a clearly deleterious effect on the viral life cycle (Wetherill, 
Holmes et al. 2012, Royle, Dobson et al. 2015).  
 
E6 is a small protein of around 150 amino acids, containing four zinc-binding Cys-
X-X-Cys (CXXC) motifs, whereas E7 is a small zinc-binding protein of 100 amino 
acids containing two CXXC motifs. Both E6 and E7 play the role of major 
oncoproteins, and will be discussed in more depth later in this chapter.  
 
The viral capsid proteins L1 and L2 are approximately 500 amino acids long and are 
expressed during late stages of infection.  
All of these genes are coordinately expressed during the viral life cycle during the 
differentiation of the infected epithelium. The roles of these genes during different 
phases of the virus life cycle are described below and are illustrated in Figure 3.  
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Figure 2. Typical HPV genome organization, represented by the HPV-16 
genome, showing the different ORF of the virus genes.   
The HPV genome contains a non-coding upstream regulatory region (URR), also 
called the long control region (LCR), of about 400 to 1,000 bp long.  It harbors an 
origin of replication (ori), a promoter for early genes, four E2 binding sites and at 
least 20 other binding sites for host cell transcription factors, many of which are 
specific for epithelial cells.  The Early region, encodes the viral E1, E2, E4, E5, E6 
and E7 proteins. E1 acts as a helicase and binds to the ori for initiation of viral DNA 
replication. E2 functions as a viral transcription factor, and also regulates the 
expression of the E6 and E7 proteins. E5 is the minor oncoprotein and interacts with 
the EGFR and also suppresses host MHC I/II gene expression. E6 and E7 are the 
major oncoproteins and are essential throughout the viral life cycle and for the 
development of malignancy. The Late region encodes the structural capsid proteins: 
L1 and L2. E4 is also a late protein, and interacts with the host cytoskeleton, 
favoring the release of new viral particles.  
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Different stages of productive viral life cycle 
 
Viral access to epithelium  
HPVs are exclusively intraepithelial pathogens and their productive viral life cycle is 
intimately dependent upon the keratinocyte differentiation program. Infection by 
papillomaviruses requires the virus to access the dividing epithelial basal layer, 
where infection is speculated to occur through micro abrasions in the epithelium 
(Doorbar 2005). It is believed that virus infects basal keratinocytes, which possess a 
stem cell phenotype. The means of virus entry into the basal cells appears to be 
diverse in different HPV types, for example, HPV-31 entry is mediated by a 
caveolin-dependent mechanism (Smith, Campos et al. 2007), while HPV-16 entry is 
mediated by a clathrin- and caveolin-independent pathway (Spoden, Freitag et al. 
2008, Spoden, Kuhling et al. 2013).  
Studies in HR HPVs have shown that the epithelial cells around the squamo-
columnar junction of the cervical transformation zone are more susceptible to HPV 
infection and cancer progression (Grayson, Rhemtula et al. 2002, Herfs, Yamamoto 
et al. 2012). The viral capsid proteins play a major role during infectious entry. The 
virus requires the presence of certain cellular receptors, such as heparin sulphate 
proteoglycans (HSPGs) and α-integrins  (Joyce, Tung et al. 1999, Giroglou, Florin et 
al. 2001, Shafti-Keramat, Handisurya et al. 2003, Dasgupta, Bienkowska-Haba et al. 
2011). Following the interaction of the virions with the host cell receptors, the capsid 
undergoes a conformational change, which leads to exposure of the L2 amino 
terminus, leading to its cleavage by secreted furin (Richards, Lowy et al. 2006). The 
viral particles are then internalised via endocytosis after the attachment (Selinka, 
Giroglou et al. 2002, Bousarghin, Touze et al. 2003, Day, Lowy et al. 2003, Culp and 
Christensen 2004). The internalization step also appears to require the active 
proliferation of the target cells (Broniarczyk, Ring et al. 2018).  After entering the 
cell, the viral particles are transported and processed via the endocytic transport 
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machinery. In the initial steps, the viral capsid begins to disassemble as a result of 
acidification of endocytic compartments (Smith, Campos et al. 2008), this mediates 
the cytosolic exposure of the L2 proteins (DiGiuseppe, Keiffer et al. 2015) and 
allows  L2 to associate with various cellular proteins that are part of endocytic 
sorting pathways, including the sorting nexin family of proteins, components of the 
retromer, and also the ESCRT complex (Bergant Marusic, Ozbun et al. 2012, 
Broniarczyk, Bergant et al. 2014, Pim, Broniarczyk et al. 2015, Popa, Zhang et al. 
2015). Interaction of L2 with SNX17, which is involved in endosomal recycling 
pathways, helps L2 in escaping lysosomal degradation (Kamper, Day et al. 2006, 
Day, Lowy et al. 2008, Smith, Campos et al. 2008, Dabydeen and Meneses 2009). In 
the later steps of endocytic maturation, the L2-DNA complex is separated from L1, 
which is achieved via cyclophilins (Bienkowska-Haba, Williams et al. 2012). Most 
of the L1 protein is degraded in the lysosome (Spoden, Freitag et al. 2008, Buck, 
Day et al. 2013), but a small percentage of it remains associated with the L2/vDNA. 
At the same time, L2 mediates the transport of viral DNA through the trans-Golgi 
network to the host nucleus. Nuclear entry is strictly dependent on mitosis (Sun, 
Frazer et al. 1995, Florin, Becker et al. 2004, Bossis, Roden et al. 2005, Pyeon, 
Pearce et al. 2009, Broniarczyk, Massimi et al. 2015). Following nuclear envelope 
breakdown during mitosis (Aydin, Weber et al. 2014), the L2-DNA complex, plus 
the small amount of residual L1, is localised to PML bodies, where initiation of viral 
transcription is believed to occur (Day, Baker et al. 2004, DiGiuseppe, Bienkowska-
Haba et al. 2017). 
  
Viral establishment and maintenance 
After infection of basal cells, a round of viral DNA replication takes place that 
appears to be independent of the cell cycle, and which amplifies the viral copy-
number to around 50 to 100 copies per cell. After this round of DNA replication, the 
viral genome is established as a stable episome within the cell, and this is mediated 
by expression of the viral replication proteins, E1 and E2 (Wilson, West et al. 2002). 
The E1 protein is the viral origin-binding protein, recognizing and binding the viral 
17 
 
origin of replication (ori), a palindromic motif in the non-coding region of the viral 
genome (Dell, Wilkinson et al. 2003). E2 binding near the ori recruits the E1 protein, 
to the viral origin; this leads to the binding of other cellular proteins necessary for 
DNA replication, including DNA polymerase α-primase and replication protein-A 
(Loo and Melendy 2004). Papillomavirus genome replication is totally dependent 
upon these components of the cellular DNA synthesis machinery. The viral genome 
replication in the basal cells occurs together with the cellular DNA during S-phase 
synchrony. E2 is not only involved in viral DNA replication, but is also involved in 
transcriptional regulation. It can regulate the viral Early promoter, and controls 
expression of the viral oncogenes E6 and E7. It is not yet clear whether E2-mediated 
transcriptional regulation is important in basal epithelial cells, as the nucleosomal 
structure of the viral DNA may not be compatible with efficient activation of the 
Early promoter (Bechtold, Beard et al. 2003). Knockout mutants in the viral genome 
have shown that both E1 and E2 are required for viral genome maintenance in the 
basal layer (Stubenrauch, Lim et al. 1998). The increased proliferation of suprabasal 
epithelial cells is linked to the expression of the viral oncogenes, E6 and E7, in 
cervical lesions caused by HPVs. During the natural course of infection, the activity 
of E6 and E7 causes an expansion of replication competent cells, in order to enhance 
the production of progeny virions. For the replication of viral episomes in the 
suprabasal cells, E6 and E7 play an important role by driving the cells into S phase. 
It is important to note that these events occur in cells that are terminally 
differentiating and would have normally exited the cell cycle (Sherman, Jackman et 
al. 1997). Differentiation is delayed in these cells and cells are maintained in a 
pseudo-S-type state followed by G2/M phase where viral genome amplification 
occurs. The mechanism by which HPVs disrupt the cell cycle control is well-
understood. E7 associates with pRb (retinoblastoma protein) and other pocket protein 
family members (p130, pRB and p107),  leading to the disruption of the association 
between pRb and the E2F transcription factor (Dyson 1998). Additionally, E7 
abolishes the activities of histone deacetylases (Brehm, Nielsen et al. 1999) and the 
cyclin-dependent kinase inhibitors p21 and p27 (Zerfass-Thome, Zwerschke et al. 
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1996, Funk, Waga et al. 1997, Jones, Alani et al. 1997), which helps to promote cell 
cycle progression and transcription. In high-risk HPV type infections, a key role of 
E6 is its association with p53, which mediates p53 ubiquitination and degradation 
(Scheffner, Werness et al. 1990, Scheffner, Munger et al. 1991). The reduction of 
p53 levels in the basal layer contributes to perturbation of p53 transcriptional 
activity, which subsequently reduces levels of the Notch receptor on the cell surface. 
Since Notch signaling plays a critical role in regulating basal cell density and 
commitment to differentiation, HPV-induced reduction in Notch activity thereby 
provides the cells with a competitive advantage over its neighboring uninfected cells, 
thus favoring expansion of infected basal cells (Kranjec and Doorbar 2016). 
Degradation of p53 also protects cells from growth arrest or apoptosis in response to 
the E7-mediated cell-cycle entry in the mid-epithelial layers. 
Viral packaging and release 
Packaging of virus genome into infectious particles is the final stage of the 
productive viral life cycle. After the onset of genome amplification, the capsid 
proteins L1 and L2 start to accumulate in the cell (Florin, Sapp et al. 2002) and the 
assembly of infectious virions in the upper epithelial layers also requires the activity 
of  E2 (Day, Roden et al. 1998). It is thought that recruitment of the L1 protein to 
PML bodies by L2 enhances capsid protein packaging ability (Zhou, Stenzel et al. 
1993, Stauffer, Raj et al. 1998, Florin, Sapp et al. 2002), and some HPV L2 proteins 
can associate directly with the nascent viral DNA (Fay, Yutzy et al. 2004). The virus, 
after its escape from the epithelial cells, must survive in the harsh extracellular 
environment, and this is thought to be mediated by the E1^E4 protein. The amyloid 
fibres that are formed with the help of transglutaminase 3, further help to disrupt the 
normal cornified envelope of the upper epithelial cells, thus supporting the dispersal 
of new virions (Brown, Kitchin et al. 2006, McIntosh, Martin et al. 2008). 
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Figure 3. Productive life cycle of HPV and HPV-induced malignancy.  
Human papillomaviruses infect the basal cells through micro-ruptures in the 
epithelium.  Uninfected epithelium is shown on the left in green and HPV-infected 
epithelium is shown in the middle.  The viral genomes stay in the nucleus as low 
copy-number episomes, and expression of the viral early genes begins. After the 
division of basal cells, some newly formed cells move up in the epithelium and start 
to terminally differentiate. In these differentiated HPV-positive cells the productive 
phase of the viral life cycle takes place. Activation of E6 and E7 allows viral genome 
amplification in cells that normally would have exited the cell cycle. In the later 
phase, the L1 and L2 capsid proteins are synthesized and the viral genome is 
encapsidated; ultimately mature virions are released from the epithelium. On the 
right side, the HPV-induced malignant transformation of epithelium, often as a 
consequence of a persistent infection is shown. At this stage, elevated levels of E6 
and E7 oncoproteins are observed.  
 
 
20 
 
The HPV Oncoproteins 
 
Cervical cancer does not develop in every individual who is infected with high-risk 
HPV types. When the immune system of an individual fails to clear the HPV 
infection, it can develop into a malignancy with the viral DNA frequently integrated 
into the host genome, resulting in the loss of E1, E2, E4 and E5 together with 
uncontrolled expression of the E6 and E7 oncoproteins  (Moody and Laimins 2010, 
Doorbar, Egawa et al. 2015). So far many interacting partners of the E6 and E7 
oncoproteins have been identified, which contribute in different ways to both the 
virus life cycle and malignant progression.  
HPV E7 
E7 is a small polypeptide of approximately 100 amino acids, exists as a dimer, 
localized in the cytoplasm (Smotkin and Wettstein 1987, Huh, Zhou et al. 2007, 
Nguyen, Eichwald et al. 2007, Ressler, Scheiden et al. 2007), and can also be found 
in the nucleus (Sato, Watanabe et al. 1989, Greenfield, Nickerson et al. 1991). E7 
was the first HPV protein to be defined as an oncoprotein that could induce cell 
transformation (Kanda, Furuno et al. 1988, Phelps, Yee et al. 1988, Vousden, 
Doniger et al. 1988, Watanabe, Kanda et al. 1989). E7 contains three conserved 
regions (CRs); CR1 and CR2, found at the N-terminus, and the more C-teminally 
located CR3, as shown in Figure 4. The CR2 domain contains a conserved Leu-X-
Cys-X-Glu (LXCXE) motif, through which it binds the Pocket protein family, and 
Casein Kinase II (CKII)  phosphorylates the HPV-16 E7 at amino acid residues 
Serine-31 (S31) and S32, which reside in close proximity to the LXCXE motif 
(Firzlaff, Galloway et al. 1989, Barbosa, Edmonds et al. 1990). E7 is also 
phosphorylated at S71 by an unknown kinase, during the S phase of the cell cycle 
(Massimi and Banks 2000). The CR3 domain of E7 contains two CXXC motifs, 
which form a zinc-binding domain that is required for E7 dimerization (Barbosa, 
Lowy et al. 1989, McIntyre, Frattini et al. 1993, Clemens, Brent et al. 1995).  
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E7 is a multi-functional protein, able to interact with a very large number of cellular 
proteins, in many cases disturbing their normal functions. The E3 ubiquitin ligase 
complex, SCF (Skp-Cullin-F-box) is an interacting partner of E7 for its own 
ubiquitination and proteolysis (Oh, Kalinina et al. 2004), while the N-terminus of E7 
associates with neddylated cullin 2 in order to induce the ubiquitination and 
degradation of the retinoblastoma tumour suppressor (pRB),  (Huh, Zhou et al. 
2007). In addition to pRB, E7 binds to its related pocket proteins, p107 and p130 
(Lee, Russo et al. 1998, Gonzalez, Stremlau et al. 2001, Helt and Galloway 2001) 
through the LXCXE motif. These proteins have been shown to be involved in 
regulating cellular proliferation, differentiation and apoptosis (Dyson, Howley et al. 
1989, Munger, Werness et al. 1989, Dyson, Guida et al. 1992, Dyson 1998). High-
risk HPV E7 proteins also contribute to cell cycle dysregulation through multiple 
other mechanisms by associating with cyclins, and cyclin-dependent kinase 
inhibitors (CKIs) and regulating their activity. Cyclins E and A, both of which are 
under the control of E2F, are found overexpressed in E7 expressing cells (Zerfass, 
Levy et al. 1995). HPV-16 E7 also interacts with and abrogates the growth-inhibitory 
activities of the CKIs p21
Cip1
 (Funk, Waga et al. 1997, Jones, Alani et al. 1997) and 
p27KIP1 (Zerfass-Thome, Zwerschke et al. 1996). The ability of the HPV E7 
oncoprotein to overcome p21
Cip1
-mediated inhibition of cdk2 activity during 
keratinocyte differentiation contributes to the ability of E7 to allow cellular DNA 
synthesis in differentiated keratinocytes. (Favre, Breitburd et al. 1977, Jones, Alani 
et al. 1997, Swindle and Engler 1998, Noya, Chien et al. 2001, He, Staples et al. 
2003). Both p21 and p27 have also been implicated in TGF-β-mediated growth 
inhibition (Elbendary, Berchuck et al. 1994, Polyak, Kato et al. 1994, Datto, Li et al. 
1995) and thus inactivation of CKIs by HPV E7 may contribute to TGF-β-mediated 
growth arrest.  
Additionally, E7 also interacts with class I histone deacetylases (HDACs) (Brehm, 
Nielsen et al. 1999, Longworth and Laimins 2004). Studies in HPV-31 have reported 
that the interaction between E7 and HDACs results in increased levels of E2F2-
mediated transcription and replication in differentiating cells (Longworth, Wilson et 
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al. 2005), potentially favoring S-phase progression. E7 can also associate with 
histone acetyl transferases (HATs), such as p300, pCAF, and SRC1 (Huang and 
McCance 2002, Avvakumov, Torchia et al. 2003, Bernat, Avvakumov et al. 2003, 
Baldwin, Huh et al. 2006), and has been involved in abrogating SRC1-associated 
HAT activity (Baldwin, Huh et al. 2006).  
Both high-risk and low-risk HPV E7 have the ability to interact with the p600 
retinoblastoma protein-associated factor (Huh, DeMasi et al. 2005), which is 
identified as a microtubule-associated protein (MAP) (Shim, Wang et al. 2008) 
having ubiquitin ligase activity (Tasaki, Mulder et al. 2005). Therefore, the 
association of HPV-16 E7 with p600 through the CR1 domain may deregulate 
anoikis and protect detached cells from apoptosis, thus contributing to viral 
transformation (Gulliver, Herber et al. 1997, DeMasi, Huh et al. 2005, Huh, DeMasi 
et al. 2005). Recent studies have also identified a novel target of HPV E7, PTPN14, a 
tyrosine phosphatase and a potential tumour suppressor protein (White, Munger et al. 
2016, Szalmas, Tomaic et al. 2017). This protein is subjected to E7-induced, 
proteasome-mediated degradation through the action of p600 ubiquitin ligase. Over-
expression studies showed that PTPN14 decreases the ability of HPV-16 E7 to 
cooperate with activated EJ-ras in primary cell transformation assays (Szalmas, 
Tomaic et al. 2017). E7 also associates with centrosomal components, such as Cdk2 
and γ-tubulin (Nguyen, Eichwald et al. 2007). The increased Cdk2 kinase activity 
and interaction of E7 with the centrosome regulator γ-tubulin is associated with 
centrosome over-duplication and abnormalities  which contributes directly towards 
genome instability and tumour progression (Duensing, Liu et al. 2006). In recent 
studies, E7 has been shown to play an important role in directly activating the DNA 
damage response pathway in differentiated human keratinocyte cells and it has been 
shown that ATM signaling is required for genome amplification (Moody and 
Laimins 2009, Banerjee, Wang et al. 2011). This is discussed in detail later in the 
DNA damage response section (Page no. 59-63).  Some o the different interaction 
partners and associated activities of E7 oncoprotein are shown in Figure 5.  
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Figure 4.  Typical structure of the E7 oncoprotein.  
Schematic diagram showing E7 domains: CR1 and CR2 core domain in its N-
terminal part and a C-terminal CR3 or Zinc finger domain. The LXCXE motif 
embedded within the CR2 domain is responsible for interaction with pRB and other 
pocket proteins; also it contains the region for CKII phosphorylation at S32 and S34 
residues.  
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Figure 5. Some of the interacting partners of high-risk HPV E7 and their 
associated activities. 
The E7 association with pRB leads to the proteasome-mediated degradation of pRB 
and promote S-phase competence in differentiated epithelial cells. Interaction of E7 
with p21 and p27 helps in promoting cell proliferation, while the interaction between 
E7 and HDACs results in increased levels of E2F2-mediated transcription and 
replication in differentiating cells. Interaction of E7 with p600 potentially affects 
anoikis, and also targets PTPN14 for degradation. E7 negatively regulates the growth 
inhibitory activity of TGF-β.  E7 directly interacts with and activates ATM signaling, 
thereby regulating genome replication, while E7's association with γ-tubulin is 
associated with centrosome overduplication and abnormalities.  
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HPV E6  
HPV E6 is approximately 18kDa in size, and is composed of two 70-residue zinc 
finger domains (characterized by the presence of zinc-binding CXXC motifs) as 
shown in Figure 6 (Nomine, Masson et al. 2006). HPV-16 E6 has four mRNA 
isoforms (full-length (FL)E6, E6*I, E6*II and E6*X) (Tang, Tao et al. 2006), while 
two mRNA isoforms of E6 are seen in HPV-18 infection (FLE6, E6*I ) (Pim, 
Massimi et al. 1997) and it has been suggested that the E6*I isoform plays an 
important role in antagonising FLE6 function (Pim, Massimi et al. 1997). HPV-18 
E6 is predominantly localized within the membrane fraction, followed by the nucleus 
and there is a lesser content in the cytoplasm (Kranjec, Tomaic et al. 2016). The 
NMR and crystallographic analysis of E6 structure shows only 10% sequence 
identity between the E6N and E6C domains. Both N and C domains of E6 are 
connected by a linker.  The E6C harbors a PDZ-Binding Motif at extream carboxy-
terminus in high-risk mucosal HPVs and distinct sequences in other types.  (Nomine, 
Charbonnier et al. 2003, Suarez and Trave 2018). Structural analysis of E6 showed 
that it is a conserved scaffold with variable interaction surfaces involved in targeting 
p53 for degradation. E6 can also interact with the E6AP E3 ubiquitin ligase through 
the E6-binding site present within E6AP, comprising the “LxxLL” motif (Schwarz, 
Freese et al. 1985, Scheffner, Huibregtse et al. 1993, Talis, Huibregtse et al. 1998, 
Martinez-Zapien, Ruiz et al. 2016). The E6 protein can self-associate through its N-
terminal domain to form a dimer and this has important consequence for the 
stochiometry of how different interactions take place (shown in Figure 6). The 
structural studies show that the homodimer interface mutations that disrupt E6 
dimerization can abrogate E6-mediated p53 degradation (Zanier, ould M'hamed ould 
Sidi et al. 2012, Martinez-Zapien, Ruiz et al. 2016).  Unfortunately the structure of 
E6 PBM in E6-E6AP-p53 complex was not detectable.  
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Figure 6. Typical structure of the E6 oncoprotein.  
A) Schematic diagram of E6 structure, showing the PBM (PDZ-binding motif) and 
the phospho-consensus site for PKA and AKT kinases at the C-terminus. 
Phosphorylation at the PBM confers its association with 14-3-3 family proteins. E6, 
through the PBM, associates with PDZ domain-containing proteins including hDlg1, 
MAGI and Scribble. The C-terminal zinc finger interacts with Bak and p300/CBP 
and targets them for degradation. The two zinc finger motifs create a pocket for the 
p53 and E6AP interaction, through which E6 targets p53 for proteasomal 
degradation. B) The schematic model showing a speculative model of E6 dimer, 
associating with multiple substrates. The E6 PBM is believed to protrude in an 
unstructured conformation away from the central core of E6 protein. It is speculated 
that through such complex, E6 can target more than one PDZ domain-containing 
substrate and also p53 simultaneously.   
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Some of the key functions of E6 
 
1. Degradation of p53 tumour suppressor  
As discussed earlier, HR α-HPV E6 promotes p53 degradation through its 
association with the cellular E3 ubiquitin ligase, E6AP, preventing p53-mediated cell 
cycle arrest and apoptosis, and ensuring viral replication. Structural analysis of the 
E6-E6AP complex reveals that the alpha helix of E6 connects both the N- and C-
terminal zinc binding domains to form a deep pocket which could accommodate an 
LXXLL peptide (Vande Pol and Klingelhutz 2013, Martinez-Zapien, Ruiz et al. 
2016). This interaction is thought to be of great importance for E6 stability (Tomaic, 
Pim et al. 2009). The formation of the complex between E6-E6AP-p53 requires 
homodimerization of E6 at its N-terminus (Zanier, ould M'hamed ould Sidi et al. 
2012), and the ability of E6 to target p53 for degradation is crucially dependant on 
the formation of this complex as described and illustrated earlier in figure 6B. E6AP 
transfers ubiquitin from its C-terminal thioester cysteine bond to p53 which is then 
targeted for degradation (Scheffner, Huibregtse et al. 1993).  Ablation of E6AP 
rescues p53 levels, both as a result of E6 destabilization and the loss of ubiquitin 
ligase activity   (Hengstermann, D'Silva M et al. 2005, Tomaic, Pim et al. 2009). 
Interestingly, HPV E6 can also induce auto-ubiquitination of E6AP. The half-life of 
E6AP is shorter in HPV-positive cervical cancer cells than in HPV-negative cervical 
cancer cells and silencing of E6 can increase the levels of E6AP protein. The 
degradation of E6AP by E6 requires: i) the binding of E6 to E6AP ii) the catalytic 
activity of E6AP and iii) the 26S proteasome. Importantly, a study by Kao el al. 
demonstrates that, an HPV-16E6 SAT8–10 mutant which is unable to degrade p53, 
but can target E6AP for degradation, can still immortalize human mammary 
epithelial cells. This suggests that interaction with E6AP per se is an important factor 
for the transforming activity of the high-risk HPV E6 proteins (Kao, Beaudenon et 
al. 2000). Indeed, studies in animal models show a critical requirement of E6AP for 
E6’s full transforming ability. However, it remains to be determined how much is 
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due to the effect of E6AP on E6 stability and how much related to E6AP’s enzymatic 
activity, which is utilized by E6 to degrade its substrates.  
 
2. Degradation-independent p53 inactivation 
HR α-HPV E6 indirectly regulates the functions of p53 by altering the activation of 
p53-modifying enzymes. In response to DNA damage, ATR is activated, which 
further phosphorylates p53, thus blocking MDM2-mediated degradation of p53 
(Tibbetts, Brumbaugh et al. 1999). Recent studies suggest that E6 perturbs p53-
dependent transcriptional transactivation after the onset of the DNA damage 
response, by delaying ATR activation (Wallace, Robinson et al. 2012, White, 
Walther et al. 2014). p300, a histone acetyltransferase, acetylates p53, thus 
increasing its binding specificity and upregulating the transcription of its target genes 
(Gu and Roeder 1997). E6 interacts with CBP/p300 through its C terminal CXXC 
motif and this interaction is thought to inhibit p53 transcriptional transactivation and 
to inhibit transactivation of the p300-induced, pro-apoptotic nuclear NF-κB. 
Moreover, E6-interacting regions of p300 are important for the ability of E6 to 
inhibit p53-dependent chromatin transcription, and this correlates with inhibition of 
acetylation on p53 and nucleosomal core histones, thus, altering recruitment of p53 
and p300 to chromatin. (Patel, Huang et al. 1999, Zimmermann, Degenkolbe et al. 
1999, Thomas and Chiang 2005). E6 also targets other histone acetyltransferases, 
including hADA3 and TIP60 that also affect p53 transcriptional transactivation. E6 
inhibits the activity of transcriptional coactivator, hADA3 by proteosome-mediated 
degradation which is an alternative mechanism for inhibiting p53 transcriptional 
transactivation (Kumar, Zhao et al. 2002, Sekaric, Shamanin et al. 2007, Shamanin, 
Sekaric et al. 2008, Chand, John et al. 2014). Similarly, E6 modulates the functions 
of the TIP60 histone acetyltransferase, wherein, TIP60 is destabilized and 
subsequently p53-dependent transcription of pro-apoptotic genes is perturbed (Jha, 
Vande Pol et al. 2010).  
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The region of p53-E6 association appears to be different between the HR and the LR 
HPV types. However, studies show that p53-E6 binding is necessary, but not 
sufficient for the ability of E6 to target p53 for degradation (Crook, Tidy et al. 1991). 
The low-risk E6 binds to the C-terminal region of p53, whilst high-risk E6 has two 
distinct binding sites within p53, of which only one is responsible for p53 
degradation. (Li and Coffino 1996). Studies on HPV 11 show that low-risk E6 can 
interact with p53 through E6AP in vivo but not in vitro, and this interaction does not 
mediate p53 degradation, unlike high risk E6s (Brimer, Lyons et al. 2007, White, 
Kramer et al. 2012, Thomas, Tomaic et al. 2013). However, under certain 
circumstances, the low risk HPV-11 E6 oncoprotein has been reported to degrade 
p53 (Storey, Thomas et al. 1998).Furthermore, low risk HPV E6 proteins can inhibit 
p53 transcriptional transactivation (Kiyono, Hiraiwa et al. 1994) by repressing the 
p53 transcription of TATA box-containing promoters (Lechner, Mack et al. 1992), 
and also by maintaining p53 in the cytoplasm (Sun, Zhang et al. 2008).  
 
3. Telomerase activation, transformation and immortalization 
Another important function of E6 is to activate telomerase by a mechanism 
independent of p53 degradation, and this step is crucial for immortalization 
(Klingelhutz, Barber et al. 1994, Klingelhutz, Foster et al. 1996). E6 is involved in 
increasing hTERT activity, either through direct interaction or through interaction 
with Myc, thereby up-regulating E-box-dependent transcription of hTERT for 
immortalization (Oh, Kyo et al. 2001). E6 can cooperate with NFX1-123 to increase 
hTERT activity (Vliet-Gregg, Hamilton et al. 2013) and down-regulate the hTERT 
repressors, such as NFX1-91 (Gewin, Myers et al. 2004), p300 (James, Lee et al. 
2006) and Maz (Xu, Katzenellenbogen et al. 2013). (Klingelhutz, Barber et al. 1994, 
Klingelhutz, Foster et al. 1996). The advantage of activation of telomerase by HPV 
is not entirely clear. One of the possible advantages could be manipulation of DNA 
damage pathway for its own replication, as telomeres are associated with a variety of 
DDR proteins (Wallace and Galloway 2014). 
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4. Abrogation of apoptotic signaling  
One of the peculiar characteristics of E6 is to interact with cellular pro- and anti-
apoptotic proteins to prevent the activation of growth inhibitory pathways 
(Ishiwatari, Hayasaka et al. 1994, Nakagawa, Watanabe et al. 1995). E6 proteins can 
inhibit apoptosis in both p53-dependent and p53-independent manners. Both high 
risk and low risk E6s can interact and degrade the pro-apoptotic protein Bak through 
cooperation with the E6AP ubiquitin ligase (Thomas and Banks 1998, Thomas and 
Banks 1999). This activity is believed to be important for many HPV types, as it 
appears that cutaneous HPV types can also inhibit apoptosis in response to UV-
induced DNA damage in a manner which is dependent upon Bak degradation  
(Jackson, Harwood et al. 2000, Jackson and Storey 2000). E6 also modulates the 
functions of anti-apoptotic Bcl-2 and pro-apoptotic Bax, thereby suppressing 
apoptosis in human foreskin keratinocytes during serum-calcium switch-induced 
differentiation. In the presence of E6, the expression levels of Bcl-2 are increased, 
whereas Bax levels are decreased, thus preventing apoptosis (Alfandari, Shnitman 
Magal et al. 1999). 
Additionally, it has been shown that the RNAi-targeted inhibition of E6 expression 
in cervical cancer cells leads to the transcriptional stimulation of the PUMA 
promoter, in a p53-dependent manner and this is linked to the PUMA-dependent 
activation and translocation of Bax to the mitochondrial membrane, subsequent 
release of cytochrome c into the cytosol, and activation of caspase-3. Moreover, 
inhibition of Bax expression by RNAi efficiently reverts the apoptotic phenotype, 
which results from inhibition of E6 expression. Thus, interference with the 
p53/PUMA/Bax cascade is crucial for the antiapoptotic function of the viral E6 
oncogene in HPV-positive cancer cells (Vogt, Butz et al. 2006). E6 also manipulates 
Fas and caspase signaling by decreasing the stability and activity of Fas-associated 
death domain (FADD) and procaspase 8 in the cells. The full length E6 can directly 
interact with FADD and target it for degradation which prevents transmission of 
apoptotic signals via the Fas pathway (Filippova, Parkhurst et al. 2004, Filippova, 
Johnson et al. 2007). E6 also downregulates the expression of the pro-apoptotic 
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protein transforming growth factor-β2 (TGF-β2) and thus downregulates TGF-β2 
responsive genes (Nees, Geoghegan et al. 2000). 
 
5. Attenuation of cell-signaling 
The E6 protein targets many major cellular signaling pathways, including the NF-
κB-TNF, mammalian target of rapamycin (mTOR)-AKT, MAPK, and Notch 
pathways. The association of HPV E6 with TNF R1 interferes with the formation of 
the death-inducing signaling complex. It abrogates transduction of proapoptotic 
signals, resulting in reduced Caspase 3 and caspase 8 activation in E6-expressing 
cells (Filippova, Song et al. 2002). E6 is involved in activation of mTOR-AKT, 
which are serine/threonine kinases in the PI3K pathway (Spangle and Munger 2010) 
and E6 achieves this by degradation of the mTOR inhibitor, tuberous sclerosis 
complex 2 (TSC2) through E6AP (Lu, Hu et al. 2004, Zheng, Ding et al. 2008). This 
leads to activation of NF-κB (Basseres and Baldwin 2006) and resistance to TNF 
receptor-induced apoptosis (Dolcet, Llobet et al. 2005).  
The expression of HPV-16 E6, prevents the early fate commitment of human 
keratinocytes towards differentiation and confers a strong growth advantage to 
human keratinocytes. When E6 is expressed either alone or with E7, it induces 
combined inactivation of p53 and Notch1, thus promoting keratinocyte proliferation 
at high cell densities (Kranjec, Holleywood et al. 2017). Studies in cutaneous 
papillomavirus E6 oncoproteins show that, their association with MAML1, a co-
activator and effector of Notch-induced transcription, represses Notch signaling, 
thereby delaying keratinocyte differentiation (Brimer, Lyons et al. 2012). 
Additionally, studies have shown that the E6 mediated activation of MAPK signaling 
cooperates with deregulated Notch1 signaling to recreate features of HPV-driven 
invasive cervical carcinomas (Chakrabarti, Veeraraghavalu et al. 2004). Recent study 
shows that Foxhead box M1 (FOXM1) expression is upregulated by E6 in HPV-
positive cervical, oral, and lung cancer cells and this is linked to increased 
invasiveness and stemness through activating Wnt/β-catenin signaling pathway 
(Chen, Cheng et al. 2014). 
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Figure 7. Some of the high-risk HPV E6 interacting partners and associated 
activities.  
E6 interacts with with c-Myc and NFX-1 to induce the hTERT promoter, 
contributing toward cellular immortalization.  E6 hijacks E6AP ubiquitin ligase, 
which is essential for E6 stability and for targeting p53 for proteasome-mediated 
degradation, thus resulting in genome instability and inhibiting growth arrest. The 
E6, through its PBM, interacts with a large number of cellular PDZ domain-
containing substrates, such as Dlg and Scribble, which are cell polarity proteins and 
their interaction is believed to affect malignant progression. On the other hand, 
phosphorylation of the PBM confers its interaction with 14-3-3 proteins, which are 
important cell cycle-regulatory proteins.  The interaction of E6 with MAGI-1 
regulates cell-cell contact, proliferation, and apoptosis. E6 can stimulate mTORC1 
signaling and can inhibit interferon signaling through its interaction with AKT. E6 
associates with BAK to promote its degradation, thus preventing the induction of 
apoptosis. E6 regulates NF B functions and induces Foxhead box M1 (FOXM1)-
mediated tumor progression. E6 also regulates the Wnt/β-catenin signaling, thereby 
affecting cell proliferation and differentiation.  E6 affects the expression of miR 218 
and miR23b, and in addition, its interaction with CDK2 can affect cell cycle 
regulation. 
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The E6 PDZ binding motif (PBM): Molecular signature of cancer-causing HPV 
types  
 
The high- and low-risk HPV types exhibit major structural differences within the E6 
C-terminal region. The presence of a PDZ (PSD-95/DLG/ZO-1) binding motif 
(PBM) (Songyang, Fanning et al. 1997) in high-risk HPV types correlates with their 
oncogenic potential and this motif is absent in the majority of the low- risk HPV 
types (Kiyono, Hiraiwa et al. 1997, Lee, Weiss et al. 1997, Songyang, Fanning et al. 
1997). The high-risk HPV E6 oncoproteins, possess the canonical X-S/T-X-_COOH 
PBM sequence, although different HPV E6 types display significant degrees of 
variation within this region, as can be seen in Figure 8.  PDZ domains are 80 to 100 
amino acids in length and facilitate protein-protein interactions via ligands 
containing a PBM. Multiple copies of these PDZ domains are often found in proteins 
that are involved in multiple protein interactions, often acting as hubs for a variety of 
different signaling pathways (Fanning and Anderson 1999). Proteins with PDZ 
domains play crucial roles in regulating cell migration and invasion, in maintaining 
cell polarity and cell-cell contact, and in cell signaling (Jacob, Opper et al. 1987, 
Woods and Bryant 1991, Woods, Hough et al. 1996, Bilder, Li et al. 2000, Bilder 
2004, Subbaiah, Kranjec et al. 2011). Several studies have shown that many of these 
proteins play important roles as potential tumour suppressors (Javier 2008).  E6 
interacts with multiple PDZ-containing proteins and targets many of them, such as  
hDlg (Kiyono, Hiraiwa et al. 1997, Lee, Weiss et al. 1997), the Scribble (Nakagawa 
and Huibregtse 2000) and MAGI proteins (Glaunsinger, Lee et al. 2000) for 
proteasome-dependent degradation.  
 
Regulation of cell polarity and cell adhesion  
 
The first PDZ protein that was identified as a target of HR HPV E6 is Discs large 
(hDlg) (Kiyono, Hiraiwa et al. 1997, Lee, Weiss et al. 1997). hDlg is a member of 
the membrane-associated guanylate kinase (MAGUK) family (Gonzalez-Mariscal, 
34 
 
Betanzos et al. 2000), which are found at junctions between epithelial cells, where 
they maintain the integrity of the cell junctions, the localisation of basolateral 
membrane proteins and apico-basal cell polarity (Woods and Bryant 1991, Woods 
and Bryant 1993, Woods, Hough et al. 1996). They also act as scaffold proteins, and 
are thus involved in signal transduction from the plasma membrane to the 
downstream regulators of the cell polarity pathway and control cell proliferation 
(Anderson 1996). Mislocalisation or even loss of expression of the cell junctional 
PDZ protein complexes often results in loss of cell polarity and can contribute to 
carcinogenesis (Gateff and Schneiderman 1974, Mechler, McGinnis et al. 1985, 
Bilder, Li et al. 2000). 
 
E6 targets hDlg for degradation, thus contributing to a loss of cell polarity, 
morphological transformation and proliferation. However, the ability of E6 to target 
hDlg can be influenced both by its phosphorylation status and also its location 
(Matsumine, Ogai et al. 1996, Gaudet, Branton et al. 2000, Narayan, Massimi et al. 
2009).  Studies have demonstrated that the interaction of HR HPV types with hDlg 
protein is well conserved (Gardiol, Kuhne et al. 1999, Pim, Thomas et al. 2000).  
  
 Scribble (hScrib) belongs to cell polarity complex and is a member of the LAP 
(leucine-rich PDZ domain) family of proteins; it contains 4 PDZ domains and a 
leucine-rich region which is essential for its basolateral localisation  (Bryant and 
Huwe 2000, Santoni, Pontarotti et al. 2002, Legouis, Jaulin-Bastard et al. 2003). 
Loss of hScrib expression results in changes of cell shape, loss of monolayer 
organisation and loss of cell-cell junctions (Bilder, Li et al. 2000, Bilder and 
Perrimon 2000, Zhan, Rosenberg et al. 2008).  E6 degrades hScrib through the 
E6AP-ubiquitin ligase (Nakagawa and Huibregtse 2000, Thomas, Massimi et al. 
2005), and HPV-16 E6's interaction with hScrib is more effective than HPV-18 E6's 
(Thomas, Massimi et al. 2005). The reason behind this is a minor difference in the 
amino acid sequence of the PBM between different E6 oncoproteins. Indeed, it has 
been shown that swapping the last amino acid L/V of HPV-16 and -18 E6, 
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respectively, reverses the preference for hDlg or hScrib proteins  (Thomas, Massimi 
et al. 2005). 
 
Membrane-associated guanylate kinase (MAGI-1) is present at tight junctions, and is 
involved in regulating cell proliferation, apoptosis and cell signaling. MAGI-1 was 
originally found co-localised with one of the important components of the epithelial 
tight junctions, zonula occludens-1 (ZO-1) (Dobrosotskaya, Guy et al. 1997). The 
PDZ domain 1 of MAGI-1 protein is recognized by HPV E6 (Glaunsinger, Lee et al. 
2000), and E6 then targets it for degradation, thus leading to the disruption of tight 
junctions (Kranjec and Banks 2011, Kranjec, Massimi et al. 2014). Restoration of 
MAGI-1 expression in HPV-positive cell lines allows the tight junction proteins ZO-
1 and PAR-3 to localize at the cell-cell contact area (Kranjec, Massimi et al. 2014).  
In addition to MAGI-1, the related proteins MAGI-2 and MAGI-3 are also targeted 
by HR HPV E6 for degradation (Thomas, Laura et al. 2002).  
 
 Recent studies highlight novel function of high-risk HPV E6 oncoproteins, directly 
regulating endocytic transport pathways. This activity is carried out through 
interaction of the E6 PBM with endocytic cargo sorting machinery, via sorting nexin 
27 (SNX27). This interaction directly impacts upon rates of cargo recycling, and as a 
consequence of this, HPV-transformed cells show high levels of glucose uptake 
(Ganti, Massimi et al. 2016). This is one example of the E6-PDZ interactions that do 
not result in degradation of the PDZ domain-containing target protein, rather in the 
modulation of its function.  
 
Importance of the E6 PBM 
 
Numerous studies have shown an important role for the E6 PBM. In the viral life 
cycle, it is essential for episomal maintenance and genome amplification during a 
productive viral infection (Brimer and Vande Pol 2014). An intact E6 PBM is crucial 
for maintaining the viral copy number in undifferentiated cells (Lee and Laimins 
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2004, Delury, Marsh et al. 2013). It has also been reported to play an important role 
in the ability of E6 to induce cell transformation in certain cell types, and to play a 
role in the induction of epithelial to mesenchymal transition (Spanos, Geiger et al. 
2008). Studies on HPV-18 genomes in HFK cells have shown that cells which harbor 
E6 ΔPBM genomes, proliferate somewhat more slowly than the cells containing wild 
type genomes.  
 
Other studies in HFKs showed that the PBM of E6 is essential for  induction of 
epithelial hyperplasia in raft cultures, and also that it contributes to the maintenance 
of viral episomes (Lee and Laimins 2004, Delury, Marsh et al. 2013, Choi, Lee et al. 
2014). Moreover, the PBM has been shown to play essential roles, not only in 
genome maintenance, but also in creating a favorable environment for viral 
replication; as extended culturing/passaging of cells resulted in loss of E6 ΔPBM 
genomes (Nicolaides, Davy et al. 2011). A number of studies in Normal Immortal 
keratinocytes (NIKS) harboring HPV-16 genomes lacking E6 PBM also showed 
defects in the viral life cycle. However, in this particular case, it was potentially due 
to the loss of E6-PDZ interactions and to reduced levels of E6 protein expression 
(Nicolaides, Davy et al. 2011). However, this does not appear to be as a result of 
E6/PDZ interaction, since loss of hScrib results in a decrease in the translation of the 
E6, indicating that there are yet unknown signaling pathways downstream of hScrib 
that directly impact upon protein translation (Kranjec, Tomaic et al. 2016).       
In animal models of skin and cervical cancer, the E6 PBM also appears to play a 
major role in the induction of epithelial hyperplasia and acts in cooperation with E7 
for the induction of malignancy (Nguyen, Nguyen et al. 2003, Shai, Brake et al. 
2007). However, which of the PDZ substrates are involved in regulating these 
activities of the E6 PBM is still largely unknown. 
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Phospho-regulation of E6  
 
E6 also has a phospho-acceptor site embedded within its PBM and thus E6 can 
potentially be subject to post-translational modification by phosphorylation. Post-
translational modification plays a major role in regulating E6 function. As noted 
above, E6/Dlg recognition can be modulated by Cdk phosphorylation of Dlg 
(Narayan, Massimi et al. 2009, Boon and Banks 2013). However, a more specific 
mode of regulation is provided by phosphorylation of E6 within the PBM. Central to 
the consensus PBM is a S/T at the -2 position in all the high-risk HPV E6 
oncoproteins. This can often be phosphorylated either by PKA or AKT kinases. The 
net result thereby is inhibition of PDZ recognition. This phenomenon is generally 
recognized as effective means of regulating PBM/PDZ interactions, since the 
phosphorylation of Threonine within the PBM is incompatible with PDZ domain 
recognition (Kuhne, Gardiol et al. 2000). The molecular basis for this is well 
understood and reported for many PBM-PDZ ligand combinations. Many studies 
demonstrate that the presence of phospho group is incompatible with fitting into the 
limited space of the PDZ domain-PBM binding pocket.   
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Figure 8. Sequences of E6 PBMs. 
A representative series of different high-risk HPV types shows the presence of 
conserved PBM sequence (x-T/S-x) at the C-terminus (Shown in green). This motif 
is absent in low risk types. Also shown is the sequence upstream of phospho-
acceptor site. This sequence plays important role in E6-substrate selection.   
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14-3-3: important cell cycle regulatory proteins  
 
14-3-3 proteins are highly acidic proteins, with molecular weights of 25 to 33 kDa 
(Jones, Ley et al. 1995) and they are abundantly present in cells. There are seven 
isoforms of 14-3-3: α/β, γ, ε, ζ/δ, η, τ/θ and σ (Mackintosh 2004), and they exist as 
homo- or hetero-dimers with other 14-3-3 isoforms (Jones, Ley et al. 1995), and 
expression pattern of 14-3-3 isoforms differs in different tissue types (Yaffe, 
Rittinger et al. 1997, Kilani, Medina et al. 2008). The specificity of 14-3-3 function 
is conferred by dimerization, and only a certain combinations of 14-3-3 isoforms 
form dimers. The 14-3-3 proteins are phospho-threonine/serine binding proteins 
(Muslin, Tanner et al. 1996) and they bind to target proteins with specific 
phosphothreonine and phosphoserine motifs and alter their intercellular localization 
and activity (Muslin, Tanner et al. 1996). These proteins regulate many different 
cellular processes, as listed in Table 1, including cell cycle progression, intracellular 
protein trafficking, apoptosis, DNA damage response, DNA replication, and 
transcriptional regulation. The 14-3-3ε, γ, and ζ isoforms have been shown to 
activate Raf, PI3K, and MSK1/2 for regulation of the ERK signaling pathway in 
variety of cell types (Lin, Morrison et al. 2009, Neal and Yu 2010). Overexpression 
of 14-3-3ζ has been implicated in promoting cancer cell proliferation, whereas the 
downregulation of 14-3-3ζ inhibits cell proliferation by inducing the mitochondria-
dependent apoptosis pathway (Chatterjee, Goldman et al. 2004, Li, Zhao et al. 2008, 
Maxwell, Cherry et al. 2011). Studies in a mouse models demonstrated that 
inhibition of 14-3-3, either by difopein, a general 14-3-3 antagonist, or by 14-3-3 
siRNA, induced apoptosis in human glioma cells and suppressed  the growth of the 
tumour  (Cao, Yang et al. 2010). 14-3-3 binding has been shown to protect the 
target protein from other modifications, such as dephosphorylation (Chen and 
Wagner 1994, Dent, Jelinek et al. 1995, Jelinek, Dent et al. 1996, Chiang, Harris et 
al. 2001) and proteolysis (Weiner and Kaiser 1999, Cotelle, Meek et al. 2000). 
Interaction of 14-3-3 with certain targets can alter the ability of the target protein to 
interact with its partners. For instance, in the case of BAD, 14-3-3 binding 
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competes with the BAD-Bcl2 association, releasing Bcl2 to perform its anti-
apoptotic function (Zha, Harada et al. 1996, Hsu, Kaipia et al. 1997, Datta, Katsov 
et al. 2000). In the case of IRS-1 and PI-3 kinase, 14-3-3 binding to IRS-1 
attenuates its ability to recruit and activate PI-3 kinase (Kosaki, Yamada et al. 
1998). 
 
14-3-3 functions in cell cycle checkpoints 
 
When cells encounter cell cycle checkpoint activation in response to DNA damage, 
Cdc25 is phosphorylated by TAK or Chk1/Chk2 at S216 (Peng, Graves et al. 1997, 
Sanchez, Wong et al. 1997, Peng, Graves et al. 1998, Liu, Guntuku et al. 2000), and 
this generates a 14-3-3 binding motif. As a consequence of this phosphorylation, 
Cdc25B and Cdc25C are sequestered in inactive forms in the cytoplasm by 14-3-3 
(Peng, Graves et al. 1997, Forrest and Gabrielli 2001, Giles, Forrest et al. 2003, 
Uchida, Kuma et al. 2004, Esmenjaud-Mailhat, Lobjois et al. 2007, Astuti, Boutros 
et al. 2010, Chan, Ng et al. 2011), and cannot then dephosphorylate the Cdk1/Cyclin 
B complex thus halting the cell cycle progression into mitosis (Dalal, Yaffe et al. 
2004, Uchida, Kuma et al. 2004, Hermeking and Benzinger 2006, Esmenjaud-
Mailhat, Lobjois et al. 2007).  
In the G1/S phase, Cdc25A is phosphorylated by Chk1 (Sanchez, Wong et al. 1997, 
Jin, Shirogane et al. 2003) and this allows the interaction of Cdc25A with 14-3-3γ in 
a phosphorylation-dependent manner, which ultimately leads to sequestration of 
Cdc25A in the cytosol, triggering its degradation (Chen, Ryan et al. 2003, Jin, 
Shirogane et al. 2003, Kang, Wei et al. 2008, Kasahara, Goto et al. 2010).  14-3-3σ 
can associate directly with Cdk2 and Cdk4, and thereby prevent cell cycle entry by 
inhibiting cyclin-Cdk function (Laronga, Yang et al. 2000).  
14-3-3 can associate with phosphorylated p53, shifting the dimer-tetramer 
equilibrium of p53 to the DNA-binding tetrameric form, and leading to form a high 
affinity complex with DNA (Waterman, Stavridi et al. 1998, Rajagopalan, Jaulent et 
al. 2008). Recent studies have shown that phosphorylation of p53 at S366 or T387 
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leads to its association with 14-3-3 γ and ε, and that this interaction enhances p53's 
DNA binding ability 10-fold, thereby enhancing p21 transcriptional activation 
(Rajagopalan, Jaulent et al. 2008).  
Additionally, phosphorylation of p27 by AKT at T157 confers its interaction with 
14-3-3 β, ε, γ, ζ and θ, whilst phosphorylation of p27 at T198 confers interaction 
with 14-3-3 ε, η and τ, but not β and ζ, thus retaining p27 in the cytosol (Fujita, Sato 
et al. 2002, Shin, Yakes et al. 2002, Viglietto, Motti et al. 2002, Sekimoto, Fukumoto 
et al. 2004, Kossatz, Vervoorts et al. 2006, Short, Dere et al. 2010).  
 
 
Table 1. Different 14-3-3 isoforms and their respective functions during the cell 
cycle.  
 
Phospho-regulation of 14-3-3  
 
14-3-3 proteins themselves are regulated by phosphorylation, which in turn can 
affect 14-3-3 dimerisation. 14-3-3 can be phosphorylated at residues S58, S59, S64, 
S185 and S233 by several different kinases (Dubois, Howell et al. 1997).  PKA 
phosphorylation of 14-3-3ε at S58 has been shown to affect its dimerisation and 
affects its interaction with p53 (Gu, Jin et al. 2006). Likewise, phosphorylation of 
14-3-3ζ at S58 by MAPK-activated protein kinase 2 inhibits the dimerisation of 14-
3-3 and its association with Raf-1 (Powell, Rane et al. 2003). Additionally, DNA 
damage-dependent association of phosphorylated Chk1 with 14-3-3 proteins 
mediates an important step along the DNA-damage checkpoint pathway, perhaps by 
Cellular process Target Sequel 
14-3-3 γ, η, ζ/δ and ε Phosphorylation of Cdc25 Regulation of CHK 1 kinase 
14-3-3 η, ζ/δ and ε Wee 1, CDK1 Cell cycle regulation 
14-3-3 γ, ε, σ and τ/θ p53 activation Cell cycle regulation via 
ATM/ATR activation 
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directing Chk1 to a particular substrate or to a particular location within the cell 
(Chen, Liu et al. 1999). The stimulated association of Chk1 with 14-3-3 proteins is 
compromised in mutants defective for the DNA-damage checkpoint pathway 
suggesting that their interaction is critically dependent on DDR. This also highlights 
the regulation of phosphorylation dependent 14-3-3 associated activities in DDR 
pathway. 
  
A link between E6 PBM-14-3-3 and p53 
 
Interestingly, a number of recent studies with HPV-16 and HPV-18 genomes in 
NIKS cell lines have shown that the E6 PBM is required for episomal maintenance 
of the two viral genomes.  Studies with HPV-16 genomes demonstrated that wild-
type HPV-16 replicated episomally in NIKS, NIKS-p53_shRNA, and NIKS-
p53_GSE56 cells. HPV-16_E6ΔPBM (deletion of last two amino acids) was not 
maintained in NIKS cells but was maintained as an episomal plasmid in both 
NIKS_GSE56 and NIKS_p53_shRNA cells after 8 weeks of cell culture. (Lorenz, 
Rivera Cardona et al. 2013, Brimer and Vande Pol 2014). This suggests that the E6 
PBM might contribute towards perturbation of p53 functions, independently of E6’s 
ability to degrade p53. One potential common link between these observations is 14-
3-3, since this family of proteins is linked to the regulation of p53 transcriptional 
transactivation activity during cell cycle check point control (Waterman, Shenk et al. 
1995, Waterman, Stavridi et al. 1998, Rajagopalan, Jaulent et al. 2008, Rajagopalan, 
Sade et al. 2010). As noted above 14-3-3 interacts with p53 in a phosphorylation-
dependent manner (Agarwal, Agarwal et al. 1995,Waterman et al, 1998). Following 
induction of DNA damage, S376 of p53 is dephosphorylated, while S378 and T387 
are phosphorylated by Chk1 and Chk2 kinases. This allows binding of 14-3-3γ, ε, θ 
and σ proteins with p53. This in turn increases the affinity of p53 binding to DNA 
and subsequent activation of p53 responsive promoters such as p21.(Agarwal, 
Agarwal et al. 1995, Waterman, Stavridi et al. 1998, Rajagopalan, Jaulent et al. 
2008). Taken together, these findings suggest that there could be potential links 
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between E6 PBM phosphorylation and p53 transcriptional inactivation through its 
association with 14-3-3.  
 
Ubiquitin-Protein Ligases 
 
Ubiquitination is an important post-translational modification process that is 
accomplished via a catalytic cascade involving an Ub-activating enzyme (E1), an 
Ub-conjugating enzyme (E2), and an Ub-protein ligase (E3) (Hershko and 
Ciechanover 1998, Eletr, Huang et al. 2005, Lorenz, Cantor et al. 2013, Olsen and 
Lima 2013). Based on the differences in their ubiquitination mechanisms, E3 Ub-
protein ligases are classified into two groups: RING-type and HECT-type. RING 
(Really Interesting New Gene) E3s add Ub directly from E2 to the substrate, 
functioning as a scaffold (Zheng, Wang et al. 2000), as shown in Figure 9 whereas, 
HECT-type E3s add Ub from E2 to the substrate via the catalytic cysteine of the 
HECT domain (Wang and Pickart 2005, Rotin and Kumar 2009).  HECT-type E3s 
have a HECT (homologous to E6AP carboxyl-terminus) domain and a substrate 
recognition site at the N-terminus and the HECT- domain is highly conserved 
between all HECT-type E3s. This domain, as the name suggests, shows homology 
with the C-terminal region of E6AP (E6-associated protein) and it is composed of 
about 350 amino acids (Purbeck, Eletr et al. 2010).  
 
Various HECT-domain E3 ligases have been shown to be involved in a number of 
diseases and cancers. They include: E6AP, EDD, Nedd4-1, Nedd4-2, HERC1, 
HERC2, HERC5, Smurf1, Smurf2, Itch, and HETCH9. The E6AP ligase is known to 
be involved in Angleman syndrome (Albrecht, Sutcliffe et al. 1997, Rougeulle, Glatt 
et al. 1997, Vu and Hoffman 1997), in cervical cancer (Talis, Huibregtse et al. 1998), 
and is also suggested to be associated with autism (Yi, Berrios et al. 2015). EDD has 
been shown to be overexpressed in ovarian cancers (Bradley, Zheng et al. 2014). Itch 
was found to be associated with lung and stomach inflammation and in lymphoid and 
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hematopoietic hyperplasia (Fang, Elly et al. 2002). Overexpression of Smurf1 and 
Smurf2 has been found to be associated with pancreatic and esophageal squamous 
cell carcinomas (Fukuchi, Fukai et al. 2002, Loukopoulos, Shibata et al. 2007), while 
Nedd4-1 and Nedd4-2 are found associated with Liddle’s syndrome (Staub, Dho et 
al. 1996),(Reviewed in (Scheffner and Staub 2007).  
Ubiquitination of target proteins is achieved by the generation of an isopeptide bond 
between the carboxy group of the C-terminal Gly76 residue of Ub and the 3-amino 
group of Lysine residues in the substrate proteins (Rotin and Kumar 2009). 
Ubiquitination is a multistep ATP-dependent process. In the first step, a thioester 
bond is formed between the C-terminus of ubiquitin and an internal Cys residue of 
the E1. The activated ubiquitin is then transferred to a specific Cys residue of the E2 
enzyme. In the next steps, E2 either donates ubiquitin directly to the target protein 
through E3 ubiquitin ligase activity, or through specific HECT E3s.  This process 
gives rise to protein conjugates, in which the C-terminus of ubiquitin is linked by an 
isopeptide bond to specific internal Lys residues of the substrates. Substrates can be 
modified by E3s by either adding one single ubiquitin molecule 
(monoubiquitylation), adding several single ubiquitin molecules at multiple Lys 
residues (multiubiquitylation), or adding multiple ubiquitin molecules to a single 
site, forming a polyubiquitin chain (polyubiquitylation) (Hoeller, Hecker et al. 2007). 
 
The fate of ubiquitylated proteins is dependent on the type of ubiquitin chain present 
on the substrate, and also on the type of isopeptide linkage formed by the 
polyubiquitin chain. Thus, different types of Ub modifications have distinct 
functions in the cell, for example: Poly-Ub chains linked through the Lys-48 of Ub 
label the protein for proteasomal degradation, whereas poly-Ub chains linked 
through Lys-63 are involved in endocytosis and DNA repair.  Monoubiquitination is 
also connected with endocytosis and DNA repair, whilst multiubiquitination is linked 
to endosomal sorting and lysosomal degradation (Pickart and Fushman 2004, 
Haglund and Dikic 2005). The majority of Lys-48-linked polyubiquitylated proteins 
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are degraded by the 26S proteasome, while the ubiquitin moieties are recycled 
following their release by deubiquitylating enzymes (Bernassola, Karin et al. 2008). 
In addition to Lys-48 linkages, other forms of linkage for both mono- and poly-
ubiquitin chains can occur, such as Lys6, Lys29/33and Lys63, which regulate protein 
degradation as well as a wide array of other cellular activities in a proteolysis-
independent manner. In addition, non-proteolytic Lys6 and Lys11 polyubiquitin 
linkages have been shown to be associated with neurodegenerative disorders 
(reviewed in (Bernassola, Karin et al. 2008)).  
 
E6AP ubiquitin ligase 
 
The E6AP ubiquitin ligase (also called UBE3A) is a member of the HECT E3 
family. It is a 100 kDa protein that interacts with the HPV E6 protein. E6AP targets 
substrate proteins, including itself, for proteasomal degradation (de Bie and 
Ciechanover 2011). Autoregulation of E6AP via self-targeted degradation is cited as 
a mechanism for maintaining E6AP levels (Nuber, Schwarz et al. 1998, de Bie and 
Ciechanover 2011). Both loss and activation of E6AP functions are implicated in 
various human diseases, with Angelman Syndrome being the most well known 
(Nicholls and Knepper 2001, Beaudenon and Huibregtse 2008, Flashner, Russo et al. 
2013). Abrogation of E6AP by deletion or mutation of the UBE3A gene locus within 
the 15q11–13 chromosome region is associated with Angelman syndrome, a 
neurological disorder (Kishino, Lalande et al. 1997, Sutcliffe, Jiang et al. 1997, 
Matentzoglu and Scheffner 2008).  
 
Many of the naturally occurring mutations within the UBE3A gene introduce 
deletions that generate a truncated E6AP protein, lacking the intact HECT-domain. 
Although, approximately 10% of the genetic alterations correspond to point 
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mutations within the E6AP coding region (Jiang, Lev-Lehman et al. 1999), many of 
the point mutations represent loss-of-function alterations and are not able to 
ubiquitinate their substrate, however, in contrast to this, many retain the ability to 
form a thioester bond with ubiquitin (Cooper, Hudson et al. 2004).  In addition, 
duplication of the UBE3A gene is thought to result in some cases of autism disorder 
(Schaaf, Sabo et al. 2011, Smith, Zhou et al. 2011), and recent studies have found 
that Protein kinase A (PKA)-mediated phosphorylation of E6AP at T485 residue 
inhibits the E6AP activity toward itself and other substrates. An autism-linked 
missense mutation disrupts this phosphorylation site resulting in enhanced ubiquitin 
activity and thus leading to synaptic dysfunction and autism pathogenesis (Yi, 
Berrios et al. 2015). Whether this phospho-regulation of E6AP has any relevance for 
the function of E6 remains to be determined. 
 
Some of the E6AP protein's interactors include: RAD23A (Kumar, Talis et al. 1999), 
BLK (Oda, Kumar et al. 1999), MCM7 (Kuhne and Banks 1998), UBQLN1 and -2 
(Kleijnen, Shih et al. 2000, Kleijnen, Alarcon et al. 2003), the estrogen receptor (Li, 
Li et al. 2006), TSC2 (Zheng, Ding et al. 2008), annexin A1 (Shimoji, Murakami et 
al. 2009), PML (Louria-Hayon, Alsheich-Bartok et al. 2009), peroxiredoxin 1 (Nasu, 
Murakami et al. 2010), Arc (Greer, Hanayama et al. 2010), and Ring1B (Zaaroor-
Regev, de Bie et al. 2010). Amongst which Ring1B has been shown to be get 
ubiquitinated and degraded in proteasome dependent manner (Zaaroor-Regev, de Bie 
et al. 2010, Thatte and Banks 2017).  However, there is still considerable debate 
about which of them are E6AP substrates and its precise mode of action.  
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E6AP, E6 and p53 association 
 
The E6AP ubiquitin ligase was initially identified as an interacting partner of the E6 
protein encoded by HPV-16 and HPV-18 (Huibregtse, Scheffner et al. 1991, 
Scheffner, Huibregtse et al. 1993, Beer-Romero, Glass et al. 1997). In the absence of 
E6, p53 degradation is mediated by the Mdm2 ubiquitin ligase (Haupt, Maya et al. 
1997). However, in HPV-positive cells, E6 mediates degradation of p53 through its 
interaction with E6AP (Scheffner, Werness et al. 1990, Talis, Huibregtse et al. 
1998). E6-E6AP interaction occurs through a leucine-rich motif (LXXLL) motif in 
the N-terminal region of E6AP (Chen, Hong et al. 1998, Elston, Napthine et al. 1998, 
Be, Hong et al. 2001). The structural and biophysical analyses of the E6 interaction 
with E6AP showed that the N-terminal E6 Zn
2+
-binding domain primarily interacts 
with E6AP, whereas the C-terminal Zn
2+
-binding domain interacts with p53, as 
shown in Figure 10 (Nomine, Charbonnier et al. 2003, Zanier, Charbonnier et al. 
2005, Liu, Cherry et al. 2009, Zanier, Ruhlmann et al. 2010, Zanier, Charbonnier et 
al. 2013). The E6:E6AP complex binds to the DNA-binding domain of p53, which 
becomes rapidly ubiquitylated and is targeted to the 26S proteasome (Huibregtse, 
Scheffner et al. 1991). The potential to promote p53 degradation is a characteristic of 
E6 from the high-risk HPV types (e.g. HPV types 16 and 18). In contrast, the E6 
proteins from low-risk HPV types do not stably interact with E6AP in vitro, 
however, in vivo, all alpha type HPV E6 proteins can associate with E6AP 
(Huibregtse, Scheffner et al. 1991). E6 proteins from all HPV genera except Alpha 
interact with MAML1 (which regulates notch signaling) over E6AP, suggesting that 
the differences in E6 interaction with MAML1 or E6AP is a major event in 
papillomavirus evolution (Brimer, Drews et al. 2017). Although several other targets 
of E6AP have been suggested as potential mediators of E6's tumorigenic activity 
(Liu, Yuan et al. 2005), the major contribution of E6AP to HPV-associated tumour 
development is thought to be achieved through the degradation of the p53 tumour 
suppressor. 
48 
 
 
 
Figure 9. Different types of E3 ubiquitin-ligases.  
The ubiquitin-ligase E3 is classified into two ubiquitin-ligase groups based on 
differences in domain structure, they are: HECT type and RING type. RING-type 
E3s add Ub directly from E2 to the substrate, functioning as a scaffold, whereas 
HECT type E3 itself binds with cysteine residue to form an intermediate that forms 
thioester bonds with ubiquitin. 
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Figure 10. Ribbon diagrams representing the structures of E6/MBP-E6AP/p53. 
A diagram showing E6/MBP-E6AP/p53 core structure observed in the asymmetric 
unit. Red: LXXLL peptide of E6AP fused to the C-terminus of MBP (Blue); HPV-16 
E6 (Orange); HPV 16 E6 Ser81 residue (Green) and p53core (Pink) are shown.   
 
 
 
 
 
 
 
50 
 
DNA damage Response (DDR) 
 
The DNA damage response (DDR) is a complex network of cellular signaling that is 
triggered by various endogenous or exogenous factors. The endogenous factors 
include the dysfunction of DDR repair or DNA replication proteins, and exogenous 
factors include ionizing radiation, UV light, exposure to DNA-damaging chemicals 
etc. During DNA replication, spontaneous DNA alterations can occur, which lead to 
the misincorporation of dNTPs, causing: deamination; insertion or deletion of DNA 
bases; DNA depurination, or modification of DNA bases by alkylation (illustrated in 
Figure 12) (Lindahl and Barnes 2000). Additionally, reactive oxygen species 
generated in cells also trigger the oxidation of nucleotides - and incorporation of 
oxidized nucleotides causes DNA damage (Shibutani, Takeshita et al. 1991, Kamath-
Loeb, Hizi et al. 1997, Cooke, Evans et al. 2003, Hoeijmakers 2009, Jackson and 
Bartek 2009). Various forms of DNA damage can also be caused by the chemicals 
used in cancer therapy. These include cross-linking agents such as mitomycin C 
(Bizanek, McGuinness et al. 1992) and cisplatin (Brabec 2002), and topoisomerase 
inhibitors such as etoposide and camptothecin, which induce the formation of single-
strand (SSB) and double-strand breaks (DSB) in the DNA (Hande 1998, Pommier 
2006).  
 
The DDR senses, signals and facilitates the repair of damaged DNA. The DDR 
pathways are activated in order to maintain genome stability through mechanisms 
that coordinate DNA repair, cell cycle progression, transcription, apoptosis, and 
senescence (Abraham 2001, Karagiannis and El-Osta 2004, Jackson and Bartek 
2009, Branzei and Foiani 2010, Ciccia and Elledge 2010, Marechal and Zou 2013). 
Any mutation in DNA repair genes can cause genomic instability and thus may lead 
to cancer. The two central pathways activated in response to DNA damage are the 
Ataxia Telangiectasia Mutated (ATM) pathway and the ATM and Rad-3 related 
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(ATR) pathway. The ATM and ATR proteins belong to the phosphatidylinositol 3-
kinase-related kinase (PIKK) family of serine/threonine kinases. ATM is primarily 
activated in response to DSBs, whilst ATR is activated in response to a broad 
spectrum of DNA damage, including SSBs and a variety of DNA lesions that 
interfere with DNA replication.  
 
ATM and ATR  
 
The DSBs in the DNA lead to activation of the ATM pathway. The 
Mre11/Rad50/Nbs1 (MRN) complex binds to DNA at the site of the DSB and 
initiates the signals for ATM recruitment (Lee and Paull 2005). However, how 
exactly DSBs recruit activators of ATM remains unclear. This activation is through 
autophosphorylation of ATM at residue S1981, which results in the monomerization 
of ATM (ATM exist as dimers or oligomers in undamaged cells), and this has been 
shown to be essential for its activity (Bakkenist and Kastan 2003). Reactive oxygen 
species also trigger the activation of ATM, but in this case independently of the 
MRN complex (Guo, Kozlov et al. 2010). ATM further signals to various 
downstream substrates in order to initiate the DNA repair signaling. The ATM 
kinase recognizes ‘S/T-Q’ motifs on its substrates (Kim, Lim et al. 1999); one very 
well characterized substrate of ATM is Chk2, which is phosphorylated by ATM at 
the Thr68 residue in response to DSBs (Chaturvedi, Eng et al. 1999, Matsuoka, 
Rotman et al. 2000). In addition to this, ATM also phosphorylates and activates 
several other signaling proteins such as p53, BRCA1, FANCD2, H2AX and 
Nbs1(Shiloh and Ziv 2013). ATM-responsive pathways are involved in activation of 
various downstream signaling networks: p53 activation, NF-κB and microRNA 
activation, all of which are essential for gene-transcription regulation in response to 
DNA damage (Turenne, Paul et al. 2001, Wu, Shi et al. 2006, Zhang, Wan et al. 
2011). ATM activation has also been to shown be involved in nucleosome 
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remodeling and chromatin relaxation (Ziv, Bielopolski et al. 2006, Goodarzi, Noon 
et al. 2008, Polo, Kaidi et al. 2010, Goodarzi, Kurka et al. 2011, Moyal, Lerenthal et 
al. 2011) 
 
ATR activation is stimulated in response to SSBs in the DNA. Unlike ATM, the 
ATR-ATRIP heterodimer does not interact with DNA directly; instead this 
interaction occurs with the help of replication protein A (RPA), promoting ATR 
localization to the sites of replication stress (Zou and Elledge 2003). The activity of 
ATR is important to initiate several signaling cascades in response to replication 
stress. The autophosphorylation of ATR at Thr1989 is dependent on the formation of 
the RPA-ATRIP complex (Liu, Shiotani et al. 2011). Activation of ATR is a 
multistep process, and where the ATR-ATRIP recognizes the SSB-bound RPA, the 
9-1-1 (Rad9, Hus1, and Rad1) complex is simultaneously loaded at the junctions of 
ssDNA.  This promotes TopBP1-mediated ATR activation, which is required for the 
stabilization of replication forks (Delacroix, Wagner et al. 2007, Cotta-Ramusino, 
McDonald et al. 2011).  The well-characterized downstream effector of ATR is 
Chk1, which is activated upon ATR-mediated phosphorylation on residues S317 and 
S345 (Liu, Guntuku et al. 2000, Zhao and Piwnica-Worms 2001). Activation of 
Chk1 has been shown to be critical for intra-S and G2/M checkpoint responses. 
These events are illustrated in Figure 11.   
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Figure 11. DNA damage response (DDR) pathway.  
DNA damage response is a signaling cascade that is coordinated by various proteins 
and they are categorized as sensors, transducers and effectors. Double strand break 
(DSB) can be sensed by the MRN complex (sensor) to recruit and activate transducer 
ATM to activate CHK2 (effector) with the help of DDR mediators such as Tip60. 
The single strand break (SSB) can be detected by sensor protein, RPA and 9-1-1 
complex, to recruit transducer ATR, to activate CHK1 (effector), with the help of 
mediators TopBP1. The p53 and CDKs are the downstream substrates in response to 
DSB and SSB respectively.  
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Figure 12. Different intrinsic as well as extrinsic factors involved in causing 
DNA damage.  
DNA damage includes single strand break, base miss-match, double strand break, 
AP-site intra-strand crosslink and inter-strand crosslink. Based on the type of DNA 
damage, different downstream pathways are activated including cell cycle check 
point and transcriptional program activation, DNA repair or apoptosis.  
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Oxidative stress and DNA damage response 
 
The imbalance between the production of reactive oxygen species (ROS) and 
antioxidants is termed oxidative stress. The oxygen molecule (O2), the superoxide 
anion radical (·O2 −), hydrogen peroxide (H2O2), the hydroxyl radical (·OH) and 
singlet oxygen (1O2) are all classified as ROS (Ames, Shigenaga et al. 1993, Agnez-
Lima, Melo et al. 2012). Normal cellular processes also generate ROS during 
oxidative phosphorylation in the mitochondria and during the oxidation of long-
chain fatty acids in peroxisomes. (Berquist and Wilson 2012). Hypoxia is another 
contributing factor for induction of DDR thereby inducing rapid replication arrest 
(Pires, Bencokova et al. 2010). Exogenous agents such as ionizing radiation (IR), 
ultraviolet (UV) radiation, or chemotherapeutic agents can also trigger ROS 
production in cells. (Riley 1994, Cook, Gius et al. 2004, Berquist and Wilson 2012, 
Dizdaroglu 2012). As a consequence, cells have evolved an elaborate defense system 
against ROS in the form of antioxidants such as glutathione, vitamin C and vitamin E 
etc. (Masella, Di Benedetto et al. 2005).  
Various different types of DNA damage or replication stress are induced upon 
oxidative stress, including sugar moiety damage, Apurinic/apyrimidinic (AP) sites, 
purine and pyrimidine base damage, SSBs,DSBs, DNA intrastrand/interstrand 
crosslinks, protein–DNA crosslinks, nucleotide mismatched bases, stalled DNA 
replication forks, and oxidatively-generated clustered DNA lesions (OCDLs)(Ames 
and Saul 1986, Ames 1989, Lindahl 1993, Hoeijmakers 2009, Ciccia and Elledge 
2010). In response to oxidative stress-induced DNA damage, a variety of DNA 
repair and DNA damage response (DDR) pathways are employed by cells, and these 
are critically essential for the maintenance of genome integrity (Bartek and Lukas 
2003, Friedberg 2003, Barzilai and Yamamoto 2004, Ciccia and Elledge 2010, Chen, 
Li et al. 2012) (Figure 12). These pathways include: base excision repair 
(BER)/single-strand break repair (SSBR), nucleotide excision repair (NER), 
mismatch repair (MMR), homologous recombination (HR), and non-homologous 
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end joining (NHEJ) (Bartek and Lukas 2003, Friedberg 2003, Berquist and Wilson 
2012). The ATM-Chk2 and ATR-Chk1 pathways are also activated in response to 
oxidative stress-induced DNA damage (Cimprich and Cortez 2008, Chen, Li et al. 
2012).  
 
DNA damage signaling and cell-cycle checkpoints 
 
The cell cycle is a series of highly ordered processes in which cell cycle-checkpoint 
proteins play  critical  roles (Elledge 1996). The Cyclin-dependent kinases (CDKs), 
their cyclin partners, protein kinases, and phosphatases govern the progression of the 
cell cycle to the next phase (Nurse 2000). Activation of cell cycle checkpoint 
kinases, Chk1 and Chk2, by ATM and ATR respectively, suppresses the activity of 
the CDK1/cyclin B complex and thus the cell’s mitotic entry is inhibited (Nigg 2001, 
Smits and Medema 2001, Melo and Toczyski 2002). Chk1 activation by ATR kinase 
in response to DNA damage leads to cell cycle arrest in S phase, which is achieved 
by Chk1 phosphorylation of Cdc25A and its consequent degradation, resulting in the 
inhibition of CDK2 (Sorensen, Syljuasen et al. 2003, Carrassa, Sanchez et al. 2009). 
Knockdown and inhibition of Chk1 is associated with increased SSBs, aberrant fork 
structures, accumulation of DSBs, and increased phosphorylation of ATR targets 
(Syljuasen, Sorensen et al. 2005, Petermann, Woodcock et al. 2010). On the other 
hand, Chk2 functions as an effector by phosphorylating additional key substrates, 
such as the transcription factor p53 (Chehab, Malikzay et al. 2000, Shieh, Ahn et al. 
2000), the cell-cycle regulating phosphatases Cdc25A (Falck, Mailand et al. 2001) 
and Cdc25C (Peng, Graves et al. 1997), Mdm2 (Shieh, Ahn et al. 2000) and BRCA1 
(Lee, Collins et al. 2000). In addition, the Chk2 phosphorylation of transcription 
factor E2F1 on serine 364 has been shown to be involved in transcriptional 
upregulation of the proapoptotic proteins Apaf-1 and p73 (Stevens, Smith et al. 
2003). 
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Activation of DDR by viruses 
 
Studies have shown that ATM signaling is essential for efficient lytic viral DNA 
replication of various human herpesviruses, including HSV (Lilley, Carson et al. 
2005), CMV (E, Pickering et al. 2011), EBV (Li, Zhu et al. 2011, Hagemeier, 
Barlow et al. 2012), and MHV68 (Tarakanova, Leung-Pineda et al. 2007, 
Tarakanova, Stanitsa et al. 2010). The replication of polyomaviruses is also 
dependent on ATM kinase activity (Shi, Dodson et al. 2005). Adeno-associated virus 
(AAV) have been shown to activate the DNA-PK pathway during coinfection with 
adenovirus as a helper (Cervelli, Palacios et al. 2008, Schwartz, Carson et al. 2009), 
and this activation is important for its replication (Choi, Nash et al. 2010). A number 
of reports show a role of ATM activation by HIV-1 during infection (Daniel, 
Marusich et al. 2005, Lau, Swinbank et al. 2005). Activation of DNA-PK pathway 
also potentially plays an important role in retroviral integration (Daniel, Katz et al. 
1999). This suggests that many diverse viruses use DDR signaling for their 
replication. Figure 13 illustrates different viral proteins involved in modulating the 
DDR pathway.   
58 
 
 
Figure 13.  Crosstalk between viral oncoproteins and the host DDR.  
Viral oncoproteins activate E2F, cMyc and Ras cellular oncogenes in order to 
enter or re-enter the cell cycle, thereby inducing replicative stress and DNA 
damage. In response to DNA damage, ATM and ATR kinases are activated which 
regulate downstream signaling including activation of Chk2 and p53. Tumour 
virus oncoproteins modulate the function of DDR components by activating or 
suppressing their expression or activity. Different viral proteins modulating the 
components of DDR are shown.  
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HPV and the DNA Damage response  
 
Cells containing the high-risk HPVs exhibit constitutive activation of the ATM 
pathway in the absence of external DNA damage. Studies in HPV-31, HPV-16 and 
HPV-18-containing differentiating HFK cells showed activated ATM and its 
downstream substrates such as Chk2, Nbs1 and BRCA1 (Moody and Laimins 2009).  
Activation of the ATM-DDR response pathway was also shown to be required for 
amplification of HPV-31 genomes in differentiated cells (Moody and Laimins 2009), 
and different viral proteins such as E1 and E7 have also been shown to be essential 
for the recruitment of DSB repair factors to HPV replication centres (Fradet-
Turcotte, Bergeron-Labrecque et al. 2011, Sakakibara, Mitra et al. 2011, Gillespie, 
Mehta et al. 2012, Reinson, Toots et al. 2013).  
 
DDR activation during HPV maintenance, replication and amplification 
HPV genome replication is dependent on the host cell machinery and the virus uses 
the components of the DDR for limited amplification of the viral genome in the basal 
layer. As noted, the HPV viral DNA replication is dependent on the E1 and E2 
proteins, and their expression is required for the formation of replication foci that 
recruit components of the DDR (Fradet-Turcotte, Bergeron-Labrecque et al. 2011, 
Sakakibara, Mitra et al. 2011, Reinson, Toots et al. 2013). Recent studies have 
shown that the E2 protein binds to host chromatin in complex with BRD4 at the 
fragile sites in the genome (sites of replication stress) (Jang, Shen et al. 2014).  This 
interaction is essential for viral genome maintenance and nucleation of replication 
foci in vegetative viral amplification; however, it varies amongst different HPV 
types.  
HPV genomes are replicated in S-phase, in synchrony with host cell DNA 
replication, for viral genome maintenance. In this phase, both ATM and ATR 
signaling is activated, although inhibition of ATM does not affect the viral genome 
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maintenance, but it is critical for genome amplification only in differentiated cells, 
which occurs in G2/M like phase (Moody and Laimins 2009). However, this 
activation is critical for the high-risk HPV- life cycle. Recent studies have shown 
that ATM and downstream homologous recombination components associate in 
discrete nuclear foci along with the  replicating viral genomes, in both 
undifferentiated and differentiated cells (Gillespie, Mehta et al. 2012, McKinney, 
Hussmann et al. 2015).  
A number of studies in W12 cells containing episomal copies of HPV-16 genome 
demonstrated that siRNA-mediated reduction of ATM, ATR, Chk1 and several other 
DDR components results in a 40%–50% reduction in HPV-16 copy number, 
suggesting that the ATM-ATR pathway is the canonical pathway activated by HPV 
for viral genome maintenance and amplification (Edwards, Helmus et al. 2013, 
Edwards, Vidmar et al. 2013).  
 
ATM activation 
Normally, the ATM pathway is activated by Tip60-mediated acetylation. Studies 
have shown that the Tip60 levels are increased in the cells containing the whole viral 
genome, where various viral gene products are expressed, although E6 has been 
reported to degrade Tip60 (Jha, Vande Pol et al. 2010, Hong, Dutta et al. 2015). 
Also, in HPV-positive cells, expression of Tip60 is required for ATM activation as 
well as for genome amplification upon differentiation (Hong, Dutta et al. 2015). 
Studies in HPV-16 and HPV-31 have demonstrated that expression of E7 is 
sufficient to induce the recruitment of the MRN components to the site of DNA 
damage, which further facilitates the activation of ATM by autophosphorylation 
(Anacker, Gautam et al. 2014). ATM activation signals to its downstream effectors 
that are involved in DNA repair pathways. In addition to this, ATM also 
phosphorylates a cohesin protein, SMC1, in response to DNA damage. Its expression 
is elevated in HPV-positive cells and this also has been shown to be required for 
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genome amplification. The phosphorylated SMC1 is localized to distinct nuclear foci 
containing γ-H2AX and pCHK2 and it binds directly to viral DNA at conserved 
CTCF sites (Mehta, Gunasekharan et al. 2015). Taken together, these findings 
suggest that there is a critical requirement for ATM activation during the viral life 
cycle; however, it still remains unclear how exactly the ATM pathway promotes the 
amplification of viral genomes in differentiated cells.  
 
ATR activation 
In addition to activating the ATM pathway, HPV also activates the ATR pathway. 
Recent studies in HPV-18 have shown that the transient replication of viral genomes 
triggers activation of an ATR-dependent DNA damage response that subsequently 
activates ATR pathway components such as ATRIP and TopBP1 at viral replication 
centers (Reinson, Toots et al. 2013). This ATR activation is a result of replication 
stress caused by the initial amplification of viral genomes during the establishment-
phase. In addition, ATR activation is linked to the stable maintenance of viral 
episomes in primary keratinocytes. The studies in primary keratinocytes showed that 
both the total and phosphorylated levels of ATR and its substrate Chk1, are increased 
in the cells containing high-risk HPV genomes, as well as in cells expressing E6 and 
E7 alone (Yang, Liu et al. 2016). Whole genome studies showed that the 
transcription of the Topoisomerase IIβ-Binding Protein 1 (TopBP1) gene is regulated 
by STAT-5 to activate the ATR Pathway and promote HPV replication. The 
inhibition of TopBP1 results in loss of ATM/Chk1 activation, leading to a reduction 
in the stable maintenance of viral genomes in undifferentiated cells (Hong, Cheng et 
al. 2015). Recent studies showed that pharmacological inhibition of either pATR or 
pChk1 by small molecule inhibitors leads to loss of genome amplification in 
differentiating cells (Edwards, Helmus et al. 2013, Hong, Cheng et al. 2015). 
Taken together, these findings highlight the importance of both ATM and ATR for 
differentiation-dependent amplification and replication of HPV genomes. It is 
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possible that HPV activates ATR pathways to maintain replication fork integrity 
during the stress of viral replication, to activate stalled replication forks for continued 
replication of viral genomes and also to recruit replication factors at viral replication 
centers.  
 
E6/E7 and DDR 
The E6 and E7 are smart players of the HPV life cycle as they both activate the DDR 
pathways, at the same time as they inhibit the downstream consequences. E7 plays a 
critical role in promoting DDR activation for viral replication, whilst E6 targets and 
inhibits the subsequent effectors of DDR, such as the p53 tumor suppressor, thus 
avoiding growth arrest or apoptosis.  E7 also elevates the levels of homologous 
recombination proteins, including BRCA1 and RAD51 throughout the viral life 
cycle, together with NBS1. HPV-31 genome studies showed that these events are 
required for the amplification of viral genomes in differentiated cells (Anacker, 
Gautam et al. 2014, Chappell, Gautam et al. 2015). In addition, SIRT1 deacetylase 
regulates the recruitment of both NBS1 and RAD51 to viral genomes, thus 
controlling homologous recombination in productive viral replication (Langsfeld, 
Bodily et al. 2015).  E7 deregulates the E2F1 transcription factor by targeting pRB, 
and this induces the expression of Chk2, promoting viral replication (Rogoff, 
Pickering et al. 2004). Moreover, studies in HPV 16 showed that E7 induces the 
degradation of claspin, which is a Chk1 binding protein, thus promoting mitotic 
entry in the presence of an activated DDR (Spardy, Covella et al. 2009).   
Normally, activation of DDR pathways signal to p53 for concomitant growth arrest, 
however, the ability of E6 to degrade p53 is thought to be crucial for  genome 
maintenance (Thomas, Hubert et al. 1999, Flores, Allen-Hoffmann et al. 2000, Park 
and Androphy 2002). Furthermore, inactivation of p53, or expression of a dominant-
negative form of p53, rescues this effect (Lorenz, Rivera Cardona et al. 2013, Brimer 
and Vande Pol 2014). HPV modulated DDR pathway is illustrated in Figure 14.   
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Figure 14. HPV mediated modulation of the ATM and ATR DNA damage 
response pathways. HPV-induced activation of ATM is mediated via immune 
regulator STAT5 as well as TIP60. ATM activation further stimulates downstream 
effectors such as the Chk2, and HPV may utilize this activity to promote G2 arrest 
upon differentiation and can also use it for Caspase 3/7 activation. ATM also signals 
to MRN complex, Rad51, BRCA1 and SMC1 which are involved in regulation of 
homologous recombination. ATR activation in HPV positive cells is triggered by E7-
induced replication stress and requires a STAT5-directed increase in TopBP1. 
ATR/Chk1 activation further increases E2F1, which drives expression of RRM2, 
resulting in increased dNTP pools to facilitate productive viral replication.  
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AIMS OF THIS THESIS 
Previous studies have shown how E6 phosphorylation can alter substrate selection 
but there was no information on the biological consequences, or on when this might 
occur in vivo. Furthermore, there was no information on whether phosphorylation of 
E6AP might also be relevant for E6 activity. My aims were: 
 To determine when E6 was phosphorylated in vivo. 
 To identify which kinases were responsible. 
 To identify the sequence constraints controlling kinase and 14-3-3 
recognition of E6. 
 To investigate the biological consequences of E6 phosphorylation. 
 To determine how phosphorylation of E6AP could likewise affect E6 
function. 
 To begin to investigate differences in how different cancer-causing E6 
oncoproteins might respond to these different signaling pathways.                    
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CHAPTER 2: MATERIALS AND METHODS 
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Cell culture and transfection 
HeLa, H1299, HEK293 wild type (ATCC) and E6AP/KO HEK293 cells were 
maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 
10% fetal bovine serum, penicillin-streptomycin (100 U/ml), and glutamine (300 
μg/ml). All these cell lines were cultured in an incubator at 37°C with 10% CO2. 
The NIKS (Normal Immortalised Keratinocytes) (Allen-Hoffmann, Schlosser et al. 
2000), NIKS 16 E6 and NIKS 16 E6ΔPBM  cells (Nicolaides, Davy et al. 2011)  
were maintained in medium  composed of 3 parts Ham's F12 medium to 1 part 
DMEM, and supplemented with: 5% fetal bovine serum (FBS), adenine (24 μg/ml), 
cholera toxin (8.4 ng/ml), epidermal growth factor (10 ng/ml), hydrocortisone (2.4 
μg/ml),  insulin (5 μg/ml), penicillin-streptomycin (100 U/ml), and glutamine (300 
μg/ml). NIKS cell lines were cultured in an incubator at 37°C with 5% CO2. 
HEK293 and H1299 cells were transfected using the calcium phosphate precipitation 
method (Wigler, Pellicer et al. 1979). Cells were harvested after 18h. 
HeLa cells were transfected with siRNA against the appropriate genes using 
Lipofectamine RNAiMax transfection reagent (Invitrogen). The samples were 
analyzed 72h post-transfection.   
 
Plasmids and cloning  
The pCDNA-18E6 R153G and pGWI-HA:18E6 ΔPBM were provided by Boon SS. 
The pcDNA3 FLAG- p53 (Pim, Massimi et al. 1997), pGWI:HA-Dlg (Gardiol, 
Galizzi et al. 2002), pGWI HA-18E6 and pGWI HA-16E6 were kindly provided by 
Ron Javier. Flag-PML plasmids have been described previously (Guccione E. et al. 
2004). 
HA-tagged HPV-31 E6 was sub-cloned into the pGWI vector within compatible 
HindIII and EcoRI restriction enzyme sites and pcDNA3:HA-Ub(n) has been 
described previously (Tomaic, Pim et al. 2011).  
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The plasmids used for luciferase reporter assays are as follows: p21-Luciferase, 
BAX-Luciferase, MDM2-Luciferase, PUMA-luciferase and pCMV-Renilla 
luciferase were kind gifts from Dr. Giannino Del Sal, and are described in REFS.  
The pCS2-6Myc-Ring1B (Zaaroor-Regev, de Bie et al. 2010) was a kind gift from 
Prof. Aaron Ciechanover. The Ring1B was sub-cloned into the pGWI vector using 
compatible HindIII and EcoRI restriction enzyme sites. The 14-3-3 inhibitor 
plasmid, Myc-Difopein, was a kind gift from Haian Fu (Masters and Fu 2001). The 
Myc-E6AP, Myc-E6AP T485A, Myc-E6AP T485E were kind gifts from Mark Zylka 
(Yi, Berrios et al. 2015).  
The plasmids expressing GST, GST-HPV-18E6, GST-HPV-18E6R153A and GST-
HPV-18E6T156E fusion proteins (Cloned in pGEX2T vector) have been described 
previously (Boon and Banks 2013, Boon, Tomaic et al. 2015). The PBM mutants 
were generated using the GeneArt Site-Directed mutagenesis kit (Invitrogen).   
The pGEX2T-E6AP expression plasmid has been described previously (Tomaic, Pim 
et al. 2011). The pGEX2T-E6APT485A mutant was generated using the GeneArt 
Site-Directed mutagenesis kit (Invitrogen).  
The HPV-31 E6 GST-fusion proteins have been described previously (Boon and 
Banks 2013, Boon, Tomaic et al. 2015). HPV-31 E6 deletion and substitution 
mutants were generated in the pGEX2T construct using the GeneArt Site-Directed 
mutagenesis kit (Invitrogen).  
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The specific mutation or the substitution and the primer sequences are shown in the 
table below.  
E6 
Type 
Mutation Primer sequences 
18 
ET* 
F: CGACGCAGAGAAACATGATATTAAGTATGCATGG 
R: CCATGCATACTTAATATCATGTTTCTCTGCGTCG 
ETQ* 
F: CGCAGAGAAACACAATGATATTAAGTATGCATGG 
R: CCATGCATACTTAATATCATTGTGTTTCTCTGCG 
ETAA 
F:CGACGCAGAGAAACGCAGCATAATATTAAGTATGC 
R:GCATACTTAATATTATGCTGCTGTTTCTCTGCGTCG 
S82D 
F: GAGAATTAAGACATTATGACGACTCTGTGTATGG 
R: CCATACACAGAGTCGTCATAATGTCTTAATTCTC 
ΔPBM 
F: CCAACGACGCAGATAAACACAAGTATAA 
R: TTATACTTGTGTTTATCTGCGTCGTTGG 
16 ΔPBM 
F: CAAGAACACGTAGATAAACCCAGCTG 
R: CAGCTGGGTTTATCTACGTGTTCTTG 
31 
S82G 
F: GATGGTATAGATATGGCGTGTATGGAACAAC 
R: GTTGTTCCATACACGCCATATCTATACCATC 
S82A 
F: AGATGGTATAGATATGCTGTGTATGGAACAACA 
R: TGTTGTTCCATACACAGCATATCTATACCATCT 
S82D 
F: AGATGGTATAGATATGATGTGTATGGAACAACA 
R: TGTTGTTCCATACACATCATATCTATACCATCT 
ΔPBM 
F: GGAGAAGACCTCGTACTTAAACCCAAGTGTAAG 
R: CTTACACTTGGGTTTAAGTACGAGGTCTTCTCC 
E6AP T485A 
F: GTGAACGAAGAATCGCTGTTCTCTACAGC 
R: GCTGTAGAGAACAGCGATTCTTCGTTCAC 
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gRNA design and CRISPR/Cas9 mediated gene targeting 
Two different gRNAs were designed against the E6AP gene using the DNA2.0 
software. The gRNA primer sequences containing BbsI enzyme sticky ends are as 
follows:  
gRNA1 :  5’ CACCGGTTTCCAGGGGGTCCACTCG  3’ 
              5’ AAACCGAGTGGACCCCCTGGAAACC 3’ 
         
gRNA2:   5’ CACCGAAGTGGTTTTCGACAATCCA 3’ 
              5’ AAACTGGATTGTCGAAAACCACTTC 3’ 
 
gRNA1 binds at genomic locus 15:25370913-25370932 and gRNA2 at 
15:25370857-25370876. The gRNAs were cloned into pSpCas9(BB)-2A-Puro 
(PX459) using the BbsI restriction enzyme site. The Cas9-puro plasmids containing 
gRNA were then transfected into HEK293 cells and single-cell clones were selected 
using 10µg/ml puromycin (Sigma) for 4-5 weeks. The mutation in E6AP was 
verified by picking individual clones, and analyzing the relevant region of the E6AP 
genomic DNA by PCR and DNA sequencing. Verification of the loss of E6AP was 
performed by western blotting for E6AP.      
 
Inhibitors, chemicals and reagents  
The inhibitors and chemicals used to treat HeLa and C4-1 cells: 5µM AZ-20 ATR 
inhibitor (for 15h), 5µM KU-60019 ATM inhibitor (for 15h), 100nM UCN01 Chk1 
inhibitor (for 15h), 5 µM Chk2 inhibitor (for 15h), 500µM hydrogen peroxide 
(H2O2) solution (for 5h), 5mM N-acetyl-cysteine (NAC) (for 15h), 100µg/ml 
Cycloheximide solution (for 4h), 200ng/ml Nocodazole (for 15h), 2.5mM Thymidine 
(for 15h), 10 µM H-89 PKA inhibitor (for 15h), 20nM MG-132 (for 15h), (All from 
Sigma Aldrich).  
The chemotherapeutic reagents used were: 5µM Teniposide (for 15h), 50-100µM 
Cisplatin as indicated (for 15h), 10µM Triapine/3-AP (for 15h), 10µM Etoposide 
(for 15h) (All from Sigma Aldrich).  The concentration of all above chemicals was 
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optimized based on the cell toxicity and their efficacy for each cell line (By also 
considering the available information from literature).  
 
Antibodies 
Following primary antibodies were used: Anti-Myc mouse monoclonal antibody 
(Santa Cruz Biotechnology); anti-FLAG mouse monoclonal antibody, clone M2 
(Sigma); anti-β-galactosidase mouse monoclonal antibody (Promega); anti-HA 
mouse monoclonal antibody, clone HA-7, conjugated to Peroxidase (Sigma-
Aldrich); anti-14-3-3γ and 14-3-3ɀ rabbit antibodies (Santa Cruz Biotechnology); 
anti-α-actinin rabbit antibody (Santa Cruz); mouse monoclonal anti-p53 (DO-1) 
(Santa Cruz); rabbit polyclonal anti-pChk2(Thr68) (Novus Biologicals); rabbit 
polyclonal anti-pChk1(S317) and mouse monoclonal anti-Chk1 (Abcam), the rabbit 
polyclonal HPV-18 E6 phospho-specific antibody (custom-made by Eurogentec) was 
generated using H2N-RQERLQRRRET(PO3H2)QV-COOH peptide in rabbits and 
subjected to affinity purification. The mouse anti-HPV-18 E6 (Arbor Vita) have been 
described previously (Boon and Banks 2013, Boon, Tomaic et al. 2015). The 
appropriate secondary antibodies conjugated to horseradish peroxidase (HRP) 
(Dako) were used    
For immunofluorescence, mouse monoclonal anti-E6AP (BD Transduction labs), 
rabbit polyclonal anti- p53 (Santa Cruz Biotechnology) and chicken anti-(pT485) 
E6AP (A kind gift from Mark Zylka) were used. Appropriate Alexa-Fluor secondary 
antibodies (Life technologies) were used. 
 
Production and purification of GST-fusion proteins 
The appropriate expression plasmids were transformed into E. coli strain DH5-α. 
The clones harboring plasmids were grown in 40ml of Luria Broth (LB) culture 
media containing 75µg/ml Ampicillin (Sigma) overnight at 37
o
C. The overnight 
grown cultures were then transferred into 400ml of LB culture media containing 
75µg/ml Ampicillin and incubated at 37
o
C for 1h. The isopropyl-β-D-
thiogalactopyranoside (IPTG) (Sigma) to a final concentration of 1 nM was added to 
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induce recombinant protein expression and the culture was incubated for 
approximately 3h at 37
o
C on shaker. Post IPTG treatment, the bacteria were 
harvested by centrifugation at 5000 rpm for 5 minutes. Supernatant was discarded 
and the bacterial pellets were lysed with 5-10ml of 1X PBS containing 1% Triton X-
100, and sonicated once/twice for 30 seconds at 80% amplitude. The lysates were 
then centrifuged again at 10000 rpm for 15 minutes. The supernatants were collected 
and incubated with glutathione-conjugated agarose beads on a rotating wheel 
overnight at 4
o
C. The GST-fusion protein containing beads were then centrifuged at 
2000 rpm for 1 minute and the supernatant was discarded. The beads were washed 
thrice with 1X PBS containing 1% Triton X-100. The GST-fusion protein containing 
beads were then stored with 20% glycerol at -20
o
C.  
 
Luciferase assay 
The H1299 cells were transfected with appropriate plasmids expressing the 
luciferase reporters, and cell lysates were collected 24h post-transfection in the lysis 
buffer provided by the manufacturer.  The luciferase assay was performed using the 
Dual-Luciferase reporter assay system (Promega), according to the manufacturer’s 
instructions. The Firefly luciferase and Renilla luciferase readings were taken using a 
TD20/20 Luminometer (Turner Designs). 
 
In vitro binding assays   
In vitro phosphorylation of the GST-fusion proteins was carried out in the presence 
of 10µM non-radiolabelled ATP (NEB). After extensive washes, both the 
phosphorylated and non-phosphorylated GST-fusion proteins were incubated with 
100ng of purified Human recombinant 14-3-3γ protein (Abcam) at 4oC for 1h. The 
samples were then washed and analysed by SDS-PAGE and western blotting.  
 
In vitro translation  
Proteins were translated in vitro using a TNT kit (Promega) and radiolabeled with 
[35S]methionine (Perkin Elmer). The purified GST-fusion proteins were then 
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incubated with in vitro-translated proteins for 1hr at 4
o
C. Proteins were washed with 
1X PBS containing 0.1% NP-40, and were analyzed by SDS-PAGE and 
autoradiography. 
 
 
In vitro phosphorylation assays  
The GST-fusion proteins were washed with kinase buffer (25 mM Tris HCl pH 7.5, 
10mM MgCl2) containing 0.1% NP-40), prior to performing the phosphorylation 
reactions. 
Chk1 and Chk2 kinase assay: The Chk1 and Chk2 kinase assay was performed using 
the Chk1 and Chk2 kinase assay system (Promega). The proteins were then 
incubated with the respective full-length kinases (0.1-0.2μg) diluted in 1X reaction 
buffer A (provided by the manufacturer), together with 2.5μCi [32p]-γ-ATP for 1hr 
at room temperature.  
PKA kinase assay: in vitro phosphorylation of the GST-fusion proteins was carried 
out using 20μl kinase buffer containing 2.5μCi [32p]-γ-ATP and 25 Units of cAMP-
Dependent Protein Kinase Catalytic Subunit (Promega) for 30mins at 30
°
C. The 
buffer composition used for phosphorylation assay: 25 mM Tris HCl, pH 7.5, 10mM 
MgCl2 and 70mM NaCl.   
AKT kinase assay: in vitro phosphorylation of the GST-fusion proteins was carried 
out using 0.2μg of full-length AKT1 diluted in 1X Reaction Buffer A from the 
AKT1 Kinase enzyme system (Promega) for 45 minutes. The buffer composition 
used for phosphorylation assay: 25 mM Tris HCl, pH 7.5, 10mM MgCl2 and 5mM 
DTT.   
The samples were then washed with kinase buffer containing 0.1% NP-40 and 
analysed by SDS-PAGE and autoradiography. 
 
Ubiquitination assays 
The relevant plasmids were transfected into E6AP-null HEK293 cells and after 24h 
cell lysates were prepared, followed by immunoprecipitation using anti-HA- or anti-
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FLAG-conjugated agarose beads to pull down ubiquitin-conjugated proteins (Sigma-
Aldrich), as described previously (Tomaic, Pim et al. 2009). The beads were then 
washed and polyubiquitinated HHR23A or Ring1B protein, respectively, was 
detected using western blotting.   
 
 
Half-life experiments  
After 24hrs of transfection, the cells were treated with cycloheximide (50μg/ml in 
dimethyl sulfoxide [DMSO]) to block protein synthesis at different time points. 
DMSO alone-treated cells were used as the control. Cells were then lysed with SDS-
sample buffer and samples were analysed by western blotting.  
 
Cell synchronization and FACS analysis 
The HeLa cells were treated with 2.5mM thymidine for 15hrs and washed 
thoroughly with 1X PBS and supplemented with complete media. After 9hrs the 
second dose of thymidine was added to block the cells in the G1/S phase. The cells 
were washed with PBS after 15hrs and the medium was replaced. The cells were 
then harvested at different time points as follows: 0h (G1/S phase), 3hrs (S phase), 
8hrs (M1 phase), 9/10hrs (M2 phase) and 12hrs (Next G1 phase). The cell cycle 
phase analysis was done using propidium iodide staining and FACS analysis, using a 
FACScalibur Cell Sorter (Becton Dickinson).  
 
Immunofluorescence assay 
HeLa cells seeded on glass coverslips were transfected with siRNAs against 
appropriate genes for 72h. The cells were then washed with 1X PBS and fixed using 
4% paraformaldehyde for 15mins and permeabilized using PBS containing 0.1% 
Triton X-100 for 5mins. The cells were briefly incubated with 100mM glycine. 
Immunostaining was performed by incubating the coverslips in PBS containing 
appropriate antibodies for 2h at 37
o
 C in a humidified chamber.  The coverslips were 
then washed thrice with PBS and incubated with respective fluorophore conjugated 
74 
 
secondary antibodies for 30mins at 37
o
 C in a humidified chamber.  The coverslips 
were washed thrice with PBS and twice with distilled water and mounted onto glass 
slides. The images were taken using Carl Zeiss LSM510 META confocal 
microscope.  
 
 
Statistical Methods 
All experiments were performed at least thrice, and data are shown as mean and 
standard error of mean. Statistical significance was calculated using the GraphPad 
prism software. To compare two groups the paired Student’s t-test was performed. A 
p-value below 0.05 was considered statistically significant and throughout the p-
values have been defined as follows *p < 0.05, **p < 0.005, ***p < 0.0005, while 
“ns” represents a non-significant p-value above 0.05.  
For the quantification of protein levels from western bolts, the films were scanned 
and the intensity of bands was measured using ImageJ software. The final relative 
quantification values are the ratio of net band to net loading control. 
 
Analysis of qPCR array:   
Control ΔCt:  
Control target gene Ct value - Control house keeping (Reference) gene Ct value 
 
Test ΔCt:  
Test target gene Ct value – Test house keeping (Reference) gene Ct value 
 
ΔΔCt: Test ΔCt - Control ΔCt 
Fold change: 2
(-ΔΔCt)
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Differential phosphorylation of HPV E6 during the cell cycle 
Since phosphorylation plays a major role in influencing E6 substrate specificity, we 
first wanted to ascertain at what point in the cell cycle E6 is normally 
phosphorylated. To do this, HPV-18-containing HeLa cells were synchronized using 
a double thymidine block and, following release, cell extracts were made at different 
points in the cell cycle, as verified by FACS analysis (Figure 15A). The extracts 
were then analysed by western blotting using a specific antibody raised against HPV-
18 E6 phosphorylated on T156 within the E6 PBM (Boon, Tomaic et al. 2015). The 
results in Figure 15B demonstrate very low levels of E6 phosphorylation in 
asynchronously growing cells, with a slight increase in the levels of phospho-E6 in 
the G1 population, and undetectable levels of phosphorylation of E6 in the S and 
G2/M phases of the cell cycle. We also performed an analysis of E6 phospho-status 
in cells that were arrested in G2/M by nocodazole treatment, since previous work 
from the lab (Boon SS thesis) had indicated G2/M arrest could induce E6 
phosphoylation. The results, also shown in Figure 15B, show surprisingly high levels 
of E6 phosphorylation in these G2/M phase-arrested cells, indicating that nocodazole 
can also induce E6 phosphorylation. This contrasts with the results from the double 
thymidine block, where no phosphorylation of E6 was observed in the G2/M 
population of cells. In order to determine whether there is phosphorylation of E6 
when the cells re-enter G1, the assay was repeated and the cells followed for an 
extended period of time, so that the cells would complete the cell cycle and re-enter 
into G1 phase. As can be seen from Figure 15C the cells re-enter the G1 phase 12h 
after release from the double thymidine block. However, in contrast to the cells in 
the G1-arrested cells, there is no detectable phosphorylation of E6 when the cells re-
enter G1. These results suggest that in normal cycling cells the levels of E6 
phosphorylation are very low and only following cell growth arrest, albeit when 
induced through different means, does E6 become phosphorylated. These results 
suggest that there may be multiple kinases capable of phosphorylating E6, depending 
upon the precise stimulus.   
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Figure 15. HPV-18 E6 oncoprotein is differentially phosphorylated during the 
cell cycle. A) FACS analysis of HeLa cells synchronized by double thymidine block 
and subsequently released and harvested at different times to obtain cells in different 
phases of the cell cycle: G1=0h, S=3h, M1= 8h, M2=9/10h. B) Western blot analysis 
of HeLa cell extracts from G1, S, M1 and M2 and  cells probed with antibodies 
against phosphorylated E6 (18-pE6) and total E6; α-actinin was used as a loading 
control. C) FACS analysis of HeLa cells synchronized by double thymidine block 
and subsequently released and harvested at different times to obtain cells in different 
phases of the cell cycle: G1=0h, S=3h, M1= 8h, M2=9/10h and Next G1=12h. D) 
Western blot analysis of HeLa cell extracts from G1, S, M1, M2 and next G1. The 
cells were probed with antibodies against phosphorylated E6 (18-pE6) and total E6; 
α-actinin was used as a loading control. 
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We next investigated whether the nocodazole-induced E6 phosphorylation patterns 
might not, in fact, reflect the cell cycle phase per se, but might, instead, be part of a 
stress response. Indeed, nocodazole has been implicated in induction of oxidative 
stress (Signoretto, Honisch et al. 2016) and DNA damage in the cell (Dalton, Nandan 
et al. 2007, Orth, Loewer et al. 2012). One of the potential mechanisms is inhibition 
of MTH1 (Kawamura, Kawatani et al. 2016), which leads to the incorporation of 
oxidized nucleotides into the DNA and subsequent DNA damage (Gad, Koolmeister 
et al. 2014).   
To ascertain whether the phosphorylation of E6 following exposure to nocodazole 
might be an oxidative stress response, we performed a series of analyses of 
nocodazole-treated HeLa cells, using H2O2 treatment as a positive control for the 
induction of oxidative stress. The E6 phospho-status in these cell extracts was then 
analysed by western blotting. The results are shown in Figure 16A and demonstrate a 
strong increase in the levels of E6 phosphorylation in response to H2O2 and 
nocodazole treatment.  To determine whether this increase in E6 phosphorylation 
was due to induction of oxidative stress, we treated the cells with N-acetyl-cysteine 
(NAC), an antioxidant, following the exposure to H2O2 and nocodazole. As can be 
seen in Figure 16A, H2O2 and nocozadole-induced E6 phosphorylation were 
significantly reduced upon treatment with NAC, suggesting an involvement of 
oxidative stress-response kinases in E6 phosphorylation.  
Interestingly, we also found that blocking protein synthesis using cycloheximide 
(CHX) results in significantly elevated levels of phospho-E6, although, as expected, 
the total level of E6 is reduced under these conditions (Figure 16A). However, in this 
case, NAC did not reduce the phospho-E6 levels, suggesting that the cycloheximide-
induced phosphorylation of E6 is not an oxidative stress response, but rather that 
another stress-response pathway(s) might be involved.  
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Figure 16. HPV-18 E6 is phosphorylated as a result of cellular stress responses.  
A) Representative western blot analysis of HeLa cells treated with H2O2 for 4hrs, 
Nocodazole for 15 hrs or cycloheximide (CHX) for 4hrs, in the presence or absence 
of the antioxidant N-acetyl-cysteine (NAC). Blots were probed with antibodies 
against total HPV-18 E6 and HPV-18 E6 phospho T156; α-actinin was used as a 
loading control.  B) The histogram shows the quantification of pE6 normalized to 
actinin from at least three independent experiments, statistically quantified by using 
Student’s t-test; standard error of the mean is shown. P value: *= 0.05; ns=non 
significant.   
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Potential involvement of DNA Damage Response (DDR) kinases in regulation of 
E6-phosphorylation 
The above results suggest that one source of signaling through oxidative stress could 
be through stimulation of a DDR. Accordingly, we compared the known amino acid 
recognition motifs of a number of DDR kinases, including ATM, ATR, Chk1 and 
Chk2, with the sequence of the HPV-18 E6 PBM. As can be seen from Figure 17A, 
HPV-18 E6 has a good match with the consensus site for Chk1. In order to determine 
whether E6 could be phosphorylated by either Chk1 or Chk2, we performed an in 
vitro kinase assay using the purified kinases with purified HPV-18 E6 GST fusion 
protein in the presence of radiolabeled [γ-32P] ATP. The results in Figure 17B 
demonstrate that HPV-18 E6 is a very good substrate for phosphorylation by Chk1, 
but not by Chk2.  
In order to verify whether the phospho-acceptor site was T156 embedded within the 
E6 PBM, we also included the T156E mutant in the phosphorylation assays. The 
results are also shown in Figure 17B and demonstrate that the T156E mutant 
abolishes the phosphorylation of E6 by Chk1, indicating that the T156E residue is 
the primary phospho-acceptor site in HPV-18 E6. To ascertain whether any of these 
DDR kinases might indeed be involved in stress-responsive E6-phosphorylation in 
vivo, we treated HeLa cells with specific inhibitors of ATR, ATM, Chk1 or Chk2 
kinases for 15hrs and then exposed the cells to either nocodazole or H2O2. The 
results obtained are shown in Figure 18 and demonstrate that under non-stressed 
conditions the levels of E6 phosphorylation are, again, very low. Following exposure 
to nocodazole, E6 is clearly phosphorylated, but this is greatly decreased following 
inhibition of the Chk1 kinase, suggesting that this is responsible for phosphorylating 
E6 in response to nocodazole treatment (Figure 18B). In contrast, in the case of 
H2O2, the greatest inhibition of phosphorylation occurs following treatment with the 
Chk2 inhibitor (Figure 18C). This was rather surprising considering the low level of 
phosphorylation of E6 by Chk2 observed in vitro in Figure 17. However, previous 
studies had indicated that one downstream kinase activated by DDR kinases was 
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PKA (Searle, Schollaert et al. 2004, Bensimon, Aebersold et al. 2011, Marazita, 
Ogara et al. 2012). Since we had previously shown that HPV-18 E6 is a very good 
substrate for PKA in vitro (Kuhne, Gardiol et al. 2000, Boon and Banks 2013, Boon, 
Tomaic et al. 2015), we repeated the analysis but also treated cells with H89 to block 
PKA activity in the H2O2 exposed cells. The results in Figure 18D show a marked 
inhibition of H2O2-induced phosphorylation of E6 following the inhibition of either 
PKA or Chk2. These results indicate that PKA is most likely responsible for 
phosphorylating E6 following the activation of Chk2 in response to an H2O2 
oxidative stress-induced DDR. In order to further confirm the Chk2 activation after 
exposure to H2O2, we analysed the levels of phosphorylated Chk2 (Thr 68). Indeed, 
H2O2 treatment leads to a significant increase in pChk2 levels, and inhibition of ATM 
and ATR also reduced pChk2 levels. However there was a striking increase in the E6 
phosphorylation when ATM and Chk1 were inhibited (Figure 18C, D and E). In 
order to investigate whether this increase in E6 phosphorylation following inhibition 
of ATM and Chk1 was also mediated by PKA, the assay was repeated in the 
presence of the PKA inhibitor H89. The results in Figure 18E demonstrate that 
increased phosphorylation of E6 following the inhibition of ATM or Chk1 is 
mediated largely by PKA. This observation supports previous studies showing that 
Chk1 inhibition causes replication stress and activates the ATR pathway (Gagou, 
Zuazua-Villar et al. 2010, Petermann, Orta et al. 2010, Choi, Toledo et al. 2011) and 
that ATR signals activate Chk2 in response to H2O2 treatment (Zhang, Gao et al. 
2014), which subsequently activates PKA (Bensimon, Aebersold et al. 2011).   To 
justify the specificity and efficacy of the inhibitors, we analysed H2O2-induced 
phospho-Chk1 and phospho-Chk2 levels, which are ATR and ATM substrates 
respectively.  As can be seen in Figure 18E, inhibition of only ATR and ATM 
resulted in reduced levels of p-Chk2, as both of these kinases can directly 
phosphorylate Chk2 in response to H2O2-induced DDR. Similarly, only inhibition of 
ATR abolished phosphorylation of Chk1 (Figure 18F), whilst other inhibitors did not 
affect the p-Chk1 levels in response to H2O2 treatment. This supports the good 
specificity and efficacy of these inhibitors in our assays.   
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Figure 17. HPV-18 E6 is phosphorylated by the DNA damage response 
kinase Chk1.  A) The consensus phosphorylation motifs recognized by ATR, 
ATM, Chk1 and Chk2 are compared with the sequence of the carboxy-terminus 
of HPV-18 E6. B) In vitro phosphorylation assay using purified GST fusion 
proteins of of wild type HPV-18 E6 and the HPV-18 E6 T156E mutant incubated 
with Chk1 or Chk2 in the presence of [γ32P]-ATP. Upper panels show the 
autoradiograms and the lower panels show the Coomassie-stained SDS PAGE 
gels. Arrows indicate the phospho E6, the GST E6 fusion protein, the GST 
control and the auto-phosphorylated Chk1 and Chk2. 
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Figure 18. Different DDR response pathways lead to phosphorylation of E6 in 
response to different stresses.  
A-C) HeLa cells were treated with specific inhibitors of ATR, ATM, Chk1 or Chk2 
for 15h, then treated with DMSO as a control (A) or treated with Nocodazole (B) or 
H2O2 (C). Western blots were probed with antibodies against total HPV-18 E6 and 
HPV-18 E6 phospho T156. α-actinin was used as a loading control. D) The assay 
was repeated with H2O2, additionally treating cells with a specific PKA inhibitor, 
H89. The pE6 levels were detected in HeLa cells in the presence or absence of PKA 
inhibitor (H 89), as well as Chk1i and Chk2i. E) HeLa cells were treated with H2O2, 
together with a specific PKA inhibitor, H89, and DDR kinase inhibitors as indicated. 
The pChk2 levels were analysed to check the efficacy of ATMi and ATRi, and pE6 
levels were also analysed in the presence or absence of the various inhibitors. F) 
HeLa cells were treated with H2O2 together with specific DDR kinase inhibitors as 
indicated. The pChk1 levels were analysed to check the efficacy of DDR inhibitors. 
The histograms show the quantification of levels of pE6 from respective western 
blots as indicated, normalized to actinin.  
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Having shown that DDR response kinases play an important role in regulating E6 
phosphorylation, we were interested to know whether ‘DDR-modulators’ might also 
affect E6-phosphorylation. Since various chemotherapeutic agents have been shown 
to indirectly modulate the DDR pathways (Cossar, Schache et al. 2017), it was of 
interest to know what effect they might have on E6 phosphorylation. We used 
various chemotherapeutic agents that are known to target molecules involved in the 
DNA replication and DNA repair pathways, as listed in Figure 19A. HeLa cells were 
exposed to the different chemotherapeutic drugs, and the cells were then harvested 
and the levels of E6 phosphorylation ascertained by western blotting. At the same 
time, the levels of p53 expression were also analysed. The results of the analysis are 
shown in Figure 19B and demonstrate a number of interesting points. Inhibition of 
topoisomerase, ribonucleotide reductase and DNA replication all provoke a 
pronounced increase in the levels of E6 phosphorylation, suggesting that multiple 
DDRs can signal to E6. In contrast, PARP inhibitors have been documented to 
induce double-strand DNA breaks, resulting in the accumulation of DNA damage in 
the cell (Booth, Cruickshanks et al. 2013, Jelinic and Levine 2014). We used three 
different PARP inhibitors, but none of them induced E6 phosphorylation in HeLa 
cells, and this appeared to be related to the very low level of DDR activation that was 
induced in these cells following PARP inhibition, compared with H2O2 treatment, as 
determined by analysing the p-Chk1 and γ-H2AX levels (Figure 19C). Finally, none 
of the drugs induced an increase in p53 levels, consistent with E6’s ability to target 
p53 for degradation (Scheffner, Werness et al. 1990, Scheffner, Huibregtse et al. 
1993) and, in a subset of cases, p53 levels were also further reduced. This is 
consistent with previous studies showing that induction of certain DDR pathways 
can also increase the levels of E6-induced p53 degradation (Tomaic, Pim et al. 
2011). 
Having found that multiple DDR-inducing agents could increase the levels of E6 
phosphorylation, we then wanted to determine whether Chk1 or Chk2 was 
responsible. To do this we chose to analyse cisplatin: HeLa cells were exposed to 
cisplatin in the presence of different DDR kinase inhibitors. The cells were then 
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harvested and the levels of E6 phosphorylation were analysed by western blotting. 
The results in Figure 19D demonstrate that the majority of E6 phosphorylation that 
occurs following exposure to cisplatin is Chk1-dependent.  
I also observed that the total E6 levels are very low in the presence of various DNA 
damage inducing agents.  In order to determine whether a similar induction of E6 
phosphorylation takes place in the cells other than HeLa, we proceeded to repeat the 
assays in C4-1 cells which are also HPV-18 positive cervical cancer derived cells. As 
can be seen in Figure 20, both teniposide and etoposide are able to induce a strong 
phosphorylation of E6, whereas cisplatin-induced pE6 levels in C4-1 cells were 
relatively low, compared with those in HeLa cells. This could be presumably due to 
differences in the activation of DDR pathway in different cell lines. The specificity 
of anti-18-pE6 antibody was tested in NIKS and NIKS stably expressing 16E6 and 
16E6 ΔPBM, in the presence of Etoposide together with or without CBZ. HeLa cells 
treated with Etoposide or cisplatin were used as positive control for antibody. Our 
results demonstrate that the 18-pE6 antibody is highly specific (Figure 20C).   
Taken together, the above results indicate that various forms of DDR result in 
phosphorylation of E6. This can be mediated by Chk1 in response to an oxidative 
stress response following treatment with nocodazole, and in response to a DDR 
following treatment with cisplatin. However, in the case of an oxidative stress 
response induced by H2O2, the phosphorylation of E6 occurs through a Chk2- 
activated pathway that requires downstream PKA to phosphorylate E6 directly.  
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Figure 19. Exposure to DNA damage-inducing chemotherapeutic agents can 
induce E6 phosphorylation. 
A) Table showing the chemotherapeutic agents used and their cellular targets. B) 
HeLa cells were treated with the indicated drugs for 15h prior to harvesting and 
analyzing by western blot probed with antibodies against total HPV-18 E6, HPV-18 
pE6 and p53; α-actinin was used as a loading control. C) HeLa cells were either 
untreated or treated with H2O2 for 4hrs or with the indicated PARP inhibitors for 15h, 
and the levels of pChk1, total Chk1, γ-H2AX and HPV-18 pE6 were analysed by 
western blotting. The α-actinin was used as a loading control. D) The assay was 
repeated with cisplatin, additionally including specific kinase inhibitors, and the 
western blot was probed with antibodies against total HPV-18 E6, HPV-18 pE6 and 
α-actinin was used as a loading control.  
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Previous studies have reported that phosphorylation of E6 within the PBM results in 
inhibition of the PDZ interaction (Kuhne, Gardiol et al. 2000, Boon and Banks 2013, 
Boon, Tomaic et al. 2015). Therefore, the prediction from these studies is that the 
increased phosphorylation of E6 induced by DDR kinases should result in the rescue 
of certain PDZ domain containing substrates of E6 from proteasome mediated 
degradation. To investigate this, we treated HeLa cells with Triapine or cisplatin and 
assessed the levels of expression of Dlg. As a positive control, we transfected the 
cells with siRNA against E6/E7. The results in Figure 21 show that the ablation of 
E6 results in increase in the levels of Dlg protein, which is consistent with previous 
studies. Interestingly, treatment with Triapine or cisplatin also rescues the levels of 
Dlg protein expression to a degree which reflects the induction of phosphorylation of 
E6.   
 
Taken together, the results demonstrate that a functional consequence of DDR kinase 
mediated E6 phosphorylation is rescue of PDZ domain containing substrate of E6 
from E6-induced degradation, consistent with the phosphorylation event making E6 
incapable of binding PDZ domains.  
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Figure 20. E6 is susceptible to phosphorylation upon treatment with 
chemotherapeutic drugs in the C4-1 cervical cancer cell line.  
C4-1 (A) and HeLa (B) cells were treated with the indicated chemotherapeutic drugs 
for 15h. Cell extracts were then analyzed by western blot probed with antibodies 
against total HPV-18 E6 and HPV-18 pE6; α-actinin was used as a loading control. 
C) The specificity of anti-18-pE6 antibody was tested in NIKS, 16E6 and 16E6 
ΔPBM NIKS in the presence or absence of Etoposide and CBZ as indicated. HeLa 
cells treated with Etoposide or cisplatin were used as positive control for antibody.  
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Figure 21. Phosphorylation of E6 rescues Dlg1 expression in HeLa cells.  
HeLa cells were treated either with the indicated chemotherapeutic drugs, or with 
siRNA against E6/E7 plus cisplatin for 15h. Cell extracts were analyzed by western 
blot probed with antibodies against Dlg1, total HPV-18 E6 and HPV-18 pE6; α-
actinin was used as a loading control. The histogram shows quantification of Dlg 
expression normalized to actinin control.  
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The HPV-18 E6 PBM perturbs p53 transcriptional transactivation activity  
Having shown that the HPV E6 PBM can be phosphorylated by a number of stress-
response kinases in response to various cellular stresses, the next question was: what 
is the biological result of the E6 phosphorylation? Interestingly, a number of recent 
studies with HPV-16 and HPV-18 in organotypic systems have shown that the E6 
PBM is required for viral genome episomal maintenance and, furthermore, that p53 
loss can partly rescue this episome loss following the mutation of the E6 PBM 
(Lorenz, Rivera Cardona et al. 2013, Brimer and Vande Pol 2014). It is also known 
that HPVs activate the ATM/ATR DNA repair pathway and that this is necessary for 
HPV genome amplification (Moody and Laimins 2009, Reinson, Toots et al. 2013, 
Hong, Cheng et al. 2015). Taken together, these studies suggest a probable link 
between the phosphorylation of the E6 PBM and perturbation of p53 activity. One 
potential common link between these observations is 14-3-3, since this family of 
proteins is linked to the regulation of p53 transcriptional transactivation activity 
during cell cycle check-point control (Waterman, Shenk et al. 1995, Waterman, 
Stavridi et al. 1998, Rajagopalan, Jaulent et al. 2008).  
 
Therefore, we initiated a series of studies to investigate whether the E6 PBM has any 
effect on p53's transcriptional transactivation of a variety of different promoters: 
PUMA, p21, Mdm2 and BAX, using Renilla luciferase as a control of transfection 
efficiency.  Since a major function of HPV-18 E6 is the degradation of p53 through 
the ubiquitin proteasome pathway (Scheffner, Werness et al. 1990, Scheffner, 
Huibregtse et al. 1993), it was necessary to perform our studies in the presence of the 
proteasome inhibitor, CBZ (MG132). The p53-null H1299 cells were transfected 
with the appropriate reporter constructs, together with p53 and different HPV-18 E6 
expression plasmids. In the first analysis, we focused on wild type HPV-18 E6 and 
the HPV-18 E6 ΔPBM mutant. After 24hrs, cells were harvested and luciferase 
activity was measured using the dual-luciferase assay system, and the results are 
shown in Figure 22. As can be seen, there are some striking differences between 
these promoters in how the E6 PBM can modulate p53 transcriptional activity 
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following proteasome inhibition. In all cases, in the absence of proteasome inhibition 
the wild type and E6ΔPBM mutant show similar abilities to inhibit p53 
transcriptional activity. Following proteasome inhibition, the wild type E6 retains the 
ability to inhibit p53 transcriptional activity. In contrast, for the E6ΔPBM mutant this 
only holds true for the BAX promoter (Figure 22C), where both wild type and 
mutant E6 retain inhibition of p53 transcriptional activity in the presence of 
proteasome inhibitors. In the case of p21 (Figure 22A), the E6ΔPBM allows a 
modest increase in p53 transcriptional activity, but this is even more apparent with 
PUMA (Figure 22B) and Mdm2 (Figure 22D) where lack of a PBM allows a marked 
increase in the level of p53 transcriptional activity in the presence of proteasome 
inhibitors.  
In order to elucidate whether this effect was linked to the ability of E6 to be 
phosphorylated, and not due to an overall defect in PDZ interaction, we included the 
HPV-18 E6 R153G mutant, which we have shown previously to be defective in the 
phospho-recognition motif for PKA (Boon and Banks 2013) and for Chk1 (See 
Figure 28B), but which retains PDZ binding potential. The results on the Mdm2 
promoter are shown in Figure 22D and demonstrate that it has similar ability to block 
p53 transcription as the wild type E6, but that following addition of proteasome 
inhibitors this activity is compromised and there is a dramatic increase in p53 
transcriptional activity, comparable to that seen with the E6ΔPBM mutant.    
 
Taken together, these results demonstrate that HPV-18 E6 can inhibit p53 
transcriptional activity in a manner that is PBM and phospho-site dependent, 
indicating that phosphorylation of E6 within the PBM in response to a variety of 
DDR signals can directly link PBM function to the inhibition of p53 transcriptional 
activity. 
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Figure 22. The HPV-18 E6 PBM contributes towards inhibition of p53 
transcriptional transactivation activity.   
H1299 cells were transfected with the indicated promoter constructs upstream of a 
luciferase promoter (A: p21-Luc, B: PUMA-Luc, C: BAX-Luc, D: Mdm2-Luc), 
together with p53 and either wild type or mutant HPV-18 E6 in the presence or 
absence of the proteasome inhibitor CBZ. The histograms show the results from at 
least three independent experiments, quantified using Student’s t-test and the 
standard error of mean is shown. Also shown are the p values (* <0.05, **< 0.005, 
***<0.0005, ns=non significant) for the changes in the relative luciferase activity. 
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We next wanted to investigate how many other p53 responsive genes might be 
similarly regulated. But we wanted to perform our assays in a more relevant 
biological setting and to do this, we decided to focus on NIKS (Normal Immortalized 
Keratinocytes), also stably expressing wild type 16E6 or the 16E6 ΔPBM mutant.  
In the next set of assays, we wanted to monitor p53-mediated induction of p21 in the 
NIKS also stably expressing wild type 16E6 or 16E6 ΔPBM mutant in the presence 
or absence of DNA damaging agents or proteasome inhibitor. In order to ascertain 
whether there was similar effect as can be seen in the p21 promoter transcriptional 
transactivation in H1299 cells (Figure 23A), NIKS were treated with Etoposide and 
Thymidine to induce p53 DDR in the presence or absence of CBZ. The levels of p53 
and p21 were then analysed after 24h by western blotting. The results in Figure 23B 
show that  the p21 expression is elevated in 16E6 ΔPBM mutant as compared to 
NIKS expressing wild type 16E6, despite the levels of p53 being equal in both the 
cell lines.  
Having found that the PBM could affect the p53 transcriptional activity also in NIKS 
cells, we then wanted to determine whether the increased p53 transcriptional activity 
seen with the 16E6 ΔPBM mutant was due to 14-3-3. To do this, the assay was 
repeated in the presence of the pan 14-3-3 inhibitor, Difopein. The results are shown 
in Figure 24A and demonstrate that there is a modest reduction in the levels of p21 
protein expression in the presence of pan 14-3-3 inhibitor. This suggest that 14-3-3 is 
important for p53 induction of p21, which is in agreement with previous studies 
(Rajagopalan, Jaulent et al. 2008), and also provides a mechanism whereby the E6 
PBM interaction with 14-3-3 might inhibit 14-3-3 regulation of p53 transcriptional 
activity. 
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Figure 23. E6's inactivation of p53 is mediated through the PBM. 
A) H1299 cells were co-transfected with plasmids expressing the Luciferase reporter 
gene promoter p21-Luc and FLAG- p53, together with either HPV-16 E6 wild type 
or ΔPBM mutant in the presence or absence of CBZ. The histogram represents the 
mean relative luciferase readings from at least three independent experiments, and 
standard deviation is shown. Also shown is the p value (significance value: </= 0.05) 
of the changes of the relative luciferase activity. B) Western blot analysis of p53 
responsive gene, p21, in NIKS, 16E6 NIKS and 16E6 ΔPBM NIKS upon DNA 
damage-induced p53 transcriptional trans-activation, in the presence or absence of 
proteasome inhibitor (CBZ). Eto: Etoposide, Thy: Thymidine. The histogram shows 
quantification of p21 expression normalized to actinin from at least 3 independent 
western blot experiments. 
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 Figure 24. Inhibition of 14-3-3 alters E6 PBM-mediated p53 inactivation. 
A) Western blot analysis of p53 responsive gene, p21, in NIKS, 16E6 NIKS and 
16E6 ΔPBM NIKS upon DNA damage-induced p53 transcriptional trans-activation, 
in the presence or absence of proteasome inhibitor (CBZ). B) The histogram shows 
the results from at least three independent experiments, statistically quantified by 
using Student’s t-test; standard error of the mean is shown. P value: *= 0.05; ns=non 
significant. UT: Untreated, Eto: Etoposide, Thy: Thymidine. 
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We then proceeded to investigate in more detail which other p53 responsive genes 
were similarly regulated in a E6 PBM dependent manner. To do  this, we performed 
experiments using a p53 RT PCR array. This array covers 84 genes, which are 
involved in:  1. p53 Activation,  2. p53 regulation, 3. p53 interactions, 4.Apoptosis, 
5.Cell cycle and 6.DNA damage response.  
For the array analysis, we performed this in NIKS, 16E6 NIKS and 16E6 ΔPBM 
NIKS. The cells were treated with DNA damaging agent, etoposide and proteasome 
inhibitor, as before. The real-time PCR data was normalized with the GAPDH 
housekeeping gene. To calculate the fold upregulation or downregulation at the 
mRNA level, the values from the 16E6 NIKS and 16E6 ΔPBM NIKS were 
normalized to NIKS, and the data is shown in histograms in Figure 25.  Of the 84 
genes assessed, 19 were seen to be upregulated in 16E6 ΔPBM NIKS compared with 
16E6 NIKS, whilst only 3 were downregulated. Eleven of the 84 genes are direct 
targets of p53, of which four (Bbc3, Ccng1, Cdkn1a and Tnfrsf10b) were 
upregulated in 16E6 ΔPBM NIKS cells, compared with 16E6 NIKS.  
We also validated some of these targets at the protein level by western blot analysis 
and, as can be seen in Figure 13, Mcl-1, p21, p63 and E2F1 were regulated in an E6 
PBM- and 14-3-3-dependent manner. In agreement with the data from the mRNA 
analysis, the expression levels of PCNA were also elevated in 16E6 ΔPBM NIKS, 
compared with 16E6 NIKS; however, inhibition of 14-3-3 did not change these 
levels, suggesting that PCNA is regulated in a PBM-dependent, but independent 
from 14-3-3. We also tested the levels of Cyclin-B1 and EGFR, which showed 
significant differences at the mRNA level, but not at the protein level. This analysis 
suggests that E6, through its PBM, regulates various p53 responsive genes, as well as 
some of its interacting partners and regulators (Figure 26).  
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Figure 25. Analysis of p53 signaling in NIKS-16E6 and NIKS-16E6ΔPBM by 
RT PCR array.  
The histograms show the results from two independent experiments. The ΔΔCt 
values were obtained by normalizing the Ct values of genes from NIKS-16E6 and 
NIKS-16E6ΔPBM cell lines with those of NIKS cells. GAPDH was used as 
housekeeping gene to normalize the data. Student’s t-test was used for statistical 
quantification; standard error of the mean is shown. P value: *= 0.05, **=0.005. 
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Figure 26. Inhibition of 14-3-3 alters E6 PBM-mediated p53 inactivation with 
regard to certain genes. 
A and B) Western blot analysis of p53 target gene expression: Mcl-1, p21, p63, 
EGFR, PTEN, Cyclin-B1, PCNA and E2F1 protein levels were examined in NIKS, 
16E6 NIKS and 16E6 ΔPBM NIKS upon DNA damage induced by etoposide, 
together with proteasome inhibitor (CBZ), and in the presence or absence of a 14-3-3 
inhibitor. The level of DNA damage was analysed using the DNA damage marker γ-
H2AX; α-actinin was used as loading control. 
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Identification of sequence constraints governing Chk1 and PKA 
phosphorylation of HPV-18 E6 
The above studies demonstrate that multiple cellular kinases can phosphorylate E6 in 
response to a variety of different signaling pathways and stress responses. However, 
a critical question remains as to how to separate phosphorylation of E6 by different 
kinases from the basic PDZ binding function conferred by T156 residue. Therefore, I 
was next interested in analyzing whether different mutations could be introduced into 
the E6 PBM which would retain PDZ recognition but abolish phosphorylation of E6 
by different kinases.  
We have previously defined residue R153, just upstream of the HPV-18 E6 PBM, as 
being essential for PKA recognition of the E6 PBM (Kuhne, Gardiol et al. 2000, 
Boon and Banks 2013, Boon, Tomaic et al. 2015), but we have no information on 
whether sequences downstream of the phospho-acceptor site at T156 might also play 
a role in E6 phosphorylation by Chk1, PKA or AKT. This is important, as we know 
that non-canonical residues play an important role in E6 PDZ selection (Thomas, 
Dasgupta et al. 2008, Luck, Charbonnier et al. 2012, Thomas, Myers et al. 2016), 
and we wanted to determine if this was also true for kinase recognition of E6. In 
order to investigate this we produced three mutations within the HPV-18 E6 PBM: 
the wildtype sequence RRETQV was mutated to RRETQstop, RRETstop and 
RRETAA (Figure 27A). The wild type and mutant E6 proteins were expressed as 
GST fusion proteins and purified, then subjected to in vitro phosphorylation with 
purified Chk1, PKA or AKT. First, we examined which upstream residues were 
required for Chk1 recognition of E6. As shown in Figure 27B, the R153A mutation 
abolishes Chk1 phosphorylation of E6, as has previously been shown for PKA 
phosphorylation. Removal of either of the last two carboxy-terminal residues has a 
marked deleterious impact upon the ability of both Chk1 and PKA to phosphorylate 
HPV-18 E6, highlighting the critical importance of residues downstream of T156 for 
efficient kinase recognition (Figure 27B and C). Interestingly, the double mutant, 
RRETAA shows greatly reduced phosphorylation with Chk1 but not with PKA or 
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AKT. Differences in kinase recognition were also observed in the case of the 
RRETQstop mutant, where Chk1 can still phosphorylate the E6 PBM at T156, 
whereas PKA cannot. However, in the case of AKT phosphorylation, mutations 
downstream of the phospho-acceptor site had minimal impact on AKT kinase 
recognition (Figure 27D).   
These results demonstrate that both Chk1 and PKA phosphorylation of HPV-18 E6 
are critically dependent upon the presence of two amino acids immediately 
downstream of the phospho-acceptor site, but alanine substitutions are perfectly 
acceptable, while AKT kinase recognition does not depend on the presence of these 
residues. To our knowledge, this is the first demonstration that a Chk1 and PKA 
phospho-acceptor site can be affected by the proximity of the protein's carboxy-
terminus.  
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Figure 27. Kinase recognition of HPV-18 E6 is dependent on both upstream and 
downstream residues of the phospho-acceptor site.   
A) The consensus phosphorylation motifs recognized by Chk1, PKA and AKT, plus 
the 14-3-3 and PDZ interaction motifs are shown. The sequence of the carboxy-
terminus of HPV-18 E6 and the various mutations generated within this region are 
shown below. The purified GST fusion proteins were incubated with either Chk1 
(B), PKA (C) or AKT (D) and [γ-32P]ATP. Proteins were then analysed by SDS-
PAGE and autoradiography. The upper panels show representative autoradiogram of 
the different in vitro phosphorylated wild type and mutant 18E6 GST fusion 
proteins; the lower panels show the Coomassie Blue-stained gel. The histograms 
show the quantification of autoradiograms from at least three independent 
experiments; standard deviations are shown.  
C 
D 
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Different HPV E6 types show different susceptibility to phosphorylation by 
Chk1  
Previous studies had also shown a significant variation in how different HPV E6 
types could be phosphorylated by AKT or PKA (Boon and Banks 2013, Boon, 
Tomaic et al. 2015). Having shown that, both upstream and downstream residues 
around the phospho-acceptor site within HPV-18 E6 PBM play critical role in kinase 
recognition, we next wanted to ascertain if this is conserved throughout different 
HPV E6 types. Although, all high risk HPV E6 possesses conserved PBM at their 
carboxy-terminus, there is a high degree of variation in their sequences upstream and 
downstream of phospho-acceptor site, as shown in Figure 28A. To investigate this, 
we initiated series of in vitro kinase assays using purified Chk1 and PKA kinases 
with different HPV E6 GST-fusion proteins, in the presence of radiolabeled ATP. As 
can be seen in Figure 28B, HPV-16, -39 and -18 E6 are heavily phosphorylated by 
Chk1 kinase, whilst HPV- 31, -33, -35, -51, -56 and -68 are weakly phosphorylated. 
Similar assay was performed using PKA kinase and we observed very striking 
differences in their phosphorylation, as shown in Figure 28C. The HPV- 18 E6 and -
39 E6 are the strongest substrates of PKA, followed by HPV-58, -35 and -16 E6 
respectively. As with the Chk1 kinase, HPV- 31, -33, -51, -56 and -68 are weakly 
phosphorylated by PKA. The high degree of phosphorylation by both Chk1 and PKA 
correlates with the enriched upstream arginine residues in the case of HPV-16, -18 
and -39. The HPV-35 and HPV-58 are strong substrates of PKA but not of Chk1, 
potentially due to the presence of downstream inhibitory residues. These results 
suggest that, in agreement with previous studies, the non-canonical residues play 
critical role is kinase recognition. 
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Courtesy: Arushi Vats 
Figure 28. Different HPV E6 types display different levels of phosphorylation. 
A) The carboxy-terminus sequence of different HPV E6 types.  B and C) The 
purified GST fusion proteins were incubated with either Chk1 or PKA and [γ-
32
P]ATP. Proteins were then subjected to SDS-PAGE and autoradiographic analysis. 
Upper panel represents autoradiogram of different in vitro phosphorylated wild type 
and mutant 18E6 GST fusion proteins; lower panel, the Coomassie blue-stained gel.  
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Non-canonical residues play an important role in E6-PDZ and E6-14-3-3 
recognition  
We were next interested in ascertaining how these mutations in the HPV-18 E6 PBM 
would affect PDZ and 14-3-3 recognition. To do this we first performed an in vitro 
interaction assay using purified HPV-18 E6-GST-fusion proteins with in vitro-
translated, radiolabeled MAGI-1 and Discs Large (Dlg). The results obtained are 
shown in Figure 29A and B, and show that mutation or removal of any of the amino 
acid residues downstream of T156 destroys the ability of E6 to interact with PDZ 
substrates, confirming that PDZ recognition requires the complete consensus 
recognition motif (ETQV). 
 
We then monitored the ability of these mutants to interact with 14-3-3 following 
phosphorylation. The different HPV-18 E6-GST-fusion proteins were purified and 
subjected to in vitro phosphorylation with Chk1 kinase using non-radioactive ATP; 
following extensive washing, they were incubated with purified 14-3-3γ and 14-3-3ɀ. 
The bound protein was detected by western blotting and the results are shown in 
Figure 30A and B. As expected, the R153A and T156E mutants fail to interact with 
14-3-3 proteins, as they cannot be phosphorylated by Chk1.  The RRETstop 
mutation, which abolishes Chk1 phosphorylation, also destroys 14-3-3γ and 14-3-3ɀ 
interaction, whilst the RRETQstop mutant interacts with both 14-3-3γ and 14-3-3ɀ in 
a manner close to wild type HPV-18 E6, which is consistent with the efficiency with 
which this mutant is phosphorylated by Chk1. Surprisingly, the RRETAA double 
mutant, which shows reduced levels of phosphorylation, appears to interact strongly 
with 14-3-3ɀ, but fails to interact with 14-3-3γ. These results suggest that different 
14-3-3 isoforms might also interact with different E6s in subtly different ways 
depending on the precise sequence of the PBM as well as the degree to which E6 is 
phosphorylated.  
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To support the finding that 14-3-3 proteins can associate directly with HPV-18 E6 in 
a phosphorylation-dependent manner and to confirm that their interaction is not 
mediated by E6-bound PKA or Chk1 kinase, we made use of ATP-ϒ-S in our kinase 
assays. This form of ATP is nonhydrolyzable, or is poorly hydrolyzed compared 
with ATP. As can be seen in Figure 31A, 14-3-3γ can associate with HPV-18 E6 
when phosphorylated with PKA, but when we used ATP-ϒ-S, it fails to interact with 
E6. Similarly, 14-3-3ɀ interaction with E6 is inhibited in the presence of ATP-ϒ-S 
(Figure 31B), suggesting that the 14-3-3 association with E6 is direct and 
phosphorylation-dependent.  
Next, we also wanted to confirm the interaction of PKA with different E6-GST 
fusion proteins in the presence of ATP-ϒ-S. As can be seen in Figure 31C, the 
western blot analysis of catalytic subunit of PKA kinase shows that, the kinase is 
able to recognize the wild type and all different PBM mutants of E6. This suggests 
that differences in the phosphorylation of different E6 mutants are not due to kinase 
recognition of PBM but due to overall requirement of specific amino acids within the 
motif.      
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Figure 29. Mutations in HPV-18 E6 PBM region abolish PDZ interactions.  
The wild type and mutant 18E6 GST fusion proteins were incubated with in vitro-
translated radiolabeled ([35S]methionine) MAGI1 (A) or Dlg (B) as indicated. 
Following extensive washing, bound proteins were detected by using SDS-PAGE 
and autoradiography. Upper panel, autoradiogram; lower panel, the Coomassie Blue-
stained gel. The histograms show quantification of interaction of different 18E6 
PBM mutants with MAGI1 (data shown from 2 experiments) or Dlg1 (data shown 
from 3 experiments) (as indicated), normalized to wild type 18E6. 
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Figure 30. Non-canonical residues in the HPV-18 E6 PBM play an important 
role in E6-14-3-3 recognition.  
A direct interaction assay with GST-E6 fusion proteins and purified 14-3-3γ (A) and 
14-3-3ɀ (B). Purified GST fusion proteins were either untreated or subjected to 
phosphorylation (indicated as “P”) with Chk1 in the presence of non-radiolabeled 
ATP. They were then incubated with purified recombinant 14-3-3γ and 14-3-3ɀ. 
After extensive washing, the bound protein was detected by Western blotting using 
anti-14-3-3γ or 14-3-3ɀ antibody (upper panel). Ponceau Red staining of the 
nitrocellulose membrane shows the GST fusion proteins (lower panel).  
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Figure 31. The phospho-dependent interaction of HPV-18 E6 with 14-3-3 is 
direct. 
A direct interaction assay between GST-E6 fusion proteins and purified 14-3-3γ (A) 
and 14-3-3ɀ (B). Purified HPV-18 E6 GST fusion proteins were either untreated or 
subjected to phosphorylation (indicated as “P”) with PKA (A) or Chk1 (B) in the 
presence of non-radiolabeled ATP or ATP-ϒ-S. They were then incubated with 
purified recombinant 14-3-3γ or 14-3-3ɀ. After extensive washing, the bound protein 
was detected by Western blotting using anti-14-3-3γ or 14-3-3ɀ antibody (upper 
panel). Ponceau Red staining of the nitrocellulose membrane shows the GST fusion 
proteins (lower panel). C) Western blot analysis of interaction of PKA Caα kinase 
with different E6-GST fusion proteins in the presence of ATP-ϒ-S. 
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Having shown that the different HPV E6 types can be phosphorylated differentially, 
the next question was: Is there any direct biological consequence of this E6 
phosphorylation? As described and demonstrated earlier, HPV-18 E6 
phosphorylation within the PBM controls p53 functions by inactivating its 
transcriptional transactivation ability with respect to certain promoters. We wanted to 
test whether E6s from the different HPV types could regulate p53 functions in a 
similar way, and to determine whether it correlates with their capacity to be 
phosphorylated.  
To do that, we used the p53-responsive promoter MDM2 cloned into a luciferase 
reporter plasmid (MDM2-Luc), also including Renilla luciferase as a transfection 
efficiency control. The p53-null H1299 cells were transfected with the reporter 
construct, together with p53 and different HPV E6 expression plasmids, in the 
presence or absence of CBZ (to rescue the degradation of p53 by E6) and etoposide 
(in order to induce E6 phosphorylation). After 24hrs cells were harvested and 
luciferase activity was measured using the dual-luciferase assay system, and the 
results are shown in Figure 32. As can be seen, the HPV-18 E6ΔPBM mutant allows 
a significant increase in p53 transcriptional activity in the presence of proteasome 
inhibitor and etoposide, whilst this activity is suppressed in the case of wild type 
HPV-18 E6, suggesting a E6 phosphorylation-dependent p53 inactivation. 
Interestingly, in the presence of HPV-56 E6 and HPV-68 E6, both of which are 
poorly phosphorylated, there is a marked increase in the p53 transcriptional activity 
in the presence of proteasome inhibitor and etoposide. These data suggest that E6 
phosphorylation plays an important role in regulating p53 functions.  
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Figure 32. Phosphorylation of the E6 PBM affects the transcriptional 
transactivation of a p53-responsive promoter.  
H1299 cells were transfected with the MDM2-Luc construct (the MDM2 promoter 
cloned  upstream of a luciferase gene), together with plasmids expressing p53 and 
the following HPV E6 proteins: HPV-18 E6, HPV 18 E6 ΔPBM mutant, HPV- 39 
E6, HPV-56 E6 and HPV-68 E6, in the presence or absence of the proteasome 
inhibitor CBZ. The histograms show the luciferase assay results from at least three 
independent experiments, quantified using Student’s t-test, and showing the standard 
error of mean. Also shown are the p values (* <0.05, ns=non significant) for the 
changes in the relative luciferase activity. 
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Investigation of how phosphorylation modulates E6 utilisation of the E6AP 
ubiquitin ligase  
 
In the preceding sections, I investigated how different signaling pathways could 
modulate E6 function via phosphorylation of the E6 PBM. Whilst there is also an 
indication of how post-translational modifications of specific E6 substrates might 
affect their susceptibility to E6 targeting, there is as yet no information on how this 
might modulate E6 utilisation of its most important interacting partner, the E6AP 
ubiquitin ligase. This seems particularly important since recent studies have 
demonstrated that PKA phosphorylation of E6AP at position T485 resulted in 
decreased enzymatic activity, whilst a non-phosphorylatable mutant of E6AP 
appeared to increase the levels of ubiquitin-mediated degradation of its substrates 
(Yi, Berrios et al. 2015). These studies demonstrated that, an autism-linked missense 
mutation disrupts the phosphorylation site and this results in the synaptic dysfunction 
and autism pathogenesis. In order to firstly confirm the identity of the PKA phospho-
acceptor site in E6AP, the wild type and T485A mutant (phospho-dead) of E6AP 
were expressed as GST fusion proteins, purified and then subjected to in vitro 
phosphorylation with the catalytic subunit of PKA in the presence of radiolabeled-
ATP. As can be seen in Figure 33A, the phosphorylation of the E6AP T485A mutant 
is greatly decreased compared to wild type. This result confirms that that the T485 
residue is a major PKA phospho-acceptor site in E6AP.    
In order to begin to understand the role of phospho-regulation of E6AP in the context 
of HPV E6-induced degradation of its target proteins, we first wanted to generate a 
stable cell line in which the endogenous E6AP expression had been ablated. This 
was necessary since previous studies had shown that E6AP forms a multimeric 
complex with E6 (Martinez-Zapien, Ruiz et al. 2016) and it can also induce its own 
autoubiquitination and degradation (Kao, Beaudenon et al. 2000). Therefore, it was 
important that we perform these studies in E6AP null cells. To do this, we performed 
genome editing of HEK293 cells to knock out the endogenous E6AP using the 
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CRISPR-Cas9 system. Following selection, single-cell cloning and initial screening 
by DNA sequencing (Figure 33C), the cells were then further analysed by western 
blotting to measure any residual levels of E6AP. As can be seen from Figure 33B, 
clone 1 was completely deficient for full-length E6AP, and sequencing showed that 
it has a stop codon at residue 430; therefore this clone was chosen for all subsequent 
analyses. 
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Figure 33. The E6AP T485 residue is the major phospho-acceptor site for PKA.  
A) The purified E6AP wild-type and T485A mutant GST fusion proteins were 
incubated with PKA and [γ-32P]ATP. Proteins were then subjected to SDS-PAGE 
and autoradiographic analysis. Upper panel: autoradiogram of in vitro 
phosphorylated wild type and mutant E6AP-GST fusion proteins; lower panel, the 
Coomassie Blue-stained gel.  B) Western blot analysis of clones obtained from 
genome-editing E6AP demonstrating the efficiency of gRNAs in targeting E6AP.  C) 
DNA sequencing result showing generation of mutation in the CRISPR/gRNA 
targeted E6AP locus.  
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Phosphorylation of E6AP at T485 affects E6AP degradation of Ring1B 
Previous studies had analysed the effect of phospho-regulation of E6AP upon the 
degradation of HHR23A (Yi, Berrios et al. 2015), and we wanted to study this in the 
E6AP-null background.  Therefore, E6AP-null HEK293 cells were transfected with 
HHR23A, together with plasmids expressing either wild-type E6AP, or the T485A 
(non-phosphorylable) or T485E (phospho-mimic) mutant. After 24hrs the cells were 
harvested and proteins analysed by western blotting. The results are shown in Figure 
34A. Despite multiple attempts, we were unable to demonstrate that E6AP was 
capable of inducing degradation of HHR23A, and the reasons for this are currently 
unclear. In order to determine whether E6AP could increase the ubiquitination of 
HHR23A, we transfected the E6AP null HEK293 cells with V5-tagged HHR23A 
expression plasmid, together with the wild-type and mutant E6AP constructs and 
HA-tagged ubiquitin expression plasmids. After 24hrs the cells were harvested and 
immunoprecipitated with anti-HA-conjugated agarose beads. The ubiquitinated 
HHR23A was then detected by western blotting using the anti-V5 antibody. The 
results in Figure 34B, show that HHR23A is not polyubiquitinated in the absence of 
E6AP, but is markedly polyubiquitinated in the presence of E6AP. In agreement with 
previous studies (Yi, Berrios et al. 2015), there is further ubiquitination of HHR23A 
in the presence of the E6AP T485A mutant, while the T485E mutant shows slightly 
lower levels of polyubiquitination of HHR23A. Thus, despite not promoting 
degradation of HHR23A in our assays, the wild type and T485A mutant of E6AP can 
promote HHR23A polyubiquitination. Similarly, we tested another group of reported 
E6AP substrates: PML-1, PML-2, PML-3 and PML-5 (Louria-Hayon, Alsheich-
Bartok et al. 2009). E6AP-null HEK293 cells were transfected with Flag-PML, 
together with the wild type E6AP expression construct. After 24hrs the cells were 
harvested and proteins analysed by western blotting. As can be seen in Figure 34C, 
we observed no degradation of PML isoforms in the presence of wild type E6AP, 
rather there was an apparent increase in PML levels. Taken together, these results 
suggest that there should be great care in interpreting which cellular proteins are 
normal degradation substrates of E6AP. 
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Figure 34. Regulation of E6AP through T485 phosphorylation does not affect 
the degradation of E6AP’s normal substrates HHR23A and PML.  
A) E6AP-null HEK293 cells were transfected with the indicated plasmids and after 
24hrs the cells were harvested and protein levels analysed by western blotting. β -
galactosidase acted as a control for transfection efficiency. The right hand panel 
shows the relative values of HHR23A degradation from at least 3 independent 
assays. Standard errors of means are shown. (P value: ns>0.05). B) Cells were 
transfected with the indicated expression plasmids, and also treated with proteasome 
inhibitor. After 24hrs cells were harvested and subjected to immunoprecipitation 
with anti-HA-conjugated agarose beads. The polyubiquitinated HHR23A was then 
detected by western blotting with anti-V5 antibody. The right hand side of each blot 
shows the input levels of HHR23A used in the immunoprecipitations. C) E6AP-null 
HEK293 cells were transfected with the different isoforms of PML plasmids with or 
without wild type E6AP, after 24hrs the cells were harvested and protein levels 
analysed by western blotting. β-galactosidase acted as a control for transfection 
efficiency.  
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We then analysed another reported substrate of E6AP, Ring1B, which has also been 
shown in previous studies to be degraded by E6AP (Mortensen, Schneider et al. 
2015) (Zaaroor-Regev, de Bie et al. 2010). The E6AP-null HEK293 cells were 
transfected with plasmids expressing Ring1B, together with wild type E6AP, the 
T485A phospho-destroyed mutant or the T485E phospho-mimic mutant. After 24hrs 
the cells were harvested and proteins analysed by western blotting. The results in 
Figure 35A demonstrate that E6AP alone can induce the degradation of Ring1B, and 
this is further increased in the presence of the T485A mutant, which supports 
previous studies indicating an increased degradation capability with the T485A 
mutant (Yi, Berrios et al. 2015). Surprisingly, the phospho-mimic T485E mutant 
consistently retained some degradation activity in these assays. In order to determine 
whether E6AP could increase the ubiquitination of Ring1B, we transfected the 
E6AP-null HEK293 cells with FLAG-tagged Ring1B expression plasmid, together 
with the different E6AP mutants and HA-tagged ubiquitin expression plasmids. Cell 
were treated with proteasome inhibitor, CBZ. After 24hrs the cells were harvested 
and immunoprecipitated with anti-FLAG conjugated agarose beads. The 
ubiquitinated Ring1B was then detected by western blotting using the anti-HA-HRP 
antibody. The results in Figure 35B, show that there is a weak polyubiquitination of 
Ring1B in the absence of E6AP, but that this increases dramatically in the presence 
of wild type E6AP. There is a further slight increase in ubiquitination of Ring1B in 
the presence of the E6AP T485A mutant, whilst the T485E mutant only weakly 
ubiquitinates Ring1B. Taken together, these results, using a different substrate of 
E6AP, largely support previous studies, which indicate that mutation of the T485 
phospho-acceptor site can have an effect upon E6AP's enzymatic activity. 
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Figure 35. Regulation of E6AP through T485 affects the degradation of E6AP’s 
normal substrate, Ring1B.  
A) E6AP-null HEK293 cells were transfected with the indicated plasmids and after 
24hrs the cells were harvested and protein levels analysed by western blotting. β-
galactosidase acted as a control for transfection efficiency. B) Cells were transfected 
with the indicated expression plasmids, and treated with proteasome inhibitor, after 
24hrs were harvested and subjected to immunoprecipitation with anti-FLAG-conjugated 
agarose beads. The polyubiquitinated Ring1B was then detected by western blotting 
with anti-HA-HRP antibody. The lower panel shows the input levels of Ring1B used in 
the immunoprecipitation. The histogram shows percentage Ring1B degradation in the 
presence of wild type and mutants of E6AP. 
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HPV E6 overrides the normal phospho-control of E6AP at T485. 
Considering that E6AP is recruited by E6 for many of its activities, we were next 
interested in determining whether the phospho-mimic T485E or phospho-destroying 
T485A amino acid substitutions in E6AP could affect the ability of HPV E6 to direct 
the degradation of p53. To do this, the E6AP-null HEK 293 cells were co-transfected 
with either HPV-16 E6, HPV-18 E6 or HPV-31 E6, together with p53 and the wild type 
or mutant E6AP expression plasmids. After 24hrs the cells were harvested and the 
protein levels analysed by western blotting. The results in Figure 36A, B and C 
demonstrate that p53 is not degraded by E6 if E6AP is absent, and this is in agreement 
with many other previously published studies (Scheffner, Huibregtse et al. 1993). Co-
transfection of wild type E6AP with E6 promotes p53 degradation, and there is a 
concomitant increase in the levels of E6 expression, which is also consistent with 
previous observations showing that E6AP is required for maintaining E6 stability 
(Tomaic, Pim et al. 2009). Most interestingly, however, when we co-transfect either the 
T485A or the T485E mutants, p53 appears to be degraded with an efficiency similar to 
that observed with the wild type E6AP. These results suggest that phosphorylation of 
T485 has little effect upon the ability of either HPV-16, HPV-18 E6 or HPV-31 E6 to 
utilize E6AP for the degradation of p53.  
We then proceeded to investigate whether another HPV E6 substrate was similarly 
unaffected by T485 phospho-regulation. To do this we analysed Dlg, which is a PDZ 
domain-containing substrate of HPV E6 (Gardiol, Kuhne et al. 1999). The E6AP-null 
HEK293 cells were transfected with a Dlg expression plasmid, together with the 
different E6AP expression constructs and HPV-16 E6. After 24hrs the cells were 
harvested and the protein levels analysed by western blotting. The results in Figure 36D 
demonstrate that Dlg degradation by E6 is also unaffected by either the T485A or 
T485E amino acid substitutions. 
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Figure 36. E6AP regulation at T485 has no effect on HPV E6 degradation of p53 
and Dlg. E6AP-null HEK293 cells were transfected with plasmids expressing E6AP 
and p53, as indicated, plus plasmids expressing either HPV-16 E6 (Panel A), HPV-18 
E6 (Panel B) or HPV-31 E6 (Panel C). After 24hrs the cells were harvested and protein 
levels analysed by western blotting. β-galactosidase acted as a control for transfection 
efficiency in all assays.  D) E6AP-null HEK293 cells were transfected with E6AP, Dlg-
1 and HPV-16 E6 and after 24hrs the cells were harvested and protein levels analysed 
by western blotting. β-galactosidase acted as a control for transfection efficiency. N=3. 
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We also tested the autodegradation of wild type E6AP and the T485A and T485E 
mutants. To do that we transfected the different E6AP expression plasmids into E6AP-
null H1299 cells, and after 24 hrs we performed half-life experiments using a 
cycloheximide pulse-chase for different time points.  As can be seen in Figure 37A, we 
observed that wild-type E6AP and the T485A mutant show equivalent rates of self-
turnover during the period of the assay,  whilst the autodegradation ability of T485E 
mutant is markedly reduced, and these result are consistent with previously reported 
results (Yi, Berrios et al. 2015).  
It was clear from the analysis of p53 degradation in Figure 36 that there are significant 
differences in how the E6AP mutants are degraded by the different HPV E6 proteins, 
with HPV-16 E6 and HPV-31 E6 targeting the wild type and the two mutants with 
similar efficiency, whilst HPV-18 E6 appears to be incapable of degrading the T485A 
and T485E mutants. In order to confirm this, the assay was repeated without the 
presence of exogenously added substrate and the results obtained are shown in Figure 
37B and C, where it can be seen that HPV-16 E6 effectively degrades wild type E6AP 
and the T485A and T485E mutants, whilst HPV-18 E6 is largely defective in degrading 
the T485A and T485E mutants. These results suggest that the autodegradation activity 
of the T485E mutant can be re-activated by HPV-16 E6 and HPV-31 E6, but not by 
HPV-18 E6. In contrast, the T485A mutant, which has intrinsically more 
autoubiquitination activity (Yi, Berrios et al. 2015), can be further degraded by HPV-16 
E6 and HPV-31 E6, but not by HPV-18 E6, indicating intriguing differences in how 
these viral oncoproteins redirect E6AP activity.    
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Figure 37. Different HPV E6s uncouple normal PKA phospho-regulation of E6AP.  
 A) E6AP-null HEK293 cells were transfected with plasmids expressing E6AP and 
24hrs post transfection, the cells were treated with Cycloheximide for indicated time 
points and then the cells were harvested and protein levels analysed by western blotting. 
E6AP-null HEK293 cells were transfected with plasmids expressing E6AP, plus 
plasmids expressing either HPV-16 E6 (Panel B) or HPV-18 E6 (Panel C). After 24hrs 
the cells were harvested and protein levels analysed by western blotting. β-galactosidase 
acted as a control for transfection efficiency in all assays. The bottom panels show the 
statistical quantification using Student’s t-test. Values are shown are means from at 
least 3 independent experiments; standard error of the mean is shown. ** P<0.005. 
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 HPV E6 recruits phospho-E6AP to the nucleus in a 14-3-3-dependent manner.  
Having found that HPV E6 can redirect E6AP activity independently of its T485 
phosphorylation status, we were interested in investigating how the subcellular 
distribution of phosphorylated and non-phosphorylated forms of E6AP might appear in 
cells derived from a cervical cancer, and whether E6 might have any impact upon the 
subcellular distribution of these different forms of E6AP. In order to do this, we 
performed a series of immunofluorescence analyses in HeLa cells, which contain HPV-
18 E6. The cells were transfected with siRNA E6/E7 to determine whether the viral 
oncoproteins might modulate the distribution of the different forms of E6AP. At the 
same time, siRNA E6AP was also transfected to verify the specificity of the anti-E6AP 
antibodies. As can be seen in Figure 38A, control HeLa cells have very low levels of 
p53 and E6AP. There are also very low levels of phospho-E6AP, although interestingly, 
there does appear to be some variability in the staining for phospho-E6AP, suggesting 
there might be an element of cell cycle control in its phosphorylation. Most 
interestingly, when HeLa cells are transfected with siRNA against E6/E7 (Figure 38B), 
there is, as expected, a dramatic increase in the levels of nuclear p53 and E6AP, whilst 
the phospho-E6AP levels increase, primarily within the cytoplasmic compartment. 
These results suggest that phospho-E6AP normally resides within the cytoplasm, whilst 
non-phosphorylated E6AP is mostly found with the nucleus. However, in the presence 
of E6, both forms of E6AP accumulate within the nucleus. 
 
In order to verify the E6-mediated nuclear accumulation of phospho-E6AP we repeated 
the immunofluorescence analysis in the presence of the proteasome inhibitor MG132. 
The results obtained are shown in Figure 38A (lower panel) and, as can be seen, 
proteasome inhibition results in a dramatic increase in the amount of both total and 
phosphorylated E6AP within the nucleus.     
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Differential subcellular localization of phosphorylated proteins is often mediated 
through the activity of the 14-3-3 family of proteins (Muslin and Xing 2000). Since E6 
can also interact with certain 14-3-3 isoforms (18), we were initially interested in 
investigating whether phosphorylation of E6AP at T485 could confer interaction with 
14-3-3 proteins. To do this, we purified GST.E6AP wild type and GST.E6AP T485A 
fusion proteins and subjected them to in vitro phosphorylation with purified PKA in the 
absence of radiolabel, and then performed binding assays with recombinant 14-3-3γ. As 
a positive control we also included HPV-18 E6 in the assays. The results in Figure 39 
show that, whilst there is a strong increase in the ability of phospho-E6 to interact with 
14-3-3γ, which is in agreement with previous results (Boon and Banks 2013), 
phosphorylation of E6AP only results in a very modest increase in interaction with 14-
3-3γ, although this is dependent upon the presence of an intact phospho-acceptor site at 
T485. Whether this is a reflection of low levels of phosphorylation of E6AP, or 
intrinsically weak interaction with this particular 14-3-3 isoform remains to be 
determined.  
In order to investigate a potential role for 14-3-3 in modulating the pattern of E6AP 
expression, we performed another series of immunofluoresence analyses in HeLa cells, 
but in this case, we transfected the cells with a plasmid expressing Difopein, which has 
been shown previously to block endogenous 14-3-3 proteins from interacting with their 
substrates (Xu, Fulop et al. 2010) (Cao, Yang et al. 2010). As can be seen in Figure 
40A, there is a significant increase in the amount of phospho-E6AP in the cytoplasm 
following transfection of Difopein. In contrast, Difopein does not alter the sub-cellular 
distribution of phospho-E6AP when E6 is also removed (Figure 40B), where the 
majority of phosphorylated E6AP is found in the cytoplasm. Taken together, these 
results indicate that nuclear accumulation of phospho-E6AP in the presence of HPV-18 
E6 is in part dependent upon 14-3-3.  
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Figure 38.  Phospho-forms of E6AP have distinct subcellular distribution in HeLa 
cells.  
A) HeLa cells were transfected with control siRNA against luciferase and after 72hrs 
were incubated for a further 3hrs with either DMSO or the proteasome inhibitor CBZ. 
The cells were then fixed and patterns of protein expression monitored using anti-
E6AP, anti-p53 and anti-phosphoT485 E6AP antibodies respectively. B) HeLa cells 
were transfected with either siRNA E6/E7 or siRNA E6AP and after 72hrs the cells 
were fixed and stained for E6AP, p53 and phosphoT485 E6AP. N=3 
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Figure 39. Phosphorylation of E6AP at T485 confers its interaction with 14-3-3γ.  
The left panel shows the PKA and 14-3-3 phospho-consensus motifs. The right panel 
shows a direct interaction assay with purified 14-3-3γ. Purified GST fusion proteins 
were either untreated or subjected to phosphorylation (indicated as “P”) with PKA in 
the presence of non-radiolabeled ATP. They were then incubated with purified 
recombinant 14-3-3γ. After extensive washing, the bound protein was detected by 
Western blotting using anti-14-3-3γ antibody (upper panel), Ponceau staining of the 
nitrocellulose membrane is shown in the bottom panel. 
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Figure 40. HPV E6 recruits phospho-E6AP to the nucleus in a 14-3-3 dependent 
manner.  
A) HeLa cells were transfected with control siRNA against luciferase, plus Difopein in 
the right panel, after 72hrs the cells were fixed and patterns of protein expression 
monitored using anti anti-phosphoT485 E6AP, anti-p53 and anti-E6AP antibodies 
respectively. B) HeLa cells were transfected with either siRNA E6/E7 (left panels) or 
with siRNAE6/E7 plus with Difopein (right panels), after 72hrs the cells were fixed and 
stained for anti-phosphoT485 E6AP, anti-p53 and anti-E6AP antibodies respectively.  
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HPV-31 E6 displays a complex pattern of phosphorylation regulation  
Previously we have shown that there are interesting differences in how different kinases 
recognize E6 oncoproteins from different HPV types. We also know from previous 
studies that, unlike HPV-18 E6, HPV-31 E6 has a particularly complex pattern of 
phospho-regulation. Thus, HPV-31 E6 appears to be phosphorylated by AKT within the 
PBM, but the PKA phospho-acceptor site probably resides at S82 (Boon, Tomaic et al. 
2015). To verify that HPV-31 E6 is phosphorylated by PKA at S82, I made S82A, 
S82G and S82D substitutions, with the A and G substitutions acting to destroy the 
phospho-acceptor site, whilst the D substitution acts as a phospho-mimic, as shown in 
Figure 41A. The proteins were expressed as GST fusion proteins, purified and subjected 
to in vitro phosphorylation with PKA. The results shown in Figure 41B demonstrate 
that the S82G mutation greatly reduce phosphorylation by PKA, thus confirming S82 as 
the major phospho-acceptor site for PKA on HPV-31 E6. Intriguingly, the S82D mutant 
appeared to retain wild type levels of phosphorylation, suggesting that the incorporation 
of a negative charge at this position can promote phosphorylation by PKA at an 
additional site within the HPV-31 E6 protein. In addition, generation of the double 
mutation i.e. S82D/ΔPBM also resulted in high levels of HPV-31 E6 phosphorylation. 
This indicates that PKA can phosphorylate HPV-31 E6 at two different sites, one at S82 
and other as yet unidentified site which is recognized following phosphorylation at S82. 
I also performed phosphorylation assays using AKT and, as can be seen from Figure 
41C, the phosphorylation is only slightly decreased in the three substitution mutants at 
S82, but is abolished in the double mutant, S82A/ΔPBM, confirming that the major 
phospho-acceptor site for AKT resides within the HPV-31 E6 PBM. 
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Figure 41. The major PKA phospho-acceptor site in HPV-31 E6 resides at S82 
residue.  
A) Schematic representation of different mutants generated in HPV-31 E6 GST fusion 
proteins. B) and C) The purified HPV-31 E6 GST fusion proteins were incubated with 
PKA or AKT and [γ-32P] ATP (indicated as “P”). Proteins were then subjected to SDS-
PAGE and autoradiographic analysis. Upper panels represent autoradiograms of 
different in vitro phosphorylated wild type and mutant HPV-31 E6 GST fusion proteins; 
lower panels show the Coomassie Blue-stained gels.  
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The HPV-31 E6 phospho-acceptor site at S82 controls p53 degradation  
 
Recent structural studies on HPV-16 E6 suggest that the region around S82 in HPV-31 
E6 is likely to be important for the overall conformation of the E6 oncoprotein 
(Nomine, Masson et al. 2006). Major functions of E6 at this site include the ability to 
interact with the E6AP ubiquitin ligase and target p53 for degradation. I was therefore 
interested in determining whether mutation of HPV-31 E6 at this site might have any 
impact upon its ability to degrade p53. To investigate this, I performed a series of in 
vivo degradation assays with the S82A and S82G phospho-dead mutants and the S82D 
phospho-mimic mutant. These were co-transfected with p53 into p53-null H1299 cells, 
and the levels of p53 expression were analysed by western blotting. The results obtained 
are shown in Figure 42A and demonstrate that the S82D mutation abolishes the ability 
of HPV-31 E6 to degrade p53. In contrast, S82A and S82G retain almost wild-type 
levels of activity. These results demonstrate that alterations at the S82 phospho-acceptor 
site can impact negatively upon the ability of HPV-31 E6 to target p53 for degradation, 
suggesting that PKA phosphorylation of HPV-31 E6 could affect the ability of 31E6 to 
induce the degradation of p53. 
To examine how the S82 residue might contribute to HPV31-E6 function, I proceeded 
to investigate the stability of HPV-31 E6 when phosphorylated at S82. To do this, the 
H1299 cells were treated with proteasome inhibitor, CBZ, after co-transfection with p53 
and either wild-type or mutant HPV-31 E6. The results are shown in Figure 42B and 
surprisingly, we observed that the HPV-31 E6 S82D phospho-mimic mutant is unstable, 
thus most likely accounts for the inability of this mutant to degrade p53. Interestingly, 
when the equivalent mutation was made in HPV-18 E6, there was no major effect upon 
its ability to degrade p53, again highlighting major differences in the structure/function 
of these different HPV E6 oncoproteins.  
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Figure 42. The HPV-31 E6 phospho-acceptor site at S82 controls p53 degradation. 
 A) In vivo assay of the p53-degradation activity of wild type and mutant HPV-31E6. 
Plasmids expressing p53 and either wild-type or mutant HPV-31E6 were transfected 
into p53-null H1299 cells. After 24h the protein extracts were subjected to SDS-PAGE 
and western blotting. The upper panel shows the degradation of FLAG-p53 induced by 
wild-type or mutant HPV-31 E6, detected by anti-p53 antibody. The lower panel shows 
the transfection efficiency control, LacZ, detected by anti-β-galactosidase antibody. B) 
The in vivo degradation assay was repeated in the presence and absence of CBZ.  Wild-
type HPV-18 E6 and the HPV-18 E6S82D mutant were included for comparison.  
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I was further interested in confirming this result by immunofluorescence. To do this, 
HA-tagged wild-type 31E6 and the three substitution mutants were co-transfected with 
p53 into expressed in H1299 cells. After 24hrs the cells were fixed and stained, and the 
localisation patterns of HPV-31 E6 and p53 were ascertained by immunofluorescence. 
The results obtained are shown in Figure 43  and demonstrate that wild-type HPV-31 
E6 and the S82A and S82G substitution mutants were expressed similarly within H1299 
cells, and in no case was any co-expression with p53 observed, suggesting efficient 
degradation of p53. In contrast, the S82D phospho-mimic, although expressed at lower 
levels in agreement with the western blotting data, was also found frequently co-
localizing with p53. This indicates that the phosphor-mimic at S82 site does not simply 
induce instability of E6, but rather it is also interestingly weaker in targeting p53 for 
degradation.  
In order to gain more insight into the underlying mechanism, we performed a series of 
in vitro interaction assays with p53 and the HPV-31 E6 mutants. The results obtained 
are shown in Figure 44 and demonstrate that there are minimal changes in the ability of 
the mutant and wild type HPV-31 E6 proteins to interact with p53 (Figure 44B). 
However, there is a striking decrease in the ability of S82D mutant to interact with 
E6AP.  
These results suggest that PKA phosphorylation of HPV-31 E6 at S82 could negatively 
regulate its ability to degrade p53. This appears to be mediated through an inhibition of 
interaction with E6AP, which has two direct consequences: reduction of E6 stability 
and subsequent loss of p53 degradation ability.  
Taken together, these results demonstrate a complex pattern of phospho-regulation of 
HPV-31 E6. I have confirmed the existence of at least two phospho-acceptor sites, one 
for AKT within the PBM, and one for PKA at the S82 residue. However, the S82D 
phospho-mimic mutation suggests the existence of a further phospho-acceptor site 
within the HPV-31 E6 protein.  
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Figure 43.  The HPV-31 E6 phospho-acceptor site at S82 controls p53 degradation.  
The p53-null H1299 cells were transfected with HA-tagged wild-type 31E6 and mutants 
of HPV-31 E6 together with p53. The cells were fixed 24h post-transfection and 
localization of proteins was observed with immunofluorescence (Green indicates HA 
31E6 and Red indicated p53).    
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Figure 44.  HPV-31 E6 phospho-mimetic mutant show reduced  E6AP interaction. 
The wild-type and mutant HPV-31 E6 GST fusion proteins were incubated with in 
vitro-translated radiolabeled E6AP (A) and p53 (B), as indicated. Following extensive 
washing, bound proteins were detected using SDS-PAGE and autoradiography. Upper 
panel, autoradiogram; lower panel, the Coomassie Blue-stained gel. C) The histogram 
shows quantification of E6AP interaction with wild type and different mutants of 31E6. 
The numbers were normalized to wild type control.    
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CHAPTER 4: DISCUSSION 
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PART:1  
1. Phosphorylation of HPV E6 within the PDZ Binding Motif by DNA Damage 
Response kinases is linked to E6 inhibition of p53 transcriptional activity 
 
1.1 E6 phosphorylation: A result of stress response 
 
The high-risk HPV E6 oncoproteins are characterized by the presence of a carboxy 
terminal PBM, embedded within which is a phospho-acceptor site, phosphorylation 
of which inhibits PDZ binding activity and confers interaction with 14-3-3 proteins 
(Boon and Banks 2013, Boon, Tomaic et al. 2015). Thus, this site offers the 
potential of fine-tuning E6’s activity with respect to a number of different 
interaction partners, both within the normal viral life cycle and during the 
development of malignancy. Previously, we had shown that AKT and PKA could 
both potentially phosphorylate E6 within the PBM in vitro (Boon and Banks 2013, 
Boon, Tomaic et al. 2015), but we had little evidence about which kinases normally 
phosphorylate endogenously-expressed E6 in cells derived from cervical cancers. 
Here we show that E6 is normally only very weakly phosphorylated, if at all, during 
the normal cell cycle. However, following the induction of a variety of stress 
response kinases, and in particular those associated with the DDR, there is a 
dramatic increase in the levels of E6 phosphorylation. The bulk of this 
phosphorylation appears to be mediated via Chk1, and this therefore directly links 
regulation of the E6 PBM activity to induction of the DDR, which is known to play 
a critical role in the normal viral life cycle and potentially in the development of 
HPV-induced malignancy.  
Whilst HPV-16 and HPV-18 E6 had previously been shown to be good substrates 
for phosphorylation by both AKT and PKA, I first wanted to ascertain when 
endogenously expressed E6 would be phosphorylated in cells derived from a 
cervical cancer. We therefore first proceeded to monitor HPV-18 E6 
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phosphorylation in HeLa cells using two different approaches: double thymidine 
block and release to follow changes through the cell cycle, and nocodazole 
treatment to analyse levels of E6 phosphorylation in G2/M. To our surprise we 
found that thymidine block and release resulted in weak E6 phosphorylation in G1/S 
arrested cells, whilst nocodazole treatment induced high levels of phosphorylation 
of E6 in G2/M arrested cells. Since no phosphorylation was observed when the cells 
cycled normally through G2/M and back into G1 after release from a double 
thymidine block, this suggested that phosphorylation of E6 might be more linked to 
a stress response than to normal progression through cell cycle. In addition, in 
previous unpublished investigations we had been unable to block the nocodazole-
induced phosphorylation of E6 using PKA inhibitors (Boon SS thesis), and we 
therefore reasoned that another pathway of E6 phosphorylation might be 
operational. Indeed, nocodazole has been implicated in the induction of oxidative 
stress responses and also in induction of a DDR (Dalton, Nandan et al. 2007, Orth, 
Loewer et al. 2012, Signoretto, Honisch et al. 2016). In agreement with this, we 
found that induction of an oxidative stress response by either H2O2 or nocodazole 
was responsible for the very high levels of E6 phosphorylation that were observed 
following exposure to these agents. Intriguingly, cycloheximide also induces very 
high levels of E6 phosphorylation, but this appears to be mediated by a different 
stress response pathway. Since protein synthesis inhibition has been shown to 
activate several kinases (Zinck, Cahill et al. 1995, Oksvold, Pedersen et al. 2012, 
Dai, Shi et al. 2013), it is possible that E6 can be phosphorylated by a variety of 
other stress response kinases. This result also argues for the use of caution in using 
cycloheximide as a means of monitoring E6 stability over time, as currently we have 
no information on what this phosphorylation might do to E6 stability. However, 
previous studies have suggested a bi-phasic half-life for E6, and this could well be 
linked to changes in E6 phosphorylation status during the course of these assays 
(Grossman, Mora et al. 1989, Kranjec, Tomaic et al. 2016).  
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1.2 Involvement of DDR kinases in inducing E6 phosphorylation 
 
Having found that oxidative stress responses were responsible for inducing E6 
phosphorylation, we next investigated which DDR pathways might also be 
involved. We noticed a very high degree of homology within the E6 PBM to a Chk1 
consensus recognition site and, indeed, using in vitro assays we found that E6 was a 
very good substrate for phosphorylation by Chk1 at residue T156 within the E6 
PBM. In contrast, the closely related Chk2 kinase appeared to be incapable of 
phosphorylating HPV-18 E6 in vitro, further demonstrating the specificity of these 
assays. In vivo the situation was rather more complicated, with different kinases 
being responsible for E6 phosphorylation, depending upon the specific stimulus. 
Thus, both H2O2- and nocodazole-induced phosphorylation of E6 involves oxidative 
stress signaling, as we demonstrated by blocking this with NAC, but the kinases 
involved are different. In the case of nocodazole, Chk1 inhibition clearly blocked E6 
phosphorylation, strongly supporting the in vitro kinase assays. However, for H2O2, 
Chk2 appeared to be involved, despite the fact that it appeared incapable of 
phosphorylating E6 in vitro. Previous studies have shown that the DDR pathway 
and Chk2 can also activate PKA (Bensimon, Aebersold et al. 2011, Marazita, Ogara 
et al. 2012), which we know from our earlier results could also be responsible for 
phosphorylating E6. Indeed, this does seem to be the case, where H2O2-induced 
phosphorylation of E6 is blocked by treatment with either a Chk2 inhibitor or the 
PKA inhibitor H89, suggesting that PKA is the kinase responsible for 
phosphorylating E6 in response to an H2O2-induced oxidative stress-induced DDR. 
Additionally, we observed that the increased phosphorylation of E6 following the 
inhibition of ATM or Chk1 is mediated largely by PKA. This is in agreement with 
previous studies suggesting that Chk1 inhibition leads to activation of the ATR 
pathway (Gagou, Zuazua-Villar et al. 2010, Petermann, Orta et al. 2010, Choi, 
Toledo et al. 2011) and to further ATR-mediated Chk2 activation in response to 
H2O2 treatment (Zhang, Gao et al. 2014), which subsequently activates PKA 
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(Bensimon, Aebersold et al. 2011). A model of how these pathways can lead to E6 
phosphorylation are shown in Figure 45.   
We then extended these studies to investigate whether clinically-relevant inducers of 
a DDR might also induce E6 phosphorylation. To do this we assessed cisplatin, as 
an agent capable of intercalating DNA and blocking DNA replication, plus 
inhibitors of topoisomerase, ribonucleotide reductase and PARP. Interestingly, 
cisplatin treatment, and also blocking topoisomerase or ribonucleotide reductase all 
induced a high level of E6 phosphorylation in HeLa cells, which in the case of 
cisplatin treatment appeared to be largely mediated by Chk1. In contrast, blocking 
PARP, which has also been linked to induction of a DDR, had no discernible effect 
upon the levels of E6 phosphorylation, suggesting that the pathways required for 
phosphorylation of E6 are not activated by PARP inhibition in HeLa cells. This 
seemed to be linked to the low level of DDR in HeLa cells upon PARP inhibition 
and suggest that the patterns of E6 phosphorylation might well vary in primary or 
recently immortalised cells from that seen in HeLa cells, which are fully 
transformed and have been maintained in tissue culture for many years.  Further 
studies will be required to investigate these aspects in more detail. .     
 
1.3 Biological consequences of E6 phosphorylation 
 
When E6 is phosphorylated in the PBM, this blocks its PDZ recognition and instead 
confers the ability to interact with 14-3-3 family members. Several previous studies 
have shown a critical requirement for the activation of DDR pathways in the HPV 
life cycle, with ATM/ATR in particular playing essential roles in genome 
amplification (Moody and Laimins 2009, Reinson, Toots et al. 2013, Spriggs and 
Laimins 2017). Recent studies have also indicated a potential link between the E6 
PBM and genome maintenance, with inactivation of p53 appearing to be able to 
compensate for loss of PBM function (Lorenz, Rivera Cardona et al. 2013). This, 
therefore, raised the obvious question of whether the E6 PBM might have an 
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additional function linking it to inactivation of p53. To investigate this, we analysed 
a panel of different p53-responsive promoters and asked whether an intact PBM 
could contribute towards the ability of E6 to block p53 transcriptional activity, both 
in the presence and absence of proteasome inhibition. We find a quite complex 
picture, where certain promoters, such as that of BAX, are inhibited by E6 
regardless of the presence of an intact PBM. In contrast, in the case of Mdm2 and 
PUMA promoters, the E6 PBM appears to play an essential role in inhibiting p53 
transcriptional activity under conditions of proteasome inhibition. Furthermore, 
using the HPV-18 E6 R153G mutant, which has been shown previously to be 
defective for phosphorylation but which retains PDZ binding activity (Boon, 
Tomaic et al. 2015), we found that this was also defective in its ability to block p53 
transcriptional activity on the Mdm2 promoter in the presence of proteasome 
inhibitors. Whilst proteasome inhibition could result in the formation of aberrant 
complexes consisting of p53, E6AP and E6, which in turn could affect p53 
transcriptional activity (Thomas, Massimi et al. 1996), the lack of activity observed 
using the R153G mutant argues against this, and instead strongly suggests that the 
major role of the PBM in this scenario is retention of the ability to be 
phosphorylated. These studies allow us to propose a model, shown in Figure 45, in 
which a variety of different cellular stresses can induce the phosphorylation of E6 
within the PBM, either directly by Chk1 or indirectly through PKA, which in turn 
can directly contribute to the ability of E6 to block p53 transcriptional activation of 
a subset of p53 responsive genes.  When we analysed various other p53-responsive 
genes, interacting partners, and regulators by using a p53 RT PCR array, there 
appeared to be interesting differences in how these genes are regulated in a 
PBM/phosphorylation-dependent manner. Moreover, some of the tested target genes 
showed a 14-3-3 dependency for E6-mediated p53 inactivation, as shown by the 
inhibition of protein expression in the presence of the 14-3-3 inhibitor Dipofein. 
Obviously, whether there is involvement of cofactors other than 14-3-3 is, as yet, 
undetermined and the precise mechanisms of E6 PBM inhibition of p53 
transcriptional activity via 14-3-3, requires further investigation.  
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In summary, the above studies provide compelling evidence of a direct link from the 
induction of oxidative stress, to the induction of a DDR, to the phospho-regulation 
of cancer-causing HPV E6 oncoproteins, and to their ability to perturb p53 
transcriptional activity on a subset of p53-responsive promoters. This is the first 
example of PBM-PDZ recognition being regulated by DDR kinases, and begins to 
explain how HPV can make use of the ATM/ATR pathway that is induced during 
viral infection, whilst at the same time overcoming some of the deleterious effects 
that would also be expected. These results are also interesting in a broader context 
of the potential regulation of PBM-PDZ recognition in response to DDR signaling, 
not only in HPV, but also in regulating different cellular processes, and in particular 
those linked to the regulation of cell polarity. For example, the interacting partner of 
Dlg, Net1 (Garcia-Mata, Dubash et al. 2007) and the Scrib interacting partner 
Vangl1 (Anastas, Biechele et al. 2012) all have PBMs that have phospho-acceptor 
sites that are remarkably similar to a Chk1 consensus. Studies to investigate whether 
cell polarity might also be subject to regulation through DDR signaling pathways is 
currently completely unexplored, but these studies suggest that this would certainly 
be worthy of further investigation.   
These results also raise the intriguing possibility that certain HPV types may be 
more responsive to certain chemotherapeutic strategies, depending upon the specific 
HPV type and the sequence of the E6 PBM. Future studies will aim to further clarify 
these possibilities by generating the R153G mutation in the C4-1 cervical cancer 
cell line using a genome editing approach. It would also be of great interest to study 
the phosphoregulation of E6 during the viral life cycle. It is tempting to speculate 
that E6 is presumably phosphorylated during the viral amplification phase, as 
studies have reported the requirement for the activation of DDR signaling, with 
ATM/ATR in particular playing essential roles in viral genome amplification in 
differentiating epithelium. Whether phosphorylation of E6 also plays a role in the 
progression to malignancy also remains to be determined.  
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Figure 45. Phosphorylation of the HPV E6 PBM links cellular stress-response 
signaling to E6 inhibition of p53 transcriptional Activity.  
The model summarizes the effect of E6 PBM phosphorylation under various stress 
conditions. Our results demonstrate the involvement of two major axes: The DNA 
damage response pathway and other cellular stress response pathway(s) having a 
number of unknown kinases. Chk1 activation links directly to E6 phosphorylation, 
whilst Chk2 activation further signals to PKA, which subsequently phosphorylates 
E6. Our studies provide compelling evidence of a direct link from the induction of 
oxidative stress and induction of DDR to the phospho-regulation of HPV E6 
oncoproteins, potentially interacting with 14-3-3 proteins, to perturb p53’s 
transcriptional activity on a subset of p53 responsive promoters.  
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PART:2  
2. The differential phosphorylation of different HPV E6 types suggests diverse 
modes of E6 PBM functions   
 
2.1 The non-canonical residues around the E6 PBM play an essential role in E6 
phospho-regulation 
The above studies demonstrated the regulation of E6 phosphorylation by multiple 
cellular kinases in response to a variety of stress responses, including DDR signaling. 
However, it is critical to dissect the two different functions of the E6 PBM and separate 
its phosphorylation by different kinases from the basic PBM-PDZ interaction. We have 
previously defined the R153 residue, which resides just upstream of the HPV-18 E6 
PBM, as being essential for PKA recognition of the E6 PBM (Kuhne, Gardiol et al. 
2000, Boon and Banks 2013, Boon, Tomaic et al. 2015), but we had no information on 
whether sequences downstream of the phospho-acceptor site at T156 might also play a 
role in E6 phosphorylation by Chk1, PKA or AKT. This is important, as we know that 
non-canonical residues play an important role in E6's selection of PDZ-containing 
targets (Thomas, Dasgupta et al. 2008, Luck, Charbonnier et al. 2012, Thomas, Myers 
et al. 2016), and we wanted to determine whether this is also true for kinase recognition 
of E6, which could potentially dissect the dual functionality of the E6 PBM.  
In this study we have identified the sequence constraints governing kinase recognition 
of the E6 PBM. Intriguingly, we find that Chk1 and PKA kinases require the presence 
of residues downstream of the phospho-acceptor site in HPV-18 E6, with interesting 
differences in kinase recognition. The PKA recognition appears to tolerate any 
downstream sequence, since the Q/A.V/A mutant is phosphorylated as efficiently as the 
wild type protein. This suggests that the differences in PKA phosphorylation of 
different E6 PBMs are all determined by differences in the upstream sequences that 
make up the PKA recognition site, and are independent of any specific downstream 
sequences. In the case of Chk1, however, the Q/A.V/A mutant phosphorylation is 
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reduced compared with wild type HPV-18 E6 and, moreover, the R153A mutant 
abolishes Chk1-mediated phosphorylation of the PBM, suggesting that both upstream 
and downstream residues play critical roles in Chk1 recognition of E6. Interestingly, 
AKT kinase recognition does not seem to be dependent on non-canonical residues 
around the PBM, suggesting interesting differences in the kinase recognition of E6. 
Furthermore, when we analysed the phosphorylation of different high-risk HPV types 
with Chk1 and PKA kinase, they showed interesting differences in the levels of E6 
phosphorylation. As mentioned earlier, previous studies have shown a significant role 
for non-canonical residues upstream of the phospho-acceptor site for PKA recognition 
(Boon and Banks 2013, Boon, Tomaic et al. 2015). Our results further highlight this 
observation, as HPV-16, -18 E6 and HPV-39 E6, which have a highly enriched stretch 
of arginine residues upstream, show very high levels of phosphorylation by Chk1 and 
PKA, whilst HPV- 31, -51, -56 and -68 E6 are only weakly phosphorylated and have 
fewer upstream arginine residues. Interestingly, HPV-33 E6, which also has a highly 
arginine-enriched sequence upstream, is phosphorylated very weakly by Chk1, 
potentially owing to the presence of an alanine residue downstream of the phospho-
acceptor site, which further supports our hypothesis. Taken together, these results 
highlight the importance of the PBM non-canonical residues in regulating E6 
phosphorylation and how it varies for different kinases. Moreover, it also sheds insights 
into differential phosphorylation of different high-risk HPV types depending on the 
specific amino acid residues present in the motif.   
 
2.2 Biochemical differences within the PBM allows E6 to control PDZ/14-3-3 
recognition  
This in depth mutational analysis of the E6 PBM also allows the efficient separation of 
E6's PDZ and 14-3-3 recognition. Our results demonstrate that any substitution within 
the PBM is deleterious to PDZ recognition, which is in support of previously reported 
findings. Furthermore, the R153A and ETstop mutant, which cannot be phosphorylated 
by Chk1 kinase, do not interact with 14-3-3, whilst the ETQstop mutant does show 
phosphorylation-dependent 14-3-3 association. Interestingly, the ETAA mutant 
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abolishes any interaction with PDZ domain-containing substrates, but retains the 
interaction with 14-3-3ɀ protein. Interestingly however, this mutant showed no 
interaction with 14-3-3γ, suggesting various differences in the recognition of different 
isoforms of 14-3-3 proteins. These results are summarized in Figure 46 and this will 
form the basis for future studies for dissecting further the relevance of 14-3-3 
interactions for different E6 activities.  
One of the direct biological consequences of these activities is to regulate p53 functions. 
Our results demonstrate that, not only the E6 PBM, but also its phosphorylation state, 
plays an important role in regulating p53's transcriptional transactivation activities (see 
above). The HPV-56 and -68 E6 proteins, which are phosphorylated only to low levels 
by both Chk1 and PKA kinases, only weakly affect p53 activation of  of the Mdm2 
promoter, whilst HPV-18 and -39 E6 proteins, which are strongly phosphorylated by 
both kinases, are very effective in suppressing p53 transcriptional activity under DNA 
damage conditions.  
This indicates that the PBM interactions of E6 contribute towards the abrogation of a 
p53 function that is independent of the ability of E6 to degrade p53, and this functional 
ablation may be necessary for viral genome maintenance.  E6 does this potentially 
through its association with 14-3-3. These studies allow us to propose a model as shown 
in Figure 47. However, understanding the molecular differences in association of 
different 14-3-3 isoforms with different HPV E6 types depending on their phospho-
status will be particularly interesting. In addition, 14-3-3 proteins also have a wide 
range of other functions in addition to those linked with the regulation of p53 and it 
remains to be determined whether E6 can also modulate any of these other functions in 
a phosphorylation dependent manner. Finally, we should not exclude the possibility that 
phosphorylation of the PBM might also regulate association with other cellular proteins, 
and studies are currently underway to investigate this possibility further.      
Taken together, these observations highlight important differences for the phospho-
regulation of E6 from diverse HPV types, and suggest potentially broader effects on E6 
function during the viral life cycle and during malignant progression.  
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Figure 46. The Non-canonical residues around HPV-18 E6 PBM play important 
role in kinase recognition of E6. 
A scheme showing the carboxy-terminus sequence of the HPV-18 E6 and role of 
specific residues in recognition by different kinases, PDZ domains and 14-3-3 
recognition. The R153 residue (Blue), and the threonine phospho-acceptor site (Red) 
are critical for the PKA and Chk1 kinase recognition and subsequent phosphorylation-
dependent 14-3-3 interaction. The residues downstream of phospho-acceptor site 
(Green) play important role in Chk1 kinase recognition and subsequent specific 14-3-3 
interactions such as 14-3-3γ. The ultimate amino acid (Green) is important for PKA 
recognition but not for Chk1.  
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Figure 47.  HPV E6 mediated perturbation of 14-3-3 and PDZ functions.  
Induction of DDR signaling enhances phosphorylation of E6, which confers increased 
interaction with 14-3-3, resulting in 14-3-3 retention in the cytosol. Retention of 14-3-3 
potentially results in retention of Cdc25A/C in the cytosol, thus inhibiting the activation 
of Cyclin-B and Cyclin-E respectively. 14-3-3 mediated inactivation of p53 results in 
inhibition of p21 transcription transactivation as well as several other p53 responsive 
promoters. The non-phosphorylated form of E6 interacts with hDlg (including 
cytoplasmic and phosphorylated nuclear forms), Scribble and other PDZ domain 
containing substrates, some of which are targeted for degradation.  
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PART:3  
3. E6 over rides the biochemical regulation of E6AP 
 
3.1 Phosphorylation of E6AP at T485 does not affect E6’s ability to degrade its 
substrates 
The cellular ubiquitin ligase, E6AP, plays a critical role in many of E6’s activities. It is 
essential for the degradation of certain E6 substrates, it is essential for maintaining E6 
protein stability and it contributes directly towards the induction of malignancy in 
transgenic animals (Herber, Liem et al. 1996, Shai, Nguyen et al. 2007, Shai, Pitot et al. 
2010, Padash Barmchi, Gilbert et al. 2016). Furthermore, loss of its expression in cells 
derived from cervical cancer induces high levels of apoptosis, and therefore the E6-
E6AP interaction remains an attractive target for the development of novel anti-HPV 
therapeutics. The recent demonstration that E6AP enzymatic activity could be 
modulated by PKA was therefore particularly relevant for understanding how this might 
affect E6 function. We show here that phosphorylation of E6AP at T485 is unlikely to 
directly affect the ability of E6 to target its substrates for proteasome-meditated 
degradation, although, depending on the specific HPV type, modulation of T485 can 
affect the ability of E6 to further promote E6AP auto-ubiquitination and degradation.  
Previous studies had shown that the E6AP T485 residue is a phospho-acceptor site for 
PKA, with a non-phosphorylatable mutant, T485A, demonstrating increased levels of 
ubiquitination activity, both with respect to an E6AP target protein, HHR23A, and also 
with respect to its own auto-ubiquitination. In contrast, a phospho-mimic mutation, 
T485E, has apparently greatly reduced levels of enzymatic activity, again both with 
respect to a normal substrate and to itself. We initially confirmed these observations in 
two ways. First we performed in vitro phosphorylation assays with purified PKA and 
demonstrated unequivocally that the major PKA phospho-acceptor site on E6AP was at 
T485. Secondly, we analysed how the T485A and T485E mutants would behave with 
respect to a different E6AP substrate, Ring1B. In agreement with previous studies, we 
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found increased levels of Ring1B degradation and a modest increase in ubiquitination in 
the presence of the T485A mutant, but reduced levels of enzymatic activity with the 
T485E mutation. It should also be noted that minor differences from previously 
published studies (Yi, Berrios et al. 2015) could be a reflection of the fact that all our 
current analyses have been performed in cells in which E6AP expression was stably 
ablated by CRISPR/Cas9, whilst previous studies analyzed the E6AP mutants in the 
context of low levels of endogenously expressed wild type E6AP, thus potentially 
complicating the interpretation.   
Importantly, when we tested the reported degradation substrates of E6AP, such as 
HHR23A, despite their being polyubiquitinated, we were unable to see their 
degradation in the presence of E6AP. Similarly, we observed no degradation of another 
reported substrate, PML, which suggests that care should be taken in differentiating 
between the in vivo interaction substrates and degradation substrates of E6AP.       
We were then interested in determining whether the same regulation of E6AP, reported 
for itself and its normal substrates, also applied to substrates that were targeted as a 
result of the interaction with E6. We analysed two very different targets, p53 and Dlg, 
each of which interacts with E6 through completely different mechanisms. In both cases 
we found a striking similarity, in that the phospho-modulation of T485 appeared to have 
no effect upon the capacity of either HPV-16 or HPV-18 E6 to degrade either of these 
cellular proteins. Similar results were also obtained with HPV-31 E6 and p53, 
indicating that this also holds true for E6 proteins from multiple HPV types. This 
suggests that E6's recruitment of E6AP overrides the normal regulatory mechanisms 
that are in place to control E6AP activity.  
Most interestingly, other aspects of the E6/E6AP interaction do appear to be affected by 
the phosphorylation status of T485. Whilst previous analyses had shown that T485A 
was active in auto-degradation and T485E was defective, we find that, depending upon 
the HPV type, these activities of E6AP are affected differently. Thus, HPV-16 E6 and 
HPV-31 E6 can efficiently target both the wild type E6AP and the T485E mutant for 
degradation, indicating that HPV-16 E6 and HPV-31 E6 can promote the auto-
degradation of E6AP, regardless of the phospho-status at T485. Interestingly, HPV-16 
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E6 and HPV-31 E6 also seem capable of further augmenting the auto-degradation 
activity of the T485A mutant.  In contrast, HPV-18 E6 can efficiently target WT E6AP 
but is defective with respect to the T485A mutant, indicating that HPV-18 E6 cannot 
further stimulate the already highly active auto-degradatory activity. In addition, despite 
T485E being very susceptible to HPV-16 E6 and HPV-31 E6 induced degradation, only 
a weak activity is seen with HPV-18 E6. This indicates that whilst HPV-18 E6 can still 
redirect an apparently inactive T458E mutant to target an E6 substrate, it cannot 
promote T485E auto-degradation. Taken together, these results demonstrate that 
different HPV E6 oncoproteins can uncouple E6AP from its normal regulation by PKA, 
presumably by conferring a structural modification upon E6AP itself, but that there are 
nonetheless quite marked differences in how different E6 oncoproteins bring this about.  
 
3.2 E6 modulates the subcellular distribution of E6AP 
Having found that E6 can significantly alter the biochemical regulation of E6AP, we 
also wanted to determine whether E6 could have any impact upon the subcellular 
distribution of phospho-E6AP. This was important since previous studies had indicated 
that phospho-E6AP was primarily located in the cytoplasm, whereas E6 is known to 
recruit E6AP to the nucleus (Daniels, Sanders et al. 1998, Vaeteewoottacharn, 
Chamutpong et al. 2005, Yi, Berrios et al. 2015). To do this we performed a series of 
immunofluorescence analyses on HeLa cells and found that in the presence of HPV-18 
E6, E6AP was largely found within the nucleus, regardless of its phosphorylation status. 
However, when E6 was removed, total E6AP was found within the nucleus and 
cytoplasm, whereas the phospho-E6AP was found almost entirely within the cytoplasm. 
This suggests that the phosphorylation of E6AP can modulate its subcellular 
distribution, but this is completely overridden by E6.  
Since changes in the subcellular distribution of many phosphorylated proteins are 
controlled by members of the 14-3-3 family (Muslin and Xing 2000), we were naturally 
interested in investigating whether 14-3-3 might play any role in the regulation of E6AP 
subcellular distribution. To do this we again made use of the 14-3-3 inhibitor, Difopein, 
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which blocks 14-3-3 interaction with its target proteins (Xu, Fulop et al. 2010). Most 
interestingly, we found that Difopein only had any effect on the subcellular distribution 
of the phospho-E6AP in the presence of E6, where, whilst having minimal effects on 
the total E6AP expression pattern, it induced a marked relocalisation of phospho-E6AP 
from the nucleus to the cytoplasm. These results indicate that E6-triggered nuclear 
accumulation of phospho-E6AP is partly dependent upon the activity of 14-3-3 family 
members. Obviously this raises a number of important questions about the precise 
mechanisms by which this occurs, but it is tempting to speculate that optimal 
recruitment of phospho-E6AP to the nucleus might require the ability of E6 to also 
recognize 14-3-3 proteins. Whether this requires phosphorylated E6 remains to be 
determined, but as the steady state levels of E6 phosphorylation are normally very low 
as shown above, this suggests that this activity is most likely independent of E6 
phosphorylation within the PBM and indicates an indirect means of of E6AP/14-3-3 
recruitment, potentially as part of a tripartite complex. Further studies will be required 
to clarify these precise mechanisms. It is also interesting to speculate as to why E6 
might recruit phospho-E6AP to the nucleus. Under normal circumstances, this form of 
the protein would be inactive, and it is quite possible that in certain phases of the cell 
cycle, or during differentiation, E6AP might become highly phosphorylated. Therefore, 
without the ability of E6 to override this phospho-regulation it is quite possible that 
there would be times when E6 would lose much of its function. Hence the recruitment 
of an apparently inactive form of the protein to the nucleus and re-activating its ability 
to degrade E6 substrates would appear to make very good virological sense. Future 
studies will obviously be required to investigate these aspects further.  
In conclusion, these studies demonstrate that E6 very efficiently overcomes the negative 
regulation of E6AP activity; however the precise mechanisms and consequences with 
respect to the ability of E6 to promote E6AP auto-ubiqutination vary somewhat between 
different HPV types, thus implying quite distinct mechanisms by which different HPV 
E6 oncoproteins redirect the E6AP ubiquitin ligase activity. This study also suggests 
that this is not a simple stimulation of an already-existing activity, but rather a 
redirection of E6AP activity toward itself as summarized in Figure 48. 
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Figure 48. The HPV E6 oncoproteins override the normal phospho-regulation of 
E6AP. 
PKA phosphorylation of E6AP at position T485 results in decreased enzymatic activity, 
whilst a non-phosphorylatable form of E6AP shows increased levels of ubiquitin-
mediated degradation of its substrates. HPV E6 is capable of overriding this regulation 
and can promote degradation of its substrates regardless of the phosphorylation status of 
E6AP. Furthermore, E6 interaction with E6AP also significantly alters how E6AP is 
subject to autodegradation.  
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PART:4 
4. HPV-31 E6 displays complex pattern of phospho-regulation 
4.1 PKA phosphoryates HPV-31 E6 at a resides outside the PBM  
Previously, it has been shown that deletion of the PBM in HPV-31 E6 does not affect 
the PKA-mediated phosphorylation of E6, suggesting that the PKA phospho-acceptor 
site resides outside the PBM. Additionally, the mass spectrometric analysis of PKA-
phosphorylated HPV-31 E6 indicated the S82 residue as a potential phospho-acceptor 
site (Boon, Tomaic et al. 2015). Therefore, in this study we have further characterized 
the differential phosphorylation of HPV-31 E6 by PKA and AKT and attempted to 
determine the functional relevance of phosphorylation at S82.   
Our studies demonstrate that the HPV-31 E6 displays a particularly complex pattern of 
phospho-regulation. We observed that the S82G mutation completely abolishes the 
phosphorylation by PKA, thus confirming S82 as the major phospho-acceptor site on 
HPV-31 E6, whilst the S82D mutation enhances the phosphorylation elsewhere in 
HPV-31 E6 protein. Surprisingly, when we analysed the S82D/ΔPBM double mutant, it 
was still highly phosphorylated by PKA. This indicates that PKA can phosphorylate 
HPV-31 E6 on at least two different sites, one at S82 and another, as yet undefined, that 
is recognized by PKA following phosphorylation of the S82 residue, but which resides 
outside the PBM. The phospho-prediction analysis suggests presence of a second PKA 
phospho-acceptor site potentially at T58, however, further biochemical analysis needs 
to be done to confirm this. On the other hand, the AKT kinase phosphorylates E6 within 
the PBM, and deletion of the PBM completely abolishes AKT-mediated 
phosphorylation of E6, suggesting differential regulation of HPV-31 E6 
phosphorylation with these different kinases. This is in marked contrast to HPV-16 and 
HPV-18 E6 where PKA and AKT both phosphorylate E6 within the PBM. In the case 
of Chk1 phosphorylation this is very weak with HPV-31 E6 and occurs within the 
PBM, but it would be interesting to investigate whether Chk2/PKA activation through 
oxidative stress might be able to induce phosphorylation of HPV-31 E6 at S82.  
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4.2 Phosphorylation at S82 most likely affects p53 degradation as a result of 
reduced interaction with the E6AP ubiquitin ligase  
Having confirmed HPV-31 E6 S82 as a phospho acceptor site for PKA we wanted to 
explore how this phosphorylation event might affect E6 activity. Intriguingly, this 
residue seems to play an important role in the ability of HPV-31 E6 to direct the 
degradation of p53.  Both the A and G substitution mutants induce the degradation of 
p53 with an efficiency similar to that of wild type E6, but the phospho-mimic 
substitution of S82D greatly reduces the ability of HPV-31 E6 to degrade p53. I also 
wanted to examine whether this residue was critical in E6 from other HPV types and so 
also analysed the equivalent S82D mutation in HPV-18 E6. In this case, the HPV-18 E6 
S82D substitution mutant was able to induce p53 degradation as efficiently as the wild 
type HPV-18 E6. These results demonstrate that inserting a phospho-mimic mutation at 
this site is not producing a general disruption in the overall basic structure of E6, but 
rather this seems specific for HPV-31 E6. Whether other HPV E6 proteins can also be 
phosphorylated at this residue with similar consequences remains to be determined.   
I then proceeded to investigate the molecular basis for loss of p53 degradation with the 
S82D mutant. Clearly one contributing explanation is the fact that this mutant appears 
to be much more weakly expressed than the wild type HPV-31 E6 protein in western 
blot analysis, and this alone might seem sufficient to explain loss of p53 degradation 
activity. However, when these mutants were analysed by immunofluorescence, it can 
clearly be seen that the S82D can co-localize with p53, whereas neither the wild type E6 
or S82A mutant could be found co-localising with p53 in these assays. This is 
consistent with the phospho-dead mutants of E6 being as efficient as wild type E6 in 
inducing p53 degradation, but that the phospho-mimic mutant, as well as being 
unstable, is also inherently defective in its ability to degrade p53. This might suggest 
that phosphorylation at S82 does not simply result in E6 instability, but also in a 
reduced ability to target p53 for degradation. To further investigate the mechanisms 
behind this, we analysed the ability of these mutants to interact with p53 and E6AP.  
We observed that there are minimal differences between wild type and mutant E6s in 
their ability to associate with p53. However, there is a striking decrease in the ability of 
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the S82D mutant to interact with E6AP, compared with the S82A or S82G mutant or the 
wild type E6. These results suggest that addition of a negative charge, most likely 
through phosphorylation by PKA on the HPV-31 E6 S82 residue, controls the 
interaction with E6AP, thereby modulating the levels of E6 expression and 
simultaneously reducing the ability to degrade p53 (Summarized in Figure 49). This has 
important implications for how we view the regulation of E6 protein from diverse HPV 
types, and suggests that phosphorylation events, depending on the specific HPV E6 
protein, can have broader effects on E6 structure and function other than simple 
regulation of the E6 PBM. 
These results raise a number of interesting questions, the most important being when 
does HPV-31 E6 become phosphorylated. Based on our studies with HPV-18 E6 in 
HeLa cells it seems unlikely that HPV-31 E6 would be phosphorylated during a normal 
cell cycle, since if this was the case, we would have expected to see PKA 
phosphorylating HPV-18 E6 in the PBM during our cell cycle analyses, since we know 
that HPV-18 E6 is an excellent substrate for PKA. This raises two other possibilities. 
The first is that that phosphorylation takes place also upon induction of a DDR through 
Chk2 activation of PKA, in manner similar to that seen for phosphorylation of the HPV-
18 E6 PBM. However, this does seem rather counter-intuitive, as it would imply less E6 
and less effect upon p53 just at a point when a DDR was being activated. One 
possibility might be that the phosphorylation at S82 under these circumstances confers 
interaction with certain 14-3-3 isoforms, which might in turn compensate for loss of 
interaction with E6AP, and might allow inhibition of p53 transcriptional activity in a 
manner similar to that seen with PBM phosphorylated HPV-18 E6. The second 
possibility is that the S82 residue becomes phosphorylated during differentiation at a 
point when high level expression of E6 is no longer required. There are reports of high 
levels of PKA activity in the upper layers of terminally differentiating keratinocytes 
(Delury, Marsh et al. 2013) so this would be consistent with this hypothesis. To resolve 
these questions, it will be necessary to look at the role of the S82 mutants in the context 
of the whole HPV-31 genome in combination with studies to monitor phosphorylation 
at this specific residue during different stages of the viral life cycle and post induction 
of a DDR. 
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Figure 49. The PKA phospho-acceptor site in HPV-31 E6 resides outside the PBM. 
The schematic representation of HPV-18 and -31 E6 structure. The phospho-consensus 
site for PKA and AKT kinases resides within the PBM of HPV-18 E6, whilst in the case 
of HPV-31 E6, the major phospho-acceptor site resides at S82 and the phosphorylation 
at this site affects the ability of E6 to degrade p53 as a consequence of reduced E6AP 
interaction.  The sequence alignment of HPV-16 (Ser81), -18 (Ser82) and -31 (Ser82) 
E6 proteins is shown.  
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Summary 
The results presented in this thesis reveal a very complex pattern of HPV E6 
phosphorylation events in response to various forms of different stresses, the precise 
form of which varies between different HPV E6 proteins, and results in similarly 
different functional readouts. This can be combined also with the effects of 
phosphorylation of a key cellular interaction partner, E6AP, which can also potentially 
impact upon E6 function in vivo. These phosphorylation events begin to form a picture 
of a highly dynamic set of E6 interactions, involving various PDZ domain containing 
substrates, switching between different 14-3-3 isoforms, which in turn can modulate 
E6AP association, substrate degradation and E6 stability. As can be seen in Figure 50 
these different activities and pathways are potentially highly amenable to inhibition via 
various small molecules, the consequences of which might have profound effects upon 
continuing cancer growth and the HPV life cycle. 
 
 
 
 
 
 
 
 
162 
 
 
Figure 50. Summary of the roles of HPV E6 phosphorylation and some of the 
associated activities during the viral life cycle and progression to malignancy.   
The HPV E6 through the PBM perturbs cell polarity by degrading PDZ-containing 
proteins and thus, allowing cells to differentiate to suprabasal layers. The rapid 
replication of the viral genome during the amplification phase creates aberrant DNA 
structures that activate DNA damage response signaling. Activation of ATR/Chk1 and 
ATM/Chk2 kinases further induce E6 phosphorylation within the PBM. This allows E6 
to interact with 14-3-3 family proteins, thus perturbing p53 transcriptional 
transactivation. E6 recruits an inactive form of pE6AP to the nucleus and re-activates its 
ability to degrade E6 substrates. The potential roles of phosphorylation of E6 during 
development of malignancy still remains to be determined.  
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